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ABSTRACT
Pancreatic ductal adenocarcinoma is highly lethal and surgical resection is the only
potential curative treatment for the disease. Tumor-specific intraoperative fluorescence
imaging could improve staging and surgical resection, thereby improving prognosis. In the
first study, hyaluronic acid derived NPs with physico-chemically entrapped indocyanine
green, termed NanoICG, were utilized for intraoperative near infrared fluorescence
detection of pancreatic cancer. NanoICG accumulated significantly in an orthotopic
pancreatic ductal adenocarcinoma model with safety profile both in vitro and in vivo. To
maximize tumor signal, while minimizing signal in healthy pancreas and RES capture of
macromolecules, in the next study, we describe the rational development of a series of
hyaluronic acid (HA) conjugates that vary in molecular weight and are conjugated to nearinfrared fluorescent (NIRF) dyes that have differences in hydrophilicity, serum protein
binding affinity, and clearance mechanism. We systematically investigated the roles of
each of these properties on tumor accumulation, relative biodistribution, and the impact of
intraoperative imaging of orthotopic, syngeneic pancreatic cancer. Overall, each HA-NIRF
conjugate displayed intra-pancreatic tumor enhancement compared to uninvolved pancreas
at 24 and 96 h. Regardless of HA molecular weight, Cy7.5 conjugation directed
biodistribution to the liver, spleen, and bowels. Conjugation of IRDye-800 to 5 and 20 kDa
HA resulted in low liver and spleen signal, while preserving tumor contrast enhancement
up to 14-fold compared to healthy pancreas. When IRDye800 was conjugated to 100 kDa
HA, the conjugate preferentially distributed to RES organs. When assessing the imaging
efficacy of HA-based conjugates in hepatic metastases, those that accumulated to the liver
utmost (HA100k-Cy7.5, HA100k-IRDye800, NanoICG) turned to aid the identification of
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hepatic malignancy with hypo-contrast. These studies demonstrate that by tuning HA
molecular weight and the physicochemical properties of the conjugated moiety, in this case
a NIRF probe, peritoneal biodistribution can be substantially altered to achieve optimized
delivery to tumors with robust contrast enhancement for intraoperative imaging to
abdominal tumors. Aside from assisting the accurate delineation of primary tumor, HANIRF conjugates demonstrated potential for identification of occult metastases in the
intraoperative setting, as a versatile tool for accurate staging.
Key words: Pancreatic ductal adenocarcinoma, hyaluronic acid, fluorescence guided
surgery, biodistribution, serum protein binding, Indocyanine green, splenic metastasis
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CHAPTER 1: INTRODUCTION
Pancreatic cancer is an intractable malignancy and the third leading cause of cancer
deaths in the USA [1]. It is likely to become the second most frequent cause of cancerassociated mortality within the next decade [2]. The disease has a relatively low occurrence
yet falls within the most common causes of cancer-related deaths [3]. It often presents at
an advanced stage, which contributes to the poor five-year survival rates of 2%-9%,
ranking firmly last amongst all cancer sites in terms of prognostic outcomes for patients.
Better understanding of the risk factors and symptoms associated with this disease is
essential to inform both health professionals and the general population of potential
preventive and/or early detection measures [4].

A slight difference in pancreatic cancer incidence among genders as well as a
significant different geographic distribution was observed: It is more common in men (5.5
per 100,000, 243,033 cases) than in women (4.0 per 100,000, 215,885 cases) [5]. The agestandardized rate incidence was highest in Europe (7.7 per 100,000 people), followed by
North America (7.6 per 100,000 people). The lowest rate was observed in Africa with an
estimated incidence of 2.2 per 100,000 people [6]. Despite advancement in the knowledge
of potential risk factors that cause pancreatic cancer and newly available tools for early
diagnosis, its incidence is estimated to increase and will include 355,317 new cases before
2040 [6].

Most of the global variation in the incidence of pancreatic cancer has been
attributed to exposure to known or suspected risk factors related to lifestyle or the
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environment [7], [8]. Tobacco smoking is likely to explain the gender differences [9], some
findings indicated that obesity and dietary style may have some effects as well [8], [10].
Additionally, aging and hereditary might play a role. On the other hand, diagnostic tools
and diagnostic modalities vary between developed and undeveloped geographic areas,
which affects the management and prognosis of patients [6].

Pancreatic cancer is mainly divided into two types: pancreatic adenocarcinoma
(PDAC), which is the most common (85% of cases) arising in exocrine glands of the
pancreas, and pancreatic neuroendocrine tumor (PanNET) , which is less common (less
than 5%) and occurs in the endocrine tissue of the pancreas [11]. Based on the clinical stage
of the tumor, pancreatic cancer is classified into four types: I (no spread or resectable), the
cancer is limited to the pancreas and has grown 2 cm (IA) or greater than 2 cm but less
than 4 cm (IB); II (local spread or borderline resectable), the cancer is > 4 cm and is limited
to the pancreas, or there is spread locally to the nearby lymph nodes; III (wider spread or
unresectable), cancer may have expanded to the nearby blood vessels or nerves, but has
not metastasized to distant sites; IV (metastatic), cancer has spread to distant organs [12].
Because PDAC and the other less common exocrine cancers are typically diagnosed at a
late stage (III or IV), it has a very poor prognosis compared to PanNET.

PDAC has a very poor prognosis. It usually lacks symptoms at its early stages.
After diagnosis, only 24% of people survive 1 year, the 5-year survival rate is 9% for
pancreatic cancer with combined stages [13]. Over the period 2014-2018, the United States
National Cancer Institute data for pancreatic cancer in both sexes and all races showed that
10% of people diagnosed at the local stage had a 5-year survival rate of 32%. If the cancer
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is at stage III, the 5-year survival rate is 12%. More than half (52%) of people were
diagnosed at stage IV and had a 5-year survival rate of 3% [6].

In contrast to the steady increase in survival observed for most cancer types,
advances have been slow for lung and pancreatic cancers [13], [14]. Even at high volume
specialty centers, where the survival rate is higher than that of the general population,
disease recurrence is still a major problem [15]. Treatment and clinical management of
pancreatic cancer are often determined by the clinical stage of the patients’ disease and are
usually focused on the question of disease resectability. Patients who have resectable tumor
are eligible for surgery and thus have a significantly improved prospect for long-term
survival [15]. Because advanced and distant metastatic disease are excluded for surgical
treatment, only a minority of patients are presented to be eligible for surgical resection [16].

More than two-thirds of PDAC occur in the head of the pancreas. Hence, abdominal
pain, jaundice, pruritus, dark urine, and alcoholic stools may be presented as symptoms.
Nevertheless, in the early stages of the disease these symptoms may be subtle and easy to
be ignored [17]. In the symptomatic patients, abdominal ultrasonography (US) is a
reasonable first imaging test. If US is not diagnostic or pancreatic cancer is highly
suggested by clinical examination, then pancreas protocol computed tomography (CT) is
the standard for diagnosis and staging [18], [19]. Abdominal CT provides an assessment
of local and regional disease extent, which determines resectability, and also evaluates the
possibility of distant metastatic spread. If CT is not possible because of lack of availability
or allergy to contrast media, magnetic resonance imaging (MRI) with contrast media can
be used for the diagnosis and staging of pancreatic cancer. MRI as well as magnetic
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resonance cholangiopancreatography, can be performed as an adjunct to CT in detecting
extrapancreatic disease (Figure 1). If a pancreatic mass is identified, subsequent
endoscopic US and fine-needle aspiration are indicated [12]. Aside from the detection of
tumor masses, serum tumor marker cancer antigen 19-9 (CA 19-9) can be used to confirm
the diagnosis and to predict prognosis and recurrence. However, CA 19-9 is not tumorspecific. It has a limited sensitivity of 50% to 75% and specificity of 80% to 85%, and
cannot distinguish between cancer and chronic pancreatitis and possibly other disease
states with chronic inflammation [12], [20]. Thus CA19-9 is not sufficient as individual
screening tool for asymptomatic patients. Despite advances in imaging technologies as well
as in vitro diagnostic testing methods, the median size of PDAC at the time of diagnosis is
~3.1 cm, which have not changed in the past three decades [21].
After diagnosis of PDAC, patients are selected for surgical resection, which is the
only potential curative treatment for PDAC. However, only 15% to 25% of patients are
eligible for surgery at their initial diagnosis [22], [23]. Preoperative imaging evaluation
determines candidacy for resection. Absolute contraindications to resection include the
presence of metastases in the liver, peritoneum, any extra-abdominal site or vascular
invasion [4]. Specifically, hepatic metastases seen on multiple detector CT (MDCT) or
Positron emission tomogram (PET) /CT is a defining characteristic of unresectability based
on the consensus-based guidelines from the National Comprehensive Cancer Network
(NCCN) [24]. More precise detection methods can lead to improved patient stratification
for the most optimal primary treatment modality-either surgery or systemic (neoadjuvant)
therapy. This stratification can prevent patients from undergoing resections without any
oncologic benefit.
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Figure 1. Schematic illustration of the key imaging modalities used for the diagnostics and
potential intraoperative modalities for pancreatic cancer. Ultrasound, (endoscopic) ultrasound; CT,
computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography.
Representative images are shown of pancreatic cancer with displayed modalities, except for
photoacoustic and Raman optical imaging. Reprinted from Pancreas, 47 (6), 675–689, W. S. Tummers,
J. K. Willmann, B. A. Bonsing, A. L. Vahrmeijer, S. S. Gambhir, and R.-J. Swijnenburg, “Advances in
Diagnostic and Intraoperative Molecular Imaging of Pancreatic Cancer,” Copyright (2018), with
permission from Wolters Kluwer Health.

Currently available imaging techniques are highly accurate at predicting
unresectable disease, but they fall short in predicting resectability of disease, mainly
because of limited sensitivity for small-volume metastatic disease. Radiographically occult
metastases (<1 cm in diameter) on the surface of the liver or peritoneum, which are rarely
visible by CT, MRI, or transabdominal US, may be visualized laparoscopically. Diagnostic
staging laparoscopy (DSL) has shown to complement the preoperative assessment of
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radiographic imaging, which has limitations for identifying regional extension of the
primary tumor and/or metastatic disease, such as peritoneal involvement [24]. The case
reported by Pandit et al. [24] clearly suggests that MDCT and PET-CT which are part of
treatment algorithm for pancreatic cancer still miss distant small metastasis. Intraoperative
US is superior to other imaging studies in characterizing hepatic metastases, but does not
improve detection of liver metastases in resectable pancreatic cancer [25].
Tumor margin-positive (R1) resections occur in up to 70% of PDAC cases, leading
to a high number of loco-regional recurrence [26], [27]. This means that for all patients
diagnosed with PDAC, only 15% of these patients will receive a radical, tumor-margin
negative (R0) resection and have a chance for prolonged survival. Therefore, improved
tools for diagnosis, accurate staging, and more effective, tumor-margin negative pancreatic
surgeries are crucial for improving surgical intervention outcomes. However, this process
is challenging at multiple stages during the surgical procedure: detection of occult distant
metastases, assessment of the extent of the primary tumor, peritumoral lymph nodes (LN),
and the resection margins. Surgeons address two critical decisions during the procedure
that will determine the long-term survival of pancreatic cancer: the absence of metastatic
and regional disease and cancer-free margins [28], [29]. However, margin-positive (R1)
resections are a frequent phenomenon (which occurs up to 70% of cases) [30], as is the
emergence of distant metastases soon after surgery [31]. Failure to identify small tumor
extensions during surgery is not surprising, due to the growth pattern of the tumor and the
inability of the surgeon to differentiate between tumor and (peritumoral) inflammation.
In summary, resection of pancreatic malignancies is hindered by high rates of local
and distant recurrence from positive margins and unrecognized metastases. Early distant
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recurrences following margin-negative resection highlight the likelihood of unrecognized
metastases at the time of surgery [32]. Accurate staging drives proper treatment of patients
with pancreatic cancer, particularly when selecting patients for surgical resection.

1.1 Current preoperative imaging tools for PDAC
1.1.1 Transabdominal and Endoscopic US
Transabdominal US is often the initial investigation performed in patients
presenting with upper abdominal pain or jaundice. However, the sensitivity of
transabdominal US for detecting PDAC varies widely depending on the size of the tumor,
ranging from 95% in tumors larger than 3 cm to 50% in tumors smaller than 1 cm [33].
Furthermore, it is difficult to differentiate adenocarcinoma from focal inflammatory
masses secondary to chronic pancreatitis [34]. The introduction of contrast medium
increases the diagnostic accuracy of transabdominal US, which can provide dynamic
information regarding the macro- and microcirculation of focal lesions and of normal
parenchyma. However, the US evaluation of the pancreas can be limited by its deep
location within the upper abdomen, as well as intervening bowel gas and subcutaneous fat.
Endoscopic US overcomes these limitations by utilizing a transducer placed within
the stomach and duodenum that’s in close proximity to the pancreas. With its high spatial
resolution, endoscopic US is able to identify focal lesions as small as 2-3 mm, potentially
enabling the early detection. Moreover, endoscopic US provides an excellent tool for
sampling suspicious lesions by fine needle aspiration or a biopsy needle. Nevertheless, in
addition to the high number of false-positive findings, endoscopic US is invasive, operator
dependent and is associated with poor inter-observer consensus for differentiating
pancreatitis from malignant pancreatic lesions, even in highly specialized centers [35], [36].
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Therefore, improving the specificity of US techniques would greatly increase the
usefulness of this imaging modality for the early detection and characterization of
pancreatic lesions.

1.1.2 Improving the specificity of US with molecularly targeted contrast
agents
The use of molecularly targeted contrast microbubbles has the potential to improve
the sensitivity and specificity of contrast-enhanced US. Targeted microbubbles are created
by attaching ligands for disease-specific biomarkers to the microbubble shell surface [37].
These ligands promote the selective targeting and retention of the acoustically active
microbubbles at the sites of disease, thereby providing contrast with adjacent non-diseased
tissue. The microbubbles remain within the vascular space after intravascular
administration, which reduces the possibility to target to molecules that are overexpressed
on the surface of endothelial cells of the tumor vasculature. Despite this apparent limitation,
multiple biomarkers crucial for angiogenesis are overexpressed in the vasculature of many
malignant tumors, including pancreatic cancer [38]. The best examples are the receptors of
vascular endothelial growth factor (VEGF). Several studies have shown successful US
imaging of VEGF receptor 2 in animal models of breast, colon, prostate and pancreatic
cancer [39]–[41]. Pysz et al.[40] developed a VEGF receptor 2-targeted US imaging
platform for the reliable detection of small foci of pancreatic cancer ( 3 mm), with a 31fold increased imaging signal intensity compared with that of normal pancreatic
parenchyma in a genetically engineered pancreatic cancer mouse model. Foygel et al. [42]
discovered and validated thymocyte antigen 1 (Thy1) as a new PDAC-associated molecular
imaging target overexpressed on the neovasculature of pancreatic cancer. Subsequent in

8

vivo imaging studies in a genetically engineered mouse model showed 4-5.5-fold increase
in the signal of pancreatic cancer foci as compared that in normal parenchyma [42]. Human
toxicity and feasibility studies on VEGF receptor-targeted microbubbles are currently
ongoing and will determine the sensitivity and efficacy of this novel imaging approach [43].
Integration of molecular imaging with endoscopic US may further show enhanced visibility
of early-stage PDAC in future clinical trials and may increase inter-observer agreement of
endoscopic US examinations.

1.1.3 CT and CT Perfusion
MDCT with intravenous contrast medium is the preferred diagnostic test for
suspected pancreatic lesions. CT features of PDAC are variable. The majority of PDAC
are hypo-attenuating relative to the surrounding pancreatic parenchyma, a small percentage
(∼ 5%) are iso-attenuating [44]. Several secondary signs of PDAC have been described to
improve the diagnostic accuracy of CT, including pancreatic ductal dilatation, interruption
of the pancreatic duct, and distal parenchymal atrophy. Ahn et al. [45] reported the
sensitivity and specificity of focal pancreatic tumor, pancreatic duct dilation, interruption
of the pancreatic duct, and distal parenchymal atrophy to be 75% and 84%, 50% and 78%,
45% and 82%, and 45% and 96%, respectively. While MDCT can be popular for diagnosis
and staging of pancreatic malignancies, the diagnostic accuracy is limited for small (< 1
cm) lesions. There are also growing concerns regarding the increased risk of developing
cancer after repeated exposure to imaging radiation. Furthermore, contrast agents currently
used for CT are limited in their applicability in patients with reduced renal function.
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In CT perfusion, functional information regarding the blood perfusion within the
tumor is obtained in addition to the anatomic or morphologic information from the
conventional CT [46]. During CT perfusion, the transit of an intravenous CT contrast
medium is monitored as it passes through a region of interest. Physiologic parameters of
the tissue can then be evaluated, including capillary permeability, fractional intravascular
blood volume, blood flow and tissue interstitial volumes. Several studies have evaluated
the use of CT perfusion imaging for the assessment of PDAC [47], [48]. CT perfusion
imaging enables detection of altered perfusion parameters and will likely translate to
improved treatment monitoring. However, it is a conspiracy that whether CT perfusion
imaging is sensitive enough for the early detection of pancreatic cancer. CT perfusion
imaging is also associated with even higher doses of radiation than conventional CT,
making it unsuitable for widespread use as a screening modality. Other techniques, such as
dual-energy CT, are being developed to increase the conspicuity of lesions at CT. However,
additional clinical experience is needed for better characterization of the lesions [49].

1.1.4 Improving the specificity of CT by using biomarker-targeted
contrast medium
A promising alternative for the nonspecific contrast media is the contrast agents
that have been encapsulated in liposomes, which are highly biocompatible and associated
with less toxicity. Studies have demonstrated the feasibility of using iodinated liposomes
with micro-CT, including the ability to detect submillimeter microvessels [50], [51].
Similar to the design of tumor specific microbubbles, attempts have been made to improve
the specificity of the technique by inserting targeted ligands into the liposomal membranes
[52]. To date, the use of CT as a molecular imaging modality has yet to be fully defined.
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The low sensitivity and the need for relatively large quantities of contrast medium currently
limits wider application of molecularly-targeted CT imaging [52].

1.1.5 Endoscopic retrograde cholangiopancreatography (ERCP)
ERCP is an invasive technique but remains the procedure of choice for highresolution assessment of biliary and pancreatic ductal anatomy. Contrast material is
injected directly into the pancreatic ducts under fluoroscopic guidance. Because PDAC is
of ductal origin, ERCP is very sensitive (78%–95%) and specific (88%–95%) for detecting
pancreatic malignancies [53], [54], though not as sensitive as endoscopic US. Moreover,
ERCP is not suitable as a screening tool given its invasiveness and associated
complications (the risk of acute pancreatitis), which are not encountered with other
noninvasive imaging modalities. Thus, ERCP is usually reserved for situations in which a
therapeutic intervention could be required, such as stent placement, when performing the
diagnostic evaluation [53].

1.1.6 MRI, diffusion-weighted MRI and MR spectroscopy
Relative to CT, MRI has the advantage of improved soft-tissue contrast resolution
and no reliance on ionizing radiation. Currently, PDAC is best detected by using nonenhanced T1-weighted fat-suppressed gradient-recalled-echo imaging followed by
contrast-enhanced imaging with gadolinium-based contrast agents [55], [56]. Normal
pancreatic tissue has high signal intensity on non-contrast T1-weighted fat-suppressed
images because of the presence of aqueous protein in the pancreatic parenchyma. Normal
pancreatic tissue demonstrates a uniform capillary blush immediately after contrast
enhancement and fades to iso-intense signal on interstitial phase images. In contrast,
pancreatic cancer has a relatively abundant fibrous stroma and sparse tumor vascularity,
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which expressed as a low signal intensity on non-contrast T1-weighted fat-suppressed
images and less enhancement than the surrounding normal pancreatic tissue [57]. Recent
reports of sensitivity and specificity of MR imaging for the diagnosis of pancreatic cancer
are 85%–93% and 72%–79%, respectively [58], [59].

Diffusion-weighted (DW) MRI is the only imaging method that can be used to
evaluate the diffusion process in vivo. DW imaging is increasingly being used within the
abdomen [60], [61]. Various malignant tumors demonstrate high signal intensity on DW
images, likely reflecting high cellularity and/or a long T2 relaxation time [62]. Several
investigators have used DW imaging to detect PDAC. Muraoka et al. [63] reported that the
apparent diffusion coefficient (ADC) in PDAC correlates with tumor fibrosis rather than
with tumor cellularity. Ichikawa et al. [61] reported a very high sensitivity (96.2%) and
specificity (98.6%) for detecting PDAC using DW imaging alone. Recent studies claimed
that pancreatic cancer exhibits a high signal intensity on DW images with a significantly
decreased ADC value compared with that of normal in parenchyma. ADC has also proven
to be helpful for differentiating pancreatic cancer from mass-forming focal pancreatitis [64],
[65]. While the results of these studies indicate that DW imaging is useful for
characterizing pancreatic lesions, it has yet to be shown for the detection of pancreatic
cancer at an earlier stage. It is also unclear about the improvement of diagnostic accuracy
when DW imaging is added to MR protocols. Kartalis et al. [66] found similar diagnostic
accuracy for pancreatic cancer when comparing their conventional MR protocol to the
same MR protocol with DW imaging added.
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MR spectroscopy provides a noninvasive measurement of biochemical information
in vivo [67]. Several investigators have described the use of MR spectroscopy to
characterize pancreatic neoplasms [68], [69]. When compared with normal pancreas,
choline-containing compounds, fatty acids, and lipids were all decreased in PDAC [67].
The authors hypothesized that the hypo-perfusion and hypo-metabolism of PDAC relative
to the surrounding pancreatic parenchyma contribute to these metabolic changes. MR
spectroscopy is a promising method for improving the sensitivity for the diagnosis of
PDAC. However, metabolic molecular information is currently limited by the relatively
low magnetic field and signal strength associated with MR spectroscopy for clinic use [67].

1.1.7 Potential improvements of MR imaging with molecularly targeted
contrast agents
MR imaging is associated with excellent soft-tissue contrast, but low sensitivity,
which makes the development of molecular probes more challenging compared with other
modalities such as positron emission tomography (PET), US, and optical imaging. Contrast
agents based on nanoparticulate probes with a high payload of contrast-generating metals
have been developed to overcome the low sensitivity. Tumor-targeted MR imaging has
been performed by using gadolinium (III)-containing micelles and liposomes,
superparamagnetic iron oxide NPs, and manganese (II) chelates [57], [70]–[72]. At present,
superparamagnetic iron oxide NPs are the most attractive due to their chemical stability
and biocompatibility, with an overall hydrodynamic diameter of less than 50 nm, much
smaller than a cell (normally 10–30 μm) [72]. The incorporation of targeted biomarkers
such plectin-1 [73] or EGFR [34], which are overexpressed in pancreatic cancer, have been
published. Targeted contrast agents were developed by attaching peptide or single-chain
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antibodies to iron oxide NPs [74], [75]. Results of these studies using tissue specimens and
animal models demonstrated the feasibility of using targeted NP probes for both ex vivo
and in vivo MR imaging. Molecular MR imaging for earlier detection of PDAC has not yet
been translated into clinical trials. Greater adoption of MR imaging is likely challenged by
the higher spatial resolution, lower cost, and greater availability of MDCT.

1.1.8 18F Fluorodeoxyglucose positron emission tomography (18FDG
PET)
Elevated uptake of 18 fluorine (18F) fluorodeoxyglucose (FDG) has been
demonstrated in most primary malignant tumors because of increased metabolism of
glucose [76]. Early studies demonstrated quantitative and selective overexpression of
glucose transporter 1 (GLUT-1) in malignant pancreatic lesions [77], while normal
pancreatic tissue has low glucose utilization due to reduced GLUT-1 density. Studies have
demonstrated that
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FDG PET has a relatively high sensitivity (88%–94%) but variable

specificity (60%–94%) for differentiating benign from malignant pancreatic masses [78]–
[80]. Compared with CT and MRI, 18FDG PET is more sensitive for the detection of small
tumors [81] and recurrent pancreatic cancer [82], [83]. However, PET has been reported
with a high rate of false-positive results, particularly in patients with mass-forming
pancreatitis [84]. With the development and combination of PET and CT, the ability of
18

FDG PET imaging to provide accurate anatomic localization has greatly improved [85],

[86]. Currently, the relatively low specificity, high cost, limited availability, and ionizing
radiation all hinder the use of PET or PET/CT as a front-line diagnostic tool for pancreatic
cancer. PET/CT can help establish the diagnosis of PDAC in patients suspected of having
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pancreatic cancer in whom CT fails to identify a discrete tumor mass or in whom fine
needle aspirations are non-diagnostic [86].

1.1.9 Improving sensitivity and specificity of PET with new radiotracers
11

C-acetate PET, which is thought to be metabolized by entering the lipid synthesis

pathway [87], may be useful for the diagnosis of malignant tumor. As the cellular uptake
of acetate is not affected by glucose metabolism,
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C-acetate may provide superior

detectability over 18FDG for malignancy and is expected to be comparably effective even
in hyperglycemic states. In a recent study, Zhao et al.[88] reported the earlier detection of
PDAC xenografts with 11C-acetate PET than with 18FDG PET, but the ratio of accumulated
radiotracer between tumor and non-tumor in 11C-acetate PET was lower than that in 18FDG
PET during the same period. Another radiotracer,
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F-fluoroethyl-D-glucopyranose

(18FEDL), which is overexpressed in peri-tumoral pancreatic acinar cells, was reported to
be helpful for the detection of small pancreatic cancer lesions [89]. Further studies are
needed to evaluate the performance of new radiotracers for detecting and characterizing
PDAC specifically.

With recent advances in nanoparticle (NP) engineering, radiolabeled antibody or
gene-based probes have been developed that target specific proteins or genes
overexpressed on the surface or inside tumor cells (or vascular endothelial cells). These
targeted probes demonstrated promise to increase diagnostic specificity. For example, the
epithelial cell surface receptor αvβ6 is overexpressed in many cancers. Hausner et al. [90]
have demonstrated the feasibility of targeting αvβ6 in vivo by using PET and a new
radiotracer. With the new probes they were able to achieve excellent tumor retention and
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fast clearance of nonspecifically bound tracer, which resulted in the signal ratio of tumorpancreas greater than 23:1 in a mouse model of PDAC. Uptake of the radiotracers by
integrin αvβ6-expressing tumors was fast and intensive, contributing to the minimized offtarget background.

Finally, given that 95% of patients with PDAC carry 12th codon activating
mutations in their KRAS2 oncogenes, attempts have been made to image mutated KRAS2
mRNA activation by using PET and nucleic acid of mutant KRAS2 peptide: by using
IGF1R (insulin-like growth factor 1 receptor)-overexpressed AsPC-1 pancreas cancer
xenografts, a [64Cu]KRAS-IGF1 radio-hybridization probe resulted in improved tumor
contrast on PET, with an 8.6-fold increase in signal intensity within the human pancreas
cancer xenografts when compared with the contralateral muscle [91].

1.2 Current intraoperative imaging tools
A major limitation of the aforementioned imaging techniques, such as CT, MRI or
PET, is that they cannot be applied in intraoperative setting due to the altered positioning
of the body and tissue manipulation by the surgeon [92]. For brain cancer surgery, the use
of MRI-guided resection has become standard practice in most cases [93]. Unfortunately,
this method is time-consuming, costly with limited acceptance. Therefore, chances are
limited that MRI-guided resection will be widely-implemented outside the field of brain
tumor surgery. Currently, the only tools available for the surgeon to ensure complete tumor
resection are visual and tactile information, frozen-section analysis by a pathologist, and
intraoperative US.
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The clinical standard-of-care for achieving negative margins have severe
limitations. Visual inspection is limited in detecting small tumors. Palpation is limited in
sensitivity and is increasingly not used due to the utilization of robotic laparoscopic surgery.
Intraoperative frozen section analysis is limited to certain tissue types, and is timeconsuming and prone to sampling error. Frozen section analysis is discrepant with
permanent pathology in 5–15% of cases [94].

Currently, the only intraoperative imaging technique that can help the surgeon
delineate PDAC from its surrounding tissue is anatomical intraoperative US. The ability to
provide high resolution real-time imaging, along with accurate lesion detection, has
established its role in PDAC surgery. Intraoperative US can be used for surgical guidance
and localization of lesions, for determining resectability, surgical planning, differentiation
between cystic and non-cystic lesions, and metastatic survey [95], [96]. However, it also
has disadvantages as being less reliable to detect superficial and small lesions [97]. Another
disadvantage is operator dependence: substantial training and experience are needed for
generating and interpreting useful images for intraoperative surgical decision-making.

1.3 The need for advanced molecular imaging in PDAC
To improve detection and patient stratification for treatment, it is imperative to
develop and improve imaging methods that specifically recognize cancer. In current
practice, the accurate identification of tumors is mainly subjective and relies heavily on the
surgeon’s experience leading to a significant variability in surgical outcomes [98]. This
inability to exactly identify tumors intraoperatively could result in: 1) incomplete resection
of tumors that could otherwise have been resected completely; 2) attempts to resect tumors
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which should have been identified as locally advanced tumors; 3) incomplete lymph node
removal due to lack of knowledge of the involved or potentially involved lymph nodes,
and 4) resection of the primary tumor in the presence of visually occult micrometastases.
In each of these situations, patients undergo operations with little or no oncological benefit,
but with a high risk of deteriorated life quality due to surgeries in their end stage of life.
There are two other challenges a surgeon might faces. First, both the benign pancreatitis
and malignant PDAC have abundant stroma, and therefore both entities are difficult to
distinguish using conventional imaging techniques. Second, the introduction of
neoadjuvant treatment regimens such as FOLFIRINOX (a combination of chemotherapy
drugs fluorouracil, leucovorin, irinotecan and oxaliplatin) was reported to increase the
tumor resectability by 51% after 4 months of treatment [99]. However, conventional
preoperative imaging modalities are often not able to differentiate between viable tumors
and chemoradiation-induced tumor necrosis and fibrosis [100]. Neotreatment effects make
differentiation between (vital) tumor and fibrotic pancreatic tissue even harder for surgeons
during the operation.

Tumor-targeted molecular imaging could provide crucial information in these
situations (Figure 2). Molecular imaging can either be performed by using conventional
imaging techniques in combination with tumor-specific imaging agents, or by the
development of novel imaging techniques, such as fluorescent, photoacoustic and Raman
optical imaging. Currently, several first-in-human clinical trials are conducted using these
techniques in pancreatic cancer patients.
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Figure 2. A schematic overview of the principle of tumor-targeted imaging in pancreatic cancer,
showing the most promising imaging modalities for early diagnosis and improved surgical
treatment, and most promising targets for this purpose. Avβ6; Integrin αvβ6, CEA;
Carcinoembryonic Antigen, EGFR; Epidermal growth factor receptor, Thy1; Thy-1 cell surface antigen,
uPAR; Urokinase receptor, VEGFR2; Vascular endothelial growth factor receptor 2, Plec1; Plectin 1,
Cath E; Cathepsin E. Reprinted from Pancreas, 47 (6), 675–689, W. S. Tummers, J. K. Willmann, B. A.
Bonsing, A. L. Vahrmeijer, S. S. Gambhir, and R.-J. Swijnenburg, “Advances in Diagnostic and
Intraoperative Molecular Imaging of Pancreatic Cancer,” Copyright (2018), with permission from
Wolters Kluwer Health.

1.4 Tumor-targeted molecular imaging strategies for PDAC
A molecular imaging approach using imaging agents that target molecular features
of cancer could lead to more precise diagnoses [101]. The common consensus is that PDAC
evolves from precursor lesions and transform into invasive carcinoma through a multistep
process, which involves the progression from pancreatic intraepithelial neoplasia (PanIN)
into PDAC [102]. Genetic alterations, such as mutations in the KRAS oncogene or p53,
DPC4, and BRCA2 tumor suppressor genes affect a core group of signaling pathways. The
processes that are altered in PDAC lead to the expression of specific biomarkers, and these
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changed biomarkers may serve as targets for tumor-specific imaging [103]. Potential
biomarkers for tumor-specific targeting must possess certain characteristics such as diffuse
upregulation through tumor tissue, strong upregulation compared to the expression in
normal and surrounding tissue, and localization on the cellular membrane [104], [105]. An
effective molecular imaging agent needs to demonstrate a high ratio of specific to nonspecific binding to make sure the signal truly reflects the molecular imaging target.

A molecular imaging agent is typically comprised of a targeting component and a
signaling component. The main purpose of a molecular imaging agent is to interrogate and
report back about a specific target (or targets) of interest during the course of a molecular
imaging study. It is important to note that there are some molecular imaging techniques
such as Raman Spectroscopy (RS) and coherent anti-stokes Raman scattering microscopy
[106] that do not necessitate the introduction of an exogenous agent for visualizing certain
biochemical targets and pathologies. In most other cases, a molecular imaging agent
designed to specifically interact with one or more molecular targets needs to be first
introduced to study biochemical processes. For the most part, the development of such an
agent is not straightforward and is therefore a key rate-limiting step in molecular imaging.

Ideally, a molecular imaging agent should have the following characteristics: good
ratio of specific to non-specific binding, high selectivity for biochemical target/process of
interest, suitable pharmacokinetics, excellent in vivo stability (metabolism should not
negatively affect functional binding), good safety profile (lack of toxicity to subject),
potential for clinical translation, time and cost effective synthesis, signal amplification, and
multiplexing capabilities [107].
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For an effective imaging agent, the ratio of specific to nonspecific binding needs to
be high. In the case of imaging low-density receptors, this ratio should be >3 [108]. High
selectivity is also an important factor, whereby the imaging agent should possess the
greatest affinity for, or functional interaction with, the intended binding site/process, but
only negligible interaction with other sites/processes [109]. Nonspecific binding occurs
due to the adhesion of an imaging agent to proteins and lipids. Although it is challenge to
predict the extent in vivo, it is generally believed that the lipophilicity of an imaging agent
is proportional to the degree of nonspecific binding [108]. Therefore, lipophilicity is an
important aspect to consider whilst designing an imaging agent.

A molecular imaging agent should display suitable pharmacokinetics (PK) for
visualizing the biochemical target/process of interest. The rate of absorption and delivery
to the target site, metabolism, excretion, and whether it will be reabsorbed in the
enterohepatic circulation all factored in. Ideally, an imaging agent would be preferred to
have rapid and specific interaction with its target, fast blood clearance, urinary excretion,
and persistent, high accumulation at the target site. Size, charge and hydrophilicity play an
important role in determining the PK profile [107], [110]. Generally, one aims to match
the half-life of an imaging agent's signaling component to its PK process of interest.

There are numerous categories of available molecular imaging agents including
small molecules, peptides, aptamers, antibodies, engineered protein fragments, NPs, or
micro-sized contrast agent. Each of these types of agents is different in size and thus
possesses different PK characteristics.
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1.4.1 Small molecules
Small molecules play an important role in molecular imaging. The small size of
chemical entities that are 500 Da means they can access and identify a large range of
molecular targets (including intracellular and CNS targets). In addition, they are generally
less likely to suffer from unfavorable biodistribution-related issues than those with large
molecular weight (MW). Typically, small molecules can escape the vasculature easily,
either passively or actively through biological barriers, interact with their targets, and clear
from circulation in a short period of time [111]. The main drawback is the time-consuming
process to discover, synthesize, and validate, and often does not afford many successful
imaging agents. Also, due to their small size, there are limitations concerning the type of
signaling component that can be attached (and hence modality that can be used). For
example, one cannot usually conjugate a large fluorophore to a small molecule without
altering the PK and targeting properties of the molecule.

1.4.2 Peptides
Peptides have emerged as a prominent class of molecular imaging agents. The
application of solid-phase peptide synthesis and phage display libraries have led to rapid
high-throughput synthesis and screening of peptide-based molecular imaging agents[112].
Peptides are easily modified, fairly small in size (up to 15 amino acids), and rapidly
clearable. They have a number of advantages over small molecules, including superior
selectivity and specificity, and tolerable for chemical modifications without altering
binding properties or kinetics [113]. Although peptides generally display a lower affinity
when compared to antibodies, they are more stable at room temperature and penetrable to
tissues/tumors [114]. Additionally, peptides are less likely to induce immunogenic
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reactions [115] compared with antibodies and are more cost effective to produce, as peptide
synthesis is much cheaper than recombinant production techniques.

Peptide imaging agents have been reported to visualize a range of targets, including
integrins [107], [116], matrix metalloproteinases [117], [118], caspases [119], [120]
somatostatin receptors [121], [122], and gastrin releasing peptide receptors [123], [124].
The main disadvantage of using peptides as target moiety is that they are prone to rapid
proteolytic degradation in vivo with a short plasma half-life. In addition, peptides used for
PET and SPECT imaging mostly require prosthetic groups [125] for radioisotope labelling,
which increased the complexity and time for synthesis, and might altered the structure
necessary for efficient binding.

1.4.3 Aptamers
Aptamers are defined as single-stranded DNA or RNA oligonucleotides that bind
to their targets with a high degree of specificity and selectivity [126]. The superior targeting
capabilities of aptamers, comparable to that of antibodies, along with their relative ease of
synthesis [127], high diversity, and inexpensive production, have made these 5-15 kDa
chemical entities attractive candidates for molecular imaging. There are several published
articles describing the labeling of aptamers with either fluorophores or radioisotopes
imaging purpose [128], [129]. However, these agents have not yet been evaluated in living
subjects. There are a few key limitations associated with using aptamers as molecular
imaging agents, including 1) low in vivo stability due to serum degradation, 2) poor
membrane passage due to their size and charge (i.e., PK is rather variable and difficult to
predict), 3) small size leading to short half-life.
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1.4.4 Antibodies
Monoclonal antibodies (mAbs), also known as immunoglobulins, are highly
specialized, ∼150 kDa, Y-shaped proteins [130]. Unlike small molecules and peptides,
mAbs are not restricted to interacting with binding pockets or active sites, but instead can
bind adhesion molecules, activation markers, antigens, and receptors [131]. Currently,
there are over 20 FDA-approved mAb therapeutic agents and greater than 8 radiolabeled
mAbs approved for SPECT molecular imaging [132]. Current efforts in the field of
antibody-based molecular imaging agents are focused towards developing chimeric,
humanized, or fully human mAb imaging agents (to eradicate immunogenicity issues) both
from a diagnostic and therapeutic standpoint. Although there are many promising mAbbased molecular imaging agents emerging for a range of different imaging platforms, their
versatility and usefulness has remained fairly limited due to their long residence in blood
and restricted ability to transverse biological barriers (e.g., the blood-brain barrier and cell
membranes).

1.4.5 Nanoparticles (NPs)
In terms of imaging agents, NPs are emerging as an exciting new set of diagnostic
tools, capable of both passive and active targeting. Since there exist a wide range of
different shaped NPs of varied size and composition with unique surface properties and
reactivities, it is not surprising that NPs are among the most flexible imaging agents with
respect to the types of imaging modalities they are compatible with. Although there is no
fixed size constraint for the NP, people typically consider them to be on the order of ∼10100 nm, and no larger than 1000 nm. Generally, NPs are larger than many proteins and
small molecules, yet smaller than cells. Their relatively large size (compared with small
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molecules and many proteins) means they are often taken up by the reticuloendothelial
system (RES). Polymer-coated “stealth” NPs, on the other hand, can avoid entrapment by
the RES from hours to days [133]. Due to their high surface area-to-volume ratio, many
NPs are able to carry substantial payloads of targeting and/or signaling moiety. This means
that for each NP bound to a target, there can be signal magnification compared with the
signal from singular molecular imaging agent. This multivalent mode is known as avidity
and is particularly important in cases where sensitivity of the imaging modality is the main
limitation (e.g., MRI). Also, due to the high density of targeting moieties that are attached
to the NP surface, they have a greater chance to bind to the target. However, the advantages
of NPs come at the cost of fewer particles being delivered to the target site, comparing to
the delivery of small molecules. This is because NPs rapidly accumulated in liver, spleen,
and bone marow following their administration, and thus less of the dose is “available” for
targeting/delivery. Key types of NPs that are currently reported in molecular imaging such
as: single-walled carbon nanotubes [134], quantum dots [135], gold NPs [136],
superparamagnetic iron oxide NPs [137].

As exciting as NP-based imaging agents are, the limitations should be noted. The
size can be a key factor concerning their nature of polydispersity. Delivery of sufficient
concentration remains a challenge, primarily due to competition of RES uptake. Other
issues including slow clearance, thereby making it difficult to distinguish NPs that bound
to the target(s) from unbound NPs. Also, heterogeneity make it challenging to predict bioperformance as it is for small molecules, in specific aspects of characterization,
toxicological study and potential translation. Whereas the growing number of approved
therapeutic NPs [138] (such as Doxil, a liposome drug delivery system used to treat AIDS-
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related Kaposi's sarcoma and ovarian cancer) is currently serving as a template for the
clinical translation of functionalized NPs for molecular imaging purposes, thus
accelerating progress in this area.

1.4.6 Multimodality imaging probes
Multimodality probes are imaging agents capable of being detected via two or more
different imaging modalities simultaneously. Since these types of probes have the potential
to generate multiple readouts concerning the same biological phenomenon, they could be
of great value for numerous clinical and basic research applications. Multimodality probes
are

predominately

NP-based

(e.g.,

superparamagnetic

iron

oxide,

gold

nanospheres/nanorods, single/multi-walled carbon nanotubes, quantum dots (QDs));
however, there are also examples of engineered proteins [139], peptides [140], and small
molecule-based probes [141]. Typical probes include MRI/optical, MRI/PET,
MRI/SPECT, PET/optical, SPECT/optical, and photoacoustic imaging (PAI)/Raman
imaging. The main challenge involved in developing and using multimodality imaging
probes is that some modalities (such as PET and MRI) differ in their sensitivities by more
than three orders of magnitude [142]. Hence, a combined probe can lead to a compromise
compared with using each component separately [143].

1.5 Physiologic concerns for developing NP imaging probes
NPs and nano-sized molecules (NMs) possess enormous potential as diagnostic
imaging agents and hold promise for the development of multimodality agents with both
imaging and therapeutic capabilities [110]. Currently, some of the most promising NPs that
are under investigation contain heavy metals, which not only pose risks for systemic
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toxicity, but prolonged particle retention that may interfere with imaging and diagnostic
tests. Creating particles with optimal clearance characteristics will minimize toxicity risks
and disease concerns by reducing the duration of exposure to these agents. Given that many
types of NPs possess easily modifiable surface chemistry, if characteristics of NPs and
NMs associated with optimal clearance were well established, it would be feasible to create
agents with more favorable clearance properties. Properties known to affect clearance
include particle composition, size, shape, surface chemistry and charge – all of which are
tunable for specific applications.

1.5.1 Vascular delivery
Upon intravenous administration, NPs and NMs enter the vascular system and are
distributed to the organs and peripheral tissues of the body. Within the vascular
compartment these particles or molecules encounter blood cells, platelets, coagulation
factors and plasma proteins. Depending on the size and charge, NPs and NMs may undergo
adsorption or opsonization by serum proteins. In addition to enhancing particle recognition
by the host immune system, adsorption/opsonization alters the effective size of the particle
and results in a particle diameter referred to as the in vivo hydrodynamic diameter (HD),
which may be considerably larger than the in vitro diameter. The HD affects blood
clearance and therefore blood half-life and whole body half-life. The HD is inversely
related to rate of glomerular filtration and is directly related to blood and whole body halflife.

The vascular endothelial cell monolayer acts as a dynamic and semi-selective
barrier that regulates transportation of fluid and macromolecules between the vascular
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compartment and the extravascular space [144]. Although the structure of the endothelial
layer varies throughout the body, the effective pore size in normal intact endothelium is
approximately 5 nm [145]. NMs with an HD less than 5 nm achieve rapid equilibrium with
the extravascular extracellular space (EES), whereas larger particles experience prolonged
circulatory times due to slow transport across the endothelium. For example, intravenously
administrated human IgG (HD:11 nm) requires 24 h to equilibrate between the vascular
compartment and the EES [145], [146]. By contrast, smaller molecules such as the
radiocolloid dextran-Technetium 99 (HD < 4 nm) could establish rapid equilibration with
the EES owing to penetration of capillary fenestrae [147]. Similar behavior has also been
observed in the lymphatic vessels with NPs. Although the lymphatic vessel endothelial
layer is more permeable than that of the vascular endothelium because of its role in
clearance of macromolecules from the EES, particles up to or smaller than 6 nm in diameter
can flow easily into and out of the lymphatic vessels [148]. Therefore, the threshold of
nano-size diffusion from the lymphatics is slightly larger than the capillaries, yet still
comparable.

Modification of NP/NM characteristics such as size and surface chemistry can
significantly alter in vivo kinetic properties. For instance, PEGylation, the process of
molecularly attaching polyethylene glycols (PEG) with different MWs to the particle
surface groups, is one of the most widely used methods for improving particle
pharmacokinetic behavior [149]. The primary effects of PEGylation include prolongation
of plasma half-life, alteration of tissue distribution and particle elimination [149].
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1.5.2 Renal clearance
The kidney is capable of rapidly removing molecules from the vascular
compartment with their original form. Renal excretion represents a desirable pathway for
NP/NM clearance as is the minimal involvement of intracellular catabolism. This route
reduces the possibility of retention and cytotoxicity as compared with the hepatobiliary
system, in which intracellular enzymatic modification is standard. Thus renal clearance is
thought to be the preferred clearance route to minimize toxicity and agent retention. Renal
clearance of intravascular agents is a multifaceted process involving glomerular filtration,
tubular secretion and finally elimination of the molecule through urinary excretion.
Glomerular filtrate flows through the fenestrate, across the glomerular basement membrane
(GBM) and through the filtration slits. Among the key nanostructural dimensions is the slit
diaphragm, whose diameter is approximately 43 nm [150]. However, after considering the
combined effects of each layer of the glomerular capillary wall, the functional or
physiologic pore size is significantly smaller-only 4.5-5 nm in diameter [151].

Glomerular filtration is highly dependent on the molecule size and is referred to as
the filtration-size threshold [150]. Molecules with an HD of less than 6 nm are typically
filtered, while those more than 8 nm are not typically capable of glomerular filtration.
Filtration of molecules within the intermediate range (6-8 nm in HD) depends upon both
size and charge of the particle. The filtration-size threshold for globular proteins has been
well studied and is generally accepted to be less than 5 nm in HD. For example, inulin (HD:
3 nm) achieves 100% renal filtration with a blood half-life of only 9 minutes [152]. The
relationship between protein size and clearance is further demonstrated by antibody
clearance data. The stabilized V-region fragment of an antibody (HD: 4 nm) demonstrates
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100% renal filtration with a serum half-life of 5 minutes [153], as compared with the
antibody’s Fab’ fragment (HD: 6.0 nm), which achieves only 9% of effective filtration with
a serum half-life of 28 min [154]. Additionally, clearance of antibody fragments is more
rapidly than that of the intact antibody, which is not efficiently filtered and has a circulation
half-life up to days.

Renal filtration of globular proteins as a function of size provides an important
framework for the understanding of general properties of renal clearance. Nevertheless, the
physical properties of NPs differ from those of proteins in several ways: NP shape, surface
chemistry and interior charge is distinct; in addition, NPs can be synthesized with a nearspherical shape and identical surface chemistry [155]. Such differences may lead to distinct
renal handling of NPs compared with protein molecules. To evaluate the effect of these
characteristics on size threshold of filtration, clearance studies of poly(aminoamine)
dendrimer-based NPs with homogenous chemical properties and near-spherical shape were
conducted. Results showed that poly(aminoamine) dendrimers with the average diameter
of 5.4 nm demonstrated effective filtration [156]. This filtration-size threshold is similar to
that of conventional macromolecules. Additionally, renal clearance studies in mice using
QDs revealed that renal excretion was observed for those with HDs ranging from 4.36 to
5.52 nm [145]. QDs larger than 8 nm (HD: 8.65 nm) did not demonstrate renal filtration
but instead exhibited uptake in RES and lung [145]. The relationship between HD, renal
clearance and total body retention was determined to be sigmoidal with the 50% point for
total body clearance at 4 h achieved with an HD of 5.5 nm [145]. These results also
suggested that the size threshold for renal filtration of NPs may be comparable to proteins
and other NMs. With this in mind, it is reasonable to conclude that NPs capable of being
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synthesized with a diameter of less than 8 nm, such as dendrimers, carbon nanotubes, silica
particles and QDs, can undergo renal clearance if other modifiable parameters (surface
charge and chemistry) are optimized for this excretion pathway.

In addition to size, surface charge is also an important determinant of the renal
handling of NP/NMs. The effect of molecular charge on renal filtration is due to at least
two factors: potential interactions between charged molecules and serum proteins, resulting
in increased HD [145], as well as the electrostatic interactions between charged molecules
and fixed charges within the glomerular capillary wall [150]. Studies using QDs as the
model for in vivo NP clearance revealed that purely anionic or cationic charge was
associated with serum protein adsorption [145]. Adsorption resulted in an increase in HD
to more than 15 nm, dramatically reducing renal filterability [145], [157], [158].
Neutralization of the NP surface via PEGylation was shown to be effective in preventing
serum protein adsorption. However, it was reported that synthesizing PEGylated QDs with
an HD of less than 10 nm was not possible [145]. Therefore, PEGylation also dramatically
reduces particle renal filtration. Interestingly, zwitterionic coatings were shown to prevent
serum protein adsorption and were associated with the highest solubility and smallest HD
[145].

Studies evaluating the effect of molecular charge on glomerular filtration of
similarly sized molecules have shown that filtration is the greatest for cationic molecules,
followed by neutral molecules, while anionic molecules are least readily filtered [150].
Direct comparison of varied charged molecules about the glomerular filtration has been
studied using charge-modified Fab’ fragments (HD: 6 nm). Weakly anionic Fab showed
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drastically less filtration compared with those that are weakly cationic [159]. Chargeselective filtration is attributed to fixed negative charges within the capillary wall [150]. It
is worth mentioning that molecular charge is of particular significance for the filtration of
molecules within the 6-8 nm range, as these particles are not small enough to undergo
charge-independent filtration, yet may still be filtered if molecular charge is favorable.

The final step in renal processing occurs at the proximal tubule where filtered
molecules may be resorbed from the tubular fluid and previously unfiltered molecules may
be actively secreted into proximal tubule lumen. Particle behavior at the proximal tubule is
an important consideration because some molecules, such as glucose, achieve 100%
reabsorption thus negating the effects of glomerular filtration. While other agents, such as
heavy metals, are highly toxic to proximal tubule cells and may potentially cause renal
damage including acute tubule necrosis, interstitial nephritis and even renal failure.
Research evaluating NP/NM reabsorption at the proximal tubule is currently limited.
Studies by Kobayashi et al. [159] indicate that some polyamine dendrimers may undergo
proximal tubule reabsorption, but further investigation of this issue is needed to gain insight
into the renal toxicity profile of NP. Evaluation of agent behavior at each step in renal
processing might lead to agents with optimal biocompatibility and clearance properties.

1.5.3 Hepatic clearance
The hepatobiliary system represents the primary route of excretion for particles that
do not undergo renal clearance. Liver provides the critical function of catabolism and
biliary excretion of blood-borne particles, serves as an important site for the elimination of
foreign substances and particles through phagocytosis [160]. Those NPs and NMs that are
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excreted via the biliary system are catabolized first through hepatocytes. All physical or
chemical catabolites must be accounted for when considering total hepatic clearance.
Therefore, the hepatic clearance is more complex than renal clearance. Phagocytic Kupffer
cells have ciliated borders and stellate branches that serve as highly adapted mechanical
traps for the removal of unwanted substances from the blood including foreign colloidal or
particulate substrates [160]. Kupffer cells possess numerous receptors for selective
endocytosis of opsonized particles (receptors for complement proteins and for the Fc part
of IgG) [160]. Hepatocytes play an important role in liver clearance through endocytosis
and enzymatic breakdown of foreign particles. Although the phagocytic capacity of
hepatocytes is much less than that of Kupffer cells, these cells represent an important
physiologic pathway for foreign particle processing and are potential sites for induced
toxicity [160]. Furthermore, hepatocytes are within the pathway for biliary excretion and
therefore particles processed by these cells are potentially excreted into the bile. Kupffer
cells are part of the RES and rely exclusively on intracellular degradation for particle
removal. Similar to all phagocytic cells of the RES, particles that are not broken down by
intracellular processes will remain within the cell and will therefore be retained longer in
the body.

Liver is functionalized to efficiently capture and eliminate particles on the scale of
10-20 nm for the clearance of viruses and other small particles. As a result of this adaptation,
agents within this size range often undergo rapid liver uptake [145]. To achieve adequate
retention times, NPs may require modification to prevent or reduce opsonization.
Molecular modification via PEGylation is a widely used mechanism to decrease first-pass
extraction and extend NP circulation. Interestingly, although uptake of particles from the
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blood to the liver may occur relatively fast, hepatic processing and biliary excretion of
these particles are pretty slow, which contributes to the prolonged retention of NPs within
the liver parenchyma itself [145].

1.6 Intraoperative molecular imaging techniques: potential for
improved intraoperative performance
1.6.1 Fluorescence molecular imaging
Over the last few years, intraoperative imaging technologies using near-infrared
(NIR) fluorescence have made enormous progress. The volume of publications in this field
has increased by eight-fold in the literature in the last 10 years [161]. Benefit of
fluorescence imaging using NIR fluorescent is the ability to image in real-time without
impeding the current clinical workflow. If surgeons were able to resect tumors and preserve
normal structures more easily, time of surgery could be shortened, thereby reducing
anesthesia time and associated risks. Furthermore, this could subsequently lower the rates
of recurrence and complications, which would improve patient outcomes and even save
costs [92]. Fluorescence imaging has already been established as a powerful tool for
guiding precise intraoperative positioning in multiple types of cancer such as liver
metastases [162], breast cancer [163], ovarian cancer [164], sentinel lymph node in
melanoma [165] , vulvar cancer [166], [167], and cervical cancer [168], [169]. However,
only the non-specific dyes methylene blue (MB) and indocyanine green (ICG) are
approved for clinical use by FDA. Second window ICG [170] accumulates in the invasive
pancreatic malignancies and provides real-time feedback during pancreatectomy [32]. NIR
imaging could help to assess the tumor response to neoadjuvant therapy as well [32]. ICG
was also found to identify residual disease during anterior mediastinal tumor resection
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[171], and allows location of pulmonary, pleural and thoracic malignancies during surgery
[172].

In order to improve clinical benefit of fluorescent imaging, incorporation of tumorspecific imaging agents will be essential. Recently, two first-in-human clinical studies have
been reported to use tumor-specific intraoperative imaging as the visual aid for the
resection of PDAC. They are antibody-based contrast agents including targeting
carcinoembryonic antigen (CEA) with SGM-101 [173] and EGFR with cetuximabIRDye800 [174]. In both cases successful PDAC imaging could be appreciated as well as
the specific identification of abdominal metastases. These trials show the proof-of-concept
that this imaging technique is possible for aiding the resection of PDAC, despite the idea
that the dense stroma of PDAC will restrict the access of targeted-imaging agents and
therapeutics [175].

1.6.2 Molecular-targeted agents for fluorescent molecular imaging
As described above, only agents targeting the CEA and EGFR receptor have been
reported to be used in clinical trials for specific NIR fluorescent imaging of PDAC. With
cetuximab-IRDye800, it was even possible to identify PDAC from peri-tumoral
inflammation [176]. Nevertheless, only preclinical work is performed for the identification
of tumor-specific targets. Gao et al. [177] synthesized an integrin αvβ6-targeted NIR
fluorescent dye-labeled contrast agent and investigated it for targeted theranostics. The
image probe bound to integrin αvβ6 in vitro and in vivo with high affinity, and when used
for surgical guidance, completely secured the tumor removal. Additionally, small size
conferred its easy extravasation and fast excretion. Zhang et al. [178] reported an optical
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imaging agent that’s suitable for both fluorescent and photoacoustic imaging. The imaging
probe consists of a cysteine knottin targeting αvβ6 that conjugated to the NIRF dye, which
is detectable in integrin αvβ6-positive tumors both in vitro and in vivo by photoacoustic
and fluorescence imaging.

Aside from developing passive and active targeting probes, site-activatable contrast
agents were also reported. Cathepsin E is a tumor-associated intracellular non-lysosomal
aspartic proteolytic enzyme which presents in PanIN lesions and PDAC but not in normal
pancreatic tissue [179]. Cathepsin E-activatable imaging probes are fluorescence quiescent
in native state, but become fluorescent upon Cathepsin E cleavage [179], [180]. Activatable
imaging probes demonstrate several advantages. The native state of the probe is optically
silent, thereby minimizing background fluorescence and enhancing tumor-to-background
ratio. Moreover, probes can be designed to be activated by varied proteases according to
the tumor histological characterization [181], [182]. The first-in-human trial was reported
by Whitley et al. [183], who assessed the imaging efficacy of protease-activatible
fluorescent imaging probe for the detection of soft tissue sarcoma and breast cancer, thus
demonstrated the potential of activatable probes for clinical translation.

Here, we report the preclinical screening of a series of HA-based macromolecular
NIRF contrast agents, for the specific detection of PDAC and associated metastases. HA
platforms utilize a natural polymer with a tropism to a receptor (CD44) overexpressed in
many cancers, and thus these carriers do not require separate targeting with an antibody or
peptide, which may translate into a lower cost of the treatment and a more stable
formulation compared to the antibody-based contrast agents. The hypothesis is, by
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investigating the effects of HA molecular weight and NIRF properties, the leading contrast
agents will reduce the contrast agents in non-specific organs and improve probe specificity
for malignancy detection.
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CHAPTER 2: NANOFORMULATION OF ICG FOR
THE INTRAOPERATIVE PROBING OF
PANCREATIC TUMOR AND METASTASES WITH
REDUCED TOXICITY
2.1 Introduction
Pancreatic ductal adenocarcinoma (PDAC) is highly lethal due to the advanced
stage at diagnosis, with a median overall survival of 15 months and 5-year survival rate of
13% [184]. Detection and surgical resection at earlier stages increases 5-year survival to
31.7  3.6 months [185]. Enhanced contrast can aid surgeons to confirm suspected
pancreatic masses and elucidate positive margins [186]. Therefore, improved tumor
imaging techniques that can better recognize cancerous lesions are essential to improve
complete removal of PDAC and subsequent survival. At present, tumor localization and
assessment of disease extension are made with visual inspection and palpation [187], which
can lead to incomplete resection or unnecessary removal of healthy tissue. Using tumorspecific contrast agents, image-guided surgery facilitates real-time, intraoperative, and
visual identification of pancreatic tumors with improved discrimination of malignant and
normal tissue [92].
Clinically available preoperative imaging modalities, such as computed
tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography
(PET), are critical to surgical planning. However, translating these results to the operating
room is difficult due to altered body positioning, tissue manipulation, and lack of sensitivity
to detect microscopic lesions [188]. Therefore, an intraoperative imaging technique with
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high accuracy and sensitivity is needed to fill the gap between preoperative and
intraoperative reality. Current techniques that are used to assess pancreatic tumor extension
intraoperatively, such as ultrasonography (US) and intraoperative frozen-section analysis
(IFSC), have limitations. Substantial experience is required to generate and interpret useful
US images during pancreatic cancer surgery [188]. Although IFSC is useful in ensuring
negative margins, it has a negative predictive value of 50% for examining pancreatic
lesions that could result in poor histological diagnosis and determination of resectability.
Clinically available preoperative imaging modalities, such as CT, MRI, and PET,
are critical to surgical planning. However, translating these results to the operating room is
difficult due to altered body positioning, tissue manipulation, and lack of sensitivity to
detect microscopic lesions.[188] Therefore, an intraoperative imaging technique with high
accuracy and sensitivity is needed to fill the gap between preoperative and intraoperative
reality. Current techniques that are used to assess pancreatic tumor extension
intraoperatively, such as US and intraoperative frozen-section analysis (IFSC), have
limitations. Substantial experience is required to generate and interpret useful US images
during pancreatic cancer surgery [188]. Although IFSC is useful in ensuring negative
margins, it has a negative predictive value of 50% for examining pancreatic lesions that
could result in poor histological diagnosis and determination of resectability [189].
Fluorescence imaging offers a potential method to detect pancreatic cancer
intraoperatively to maximize malignant tissue resection. FIGS can detect fluorescent
contrast agents with high sensitivity and spatial resolution, which minimizes contrast agent
dose and allows real-time determination of tissue status.[190], [191] For example,
AlexaFluor488 conjugated CA19-9 antibody was used to detect primary tumor and splenic
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and liver metastases of pancreatic cancer during surgical navigation.[192] Furthermore,
near infrared (NIR) FIGS can minimize interference caused by tissue auto fluorescence,
scattering, and absorption, allowing relatively deep detection of contrast agent [193], [194].
Metidi et al. [195]demonstrated usage of MMP-2 and MMP-9 cleavable peptides
conjugated Cy7 for accurate labeling of pancreatic tumors with FIGS in an orthotopic
human xenograft mouse model, this resulted in a lower metastatic burden and decreased
distant recurrence compared with resection surgery under standard bright light. Yang et al.
[196] used magnetic iron oxide NPs modified with Cy5.5 conjugated ATF (amino-terminal
fragment) of uPA (urokinase plasminogen activator) for surgical detection of pancreatic
cancer lesions. Combined, fluorophore conjugated monoclonal antibody probes were used
in animal models of pancreatic cancer with improved specificity, however, their efficacy
was limited by naturally existing cellular targets that are often heterogeneously expressed
in tumors and possibly in low abundance compared to background signals.[197] Therefore,
a more generally applicable NIR fluorescent (NIRF) probe could have potential for NIR
FIGS for reducing PDAC tumor burden.
Hyaluronic acid (HA), the principal ligand for CD44, possesses many attractive
features, including acting as a capping agent to achieve targeted and controlled payload
release, prolonging the blood circulation time, and increasing the physiological stability
and biocompatibility of drugs [198]–[200]. Incorporation of HA into a delivery system can
reduce plasma protein adsorption and immunogenicity of associated protein upon i.v.
administration, further highlighting potential as biocompatible and safe drug carrier [201]–
[204].
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Here, we report the use of a HA nanoformulation of ICG, termed NanoICG, for
tumor detection in an orthotopic, syngeneic model of pancreatic cancer. ICG is an FDAapproved NIR fluorophore that can be detected through up to 8 mm of tissue [205]–[207].
On the other hand, HA is a major component of extracellular matrix that participates in cell
proliferation, wound healing, and cancer metastasis [208]. With modifiable chemical
groups such as carboxylate, N-acetylglucosamine, hydroxyl, and acetyl moieties, HA is
readily available for chemical conjugation [209], [210]. Recently, we reported that
NanoICG increased NIR tumor signal by 2.28- and 2.25-fold compared to ICG in MDAMB-231 xenograft [211] and 4T1 syngeneic orthotopic [206] breast tumor models,
demonstrating potential for sensitive tumor detection. In this study, NanoICG was
compared to ICG as a NIR FIGS contrast agent for the intraoperative detection and
contrast-enhancement of pancreatic cancer in a syngeneic, orthotopic model. Results from
in vitro and in vivo studies indicated that NanoICG is a safe contrast agent that can
potentially be used in pancreatic tumor detection and surgical resection.

2.2 Methods
2.2.1 Materials ICG, luminol, and zymosan A were purchased from Sigma-Aldrich (St.
Louis, MO). 10-20 kDa sodium hyaluronate was purchased from Lifecore Biomedical
(Chaska, MN). HPNE cell line was provided by Dr. Michel J. Ouellette from University of
Nebraska Medical Center, while the KPC cell line was shared by Dr. Hollingsworth. HL60 cells were purchased from ATCC (Manassas, VA). HPNE cells were grown in 70%
DMEM with 25% medium M3, 5% FBS, 20 ng/mL human recombinant EGF, 1%
penicillin/streptomycin; KPC cells were grown in DMEM with 10% FBS and 1%
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penicillin/streptomycin, HL-60 was maintained in IMDM with 20% FBS. Cell counting
kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies Inc. (Rockville, MD).
Calcein AM was purchased from Invitrogen (Carlsbad, CA). 10-week-old female
C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor, ME). 5.0 chromic
gut and 5.0 nylon surgical sutures were purchased from Johnson & Johnson (Somerville,
NJ). Comprehensive diagnostic profile reagent rotor was purchased from Abaxis (Union
City, CA). All the other chemicals were purchased and used at analytical grade.

2.2.2 Preparation and Characterization of NanoICG The synthesis of
amphiphilic HA-aminopropyl-1-pyrenebutanamide (HA-PBA), preparation of NanoICG
from the entrapment of ICG during HA-PBA self-assembly, and quantification of ICG in
NanoICG were performed based on the literature.[206], [211]

The mean hydrodynamic diameter and zeta-potential of NanoICG was determined
using a Zetasizer Nano instrument (Malvern, Worcestershire, UK). NanoICG was prepared
at 0.34 mg/mL for size determination and 0.06 mg/mL for the determination of UV-visible
absorption and fluorescence emission. An Evolution 220 spectrophotometer (Thermo
Fisher Scientific, Madison, WI, USA) was used for scanning absorbance spectra (600–900
nm) and a FluoroMax-4 spectrofluorometer (Horiba, Edison, NJ, USA) was used for
quantifying fluorescent intensity of ICG, NanoICG, and disassembled NanoICG.

2.2.3 Cytotoxicity The cytotoxicity of NanoICG and empty NP (self-assembled HAPBA) were tested using the CCK-8 assay (Dojindo; Rockville, MD). HPNE and KPC cells
were seeded in 96-well plates at a density of 25,000 cells/well and allowed to adhere for
24 h. Empty NP and NanoICG were dissolved in DMEM at different concentrations (0,
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0.01, 0.05, 0.1 mg/mL) and 200 µL was added to each well. Cells were treated for 24 h and
washed twice with PBS. Next, 100 L of 10% CCK-8 reagent in DMEM was added to
each well and incubated at 37 °C. After 50 min, absorbance of each well was measured at
450 nm using a Synergy HTX multi-mode plate reader (BioTek, Winooski, VT, USA).
Relative viability was calculated as the absorbance of wells from treated cells divided by
the absorbance from wells with untreated cells.

2.2.4 Chemotaxis A chemotaxis assay was adapted from procedures from the National
Cancer

Institute’s

Nanotechnology

Characterization

Laboratory

(NCL)

(https://ncl.cancer.gov/resources/assay-cascade-protocols): ITA-8. Briefly, HL-60 cells
were suspended in serum-free IMDM (SM) and incubated overnight prior to use. 1×106
viable cells/mL (as determined by trypan blue) were dispersed onto a MultiScreen filter
plate with 3 m polycarbonate membrane (Merck Millipore, Germany) at 50,000 cells/well.
Test samples (150 µL) were added in the feeding tray. The filter plate and feeding tray
were gently assembled and incubated for 4 h. After incubation, Calcein AM (CAM)
working solution was added to appropriate wells and incubated for 1 h. The solution was
then transferred to the optical bottom plate (Thermo Fisher Scientific, Rochester, NY, USA)
on a fluorescent plate reader with 485 nm excitation/535 nm emission. Fold increase of
chemotaxis was calculated as follows:

Background Chemotaxis = Mean FUSM/CAM-Mean FUSM/PBS

Sample Chemotaxis = Mean FUTS/CAM-Mean FUSM/PBS

Fold Increase of Chemotaxis = Sample Chemotaxis/Background Chemotaxis
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where Mean FUSM/CAM = fluorescence units of HL-60 treated with SM and CAM, Mean
FUSM/PBS = fluorescence units of HL-60 treated with SM and PBS, and Mean FUTS/CAM =
fluorescence units of HL-60 treated with test samples and CAM.
The theoretical plasma concentration (TPC) of ICG and NanoICG was calculated
based on the dose administered to mice below.[212] Calculating formula was adapted from
NCL Method ITA-8. TPC of empty NP were based of the mass ratio of HA matrix in
NanoICG. The concentrations for 10 × TPC, 1 × TPC, 1/5 × TPC and 1/25 × TPC of ICG
were 5.1 M, 0.51 M, 0.10 M, 0.02 M, respectively; the concentrations for 10 × TPC,
1 × TPC, 1/5 × TPC and 1/25 × TPC of NanoICG were 38 g/mL, 3.8 g/mL, 0.76 g/mL,
0.15 g/mL, respectively. The same concentrations were used in the phagocytosis assay.

2.2.5 Phagocytosis Phagocytosis was assessed according to NCL ITA-9. The multimode reader and 96-well plate were pre-warmed to 37 °C. HL-60 cell concentration was
adjusted to 1×107 viable cells/mL (as determined by trypan blue) with complete medium.
100 L of cell suspension was added per well. 100 L of controls or test samples were
added to pre-warmed wells, followed by 100 L of luminol working solution (250 µM in
PBS). A positive control was prepared by reconstituting zymosan A in PBS with 20%
pooled normal human AB serum (Innovative Research, Novi, MI, USA) to a concentration
of 2 mg/mL. After mixing, 100 L of cell suspension was added in sample wells and mixed
thoroughly. The kinetic reading process was 1.5 h with 2.1 min reading intervals. The area
under the curve (AUC) for each kinetic reading curve from each well was calculated as
phagocytic potential.

2.2.6 Tumor model induction All animal studies were performed under an approved
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UNMC Institutional Animal Care and Use Committee protocol and procedures followed
were in accordance with the institutional guidelines per the Guidelines on the Care and Use
of Animals for Scientific Purposes. To preclinically evaluate contrast-enhancement of
pancreatic cancer by ICG and NanoICG, mature C57BL/6 mice were selected for
orthotopic tumor challenge using 10,000 LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1Cre
(KPC)-derived PDAC syngeneic cells per mouse. As described previously,[213] once
anesthetized, an approximately 5 mm incision was made into the skin and peritoneum on
the abdomen between the hip and rib. This allowed for the spleen to be exteriorized for
injection of PBS cell suspension into the body of the pancreas. The peritoneum and skin
were then secured using an internal dissolving chromic gut and a 5.0 nylon surgical suture
respectively. Animals were warmed, hydrated, and monitored through recovery. Within two
weeks of introduction of tumor cells, palpable tumors were detected in all challenged mice.

2.2.7 Near-infrared fluorescence imaging ICG (10 nmol per mouse) or NanoICG
(10 nmol ICG per mouse) in 80 L ultrapure water was intravenously injected into mice
via a tail vein (n = 5 mice per group). Mice were euthanized 24 h post injection. Prior to
imaging, the liver and spleen were removed to minimize strong ICG fluorescence due to
hepatobiliary clearance and to evaluate the ability of ICG and NanoICG to distinguish
pancreatic tumor from healthy pancreas. A custom-designed FIGS system was employed
to detect contrast enhancement of ICG and NanoICG in the pancreatic tumors. The imaging
system utilizes a handheld fiber-coupled spectroscopic unit that excites ICG and collects
wavelength-resolved NIR emission (DeltaNu; Laramie, WY, USA). The spectroscopic unit
also serves as the excitation source for a real-time wide-field imaging system (Spectropath;
Atlanta, GA, USA) that merges a NIR channel (800-950 nm) and a visible color channel
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for spatial orientation of the NIR signal. The overall design and integration of these systems
has been previously reported.[214], [215] A laser power of 80 mW at 785 nm was used for
wavelength-resolved (800-950 nm) and widefield imaging.
After FIGS, all mice were necropsied. The pancreas was removed en bloc to
preserve the anatomical integrity of the primary, stromal, and healthy tissues for
fluorescence imaging and histological sectioning. Dissected organs were imaged on a Pearl
Trilogy small animal imaging system (LI-COR Biosciences, Lincoln, NE, USA). The
fluorescence intensity of each organ was collected with the 800 nm channel and analyzed
by Image Studio Ver. 5.0 software (LI-COR Biosciences, Lincoln, NE, USA). The
periphery of each organ was identified free-handed to define the region of interest (ROI).
Average pixel intensity was used to calculate signal to noise ratio (SNR), which is defined
by average tissue intensity per pixel in an ROI/standard deviation of background ROI.
Fluorescence intensity plots of representative pancreases were analyzed with ImageJ 1.49v
software (National Institutes of Health, Bethesda, MD, USA). To compare against the
spectroscopic analysis of each pancreas that was obtained during surgery, a straight line
was drawn longitudinally across the pancreas to include as many acquisition points as
possible after whole pancreas imaging. The NIR fluorescence intensity along the line was
quantified with the plot profile function in ImageJ.

2.2.8 Histological analysis Tumor tissue and organs of metastatic interest were
embedded in OCT mounting media gel and were frozen rapidly in liquid nitrogen.
Pancreatic tissue was positioned to obtain a maximal footprint for both diseased and
healthy pancreases. These samples were cut using Cryostat (Leica Biosciences, Buffalo
Grove, IL, USA) at a thickness of 8 m. Sections from each mouse were stained with
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hematoxylin and eosin (H&E) or left unstained for NIR fluorescence microscopy.
Representative slides were imaged with an IX73 Inverted Microscope with a xenon
excitation source and captured with a DP80 Digital Camera and displayed by CellSens
Dimension 1.13 software (all from Olympus, Japan). H&E stained slides were visualized
and imaged with a bright-field filter, unstained slides were imaged for autofluorescence
with a FITC filter cube, and NIR fluorescence with an ICG filter cube. Exposure time of
ICG and NanoICG were constant throughout all the samples.

2.2.9 In vivo toxicology To evaluate the systemic toxicity of NanoICG, 15 mature
C57BL/6J mice were divided into vehicle control group, low dose group (equivalent to 10
nmol of ICG per mouse) and high dose group (equivalent to 51.6 nmol of ICG per mouse)
(5 mice each group). High dose was calculated based of FDA recommended upper limit
dosage of ICG. The mice were treated correspondingly by i.v. injection. 72 h after the
injection, whole blood was collected into lithium heparin coated blood collection tubes
(BD Vacutainer, Franklin Lakes, NJ, USA) and K2EDTA coated blood collection tubes
(BD Microtainer, Franklin Lakes, NJ, USA) by heart puncture. Comprehensive diagnostic
profile of the blood samples were determined by chemistry analyzer (Abaxis, Union City,
CA, USA) and complete blood count was determined by hematology analyzer (Abaxis,
Union City, CA, USA). Livers, lungs, spleens and kidneys were collected, fixed, sectioned
and HE-stained for pathological examination.

2.2.10 Statistical analysis Data was analyzed in Prism 7 software (Graphpad, La Jolla,
CA, USA). Cytotoxicity was analyzed using 2-way ANOVA with Tukey’s multiple
comparisons test; chemotaxis and phagocytosis were analyzed using a 1-way ANOVA and
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Tukey’s multiple comparisons test; biodistribution was analyzed using multiple t tests. In
vivo toxicity was analyzed with Kruskal-Wallis test. All data is shown as Mean ± Standard
Deviation (SD).

2.3 RESULTS
2.3.1 Characterization of NanoICG The number mean hydrodynamic diameter of
NanoICG was 70.96 ± 13.63 nm with the average polydispersity index of 0.240 ± 0.017 (n
= 6). The average zeta-potential of NanoICG was (-21.4 ± 0.289) mV. According to TEM
image (Figure 1B), the average diameter of spherically shaped NanoICG is around 40 nm.
Absorption spectra for intact NanoICG was indicative of ICG being tightly packed within
amphiphilic HA (Figure 3C). In comparison, dissolved ICG and disassembled NanoICG
(in 50/50 DMSO/H2O), has strong NIR absorbance around 785 nm, 6-fold higher than
NanoICG at the same wavelength. Correspondingly, fluorescence emission is minimized
(5-fold lower) due to packing of ICG and is indicative of ICG entrapment in the selfassembled NP (Figure 3D), which is consistent with previous reports by us and
others.[211], [216] The quenched fluorescence of NanoICG becomes activated in serum
and tissue interaction due to nonspecific interaction with protein hydrophobic
domains.[206]
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Figure 3 Physical characterization of NanoICG. (A) Percentage intensity of distribution for
hydrodynamic diameter of NanoICG; (B) TEM image of NanoICG with negative staining, scale bar
represents 100 nm; (C) UV absorbance scanning spectra of intact NanoICG and disassembled NanoICG
from 600 nm to 900 nm, as determined by UV-visible spectrophotometer; (D) Fluorescence activation of
due to NanoICG disassembly as determined by spectrofluorometer with excitation wavelength of 775 nm
and emission wavelength ranges from 790 nm to 900 nm.

2.3.2 Cytotoxicity The relative viability of HPNE and KPC cells were calculated by
normalizing to untreated cells. Overall, the relative viability of HPNE and KPC cells,
which were treated with empty NP and NanoICG, was close to 1. No significant differences
were observed between 0.1, 0.01 and 0.001 mg/mL (Figure 4). Additionally, no significant
difference was detected between empty NP and NanoICG. Empty NP and NanoICG did
not impair the metabolic activity of healthy pancreatic epithelial cells.
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Figure 4 CCK-8 assay was performed on (A) HPNE cells and (B) KPC cells treated
with variable concentrations of empty NP and NanoICG for 24 h, N = 5, no
significant differences were detected between each group.

2.3.3 Chemotaxis There was a 6.79-fold induction of chemotaxis towards complete
Figure 19 CCK-8 assay was performed on (A) HPNE cells and (B) KPC cells treated

medium (positive
control)
as compared
to PBS.
NanoICG
with variable
concentrations
of empty
NP In
andcontrast,
NanoICGICG,
for 24
h, N = 5,and
no empty NP
significant differences were detected between each group.

(p < 0.0001) showed relative values (as compared to PBS) of 0.63 ± 0.02 for 10 × TPC of
Figure 20 CCK-8 assay was performed on (A) HPNE cells and (B) KPC cells
treated with variable concentrations of empty NP and NanoICG for 24 h, N = 5, no
significant differences were detected between each group.
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ICG, 0.63 ± 0.04 for 10 × TPC of NanoICG and 0.60 ± 0.01 for 10 × TPC of empty NP (n
= 3) (Figure 5A). The lowest concentration (1/25 × TPC) of ICG, NanoICG and empty NP
showed relative chemotaxis induction (as compared to PBS) of 0.85 ± 0.02, 0.87 ± 0.03,
and 0.81 ± 0.01 times, respectively (n = 3). These results demonstrate that NanoICG and
empty NP have no significant chemoattractant properties.

2.3.4 Phagocytosis HL-60 displayed low phagocytic activity toward PBS, ICG,
NanoICG, and empty NP, regardless of test sample concentrations (Figure 5B). In
comparison, zymosan A was internalized to a significantly higher extent (p < 0.0001), with
AUC values 1.87, 1.83 and 1.93 times higher than 10 × TPC for ICG, NanoICG and empty
NP, respectively. There was no significant effect of 10 × TPC of ICG, NanoICG and empty
NP on phagocytosis as compared to PBS [1.03 ± 0.02, 1.03 ± 0.01 and 1.00 ± 0.01
respectively. (n = 6)].
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Figure 5 Chemotaxis and phagocytic assay. (A) Chemotaxis assay of HL-60 with ICG, NanoICG and
empty NP at varied concentrations based of theoretical plasma concentration (TPC) at 4 h time point.
Complete medium is IMDM with 20% FBS. Fluorescent spectra of calcein AM was collected at 485 nm
excitation/535 nm emission; (B) Phagocytic assay of NanoICG in HL-60. Zymosan A served as the
positive control while PBS was the negative control. Luminesance reading was monitored for 1.5 h with
2.1 min intervals and AUC of fluorescent signal was quantified as chemotactic response. ****p < 0.0001.
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2.3.5 Detection of ICG and NanoICG in tumor-bearing mice with IGS
ICG and NanoICG were examined for suitability for IGS as schematically depicted in
Figure 5A. Intraoperative imaging demonstrated that NanoICG and ICG could both be
detected by IGS in pancreatic tumors; however, NanoICG resulted in more complete and
intense enhancement of the tumor when compared to ICG under identical experimental
conditions (both were excited with 80 mW power at a constant distance from the tumor)
(Figure 6, bottom). Spectra collected from these regions are in close agreement with the
NIR fluorescence detected in wide-field imaging channel, indicating stronger NIR
fluorescence in mice injected with NanoICG (Figure 6, middle); at the peak emission
wavelength of 814 nm, the fluorescent signal of NanoICG treated pancreatic tumor is 2.03
times of that in ICG group. The IGS images demonstrated an improved contrast profile
with NanoICG in orthotopic PDAC detection.
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Figure 6 Schematic of FIGS and Surgical Navigation of PDAC with NanoICG. (A) Schematic of
the image-guided surgery system utilized to detect orthotopic PDAC. As described in the text, the
system utilizes both wavelength-resolved NIR spectroscopic measurements and a wide-field, multidetector video camera for real-time surgical guidance that uses the hand-held spectroscopic pen as an
excitation source. (B) Images from surgical navigation of pancreatic tumor contrast-enhanced with ICG
(left) or NanoICG (right) 24 h post i.v. injection. Livers and spleens were removed due to high
background signal from ICG clearance. Int = large intestine, PT = pancreatic tumor, St = stomach, SI
= small intestine; (Top) Color images show orthotopic PDAC and the location of the handheld
spectroscopic pen, which provides NIR spectral information and serves as an excitation source for a
widefield imaging system. (Middle) Pseudo-colored signal in the NIR channel of the widefield imaging
system and the spectroscopic signal from within the contrast-enhanced region; (Bottom) NIR signal
overlaid (cyan) onto the color image shows robust enhancement of syngeneic, orthotopic pancreatic
cancer. Contrast enhancement can be observed with both ICG and NanoICG, with NanoICG having
stronger signal (see inset middle row).

2.3.6 Ex vivo analysis of fluorescence accumulation of pancreatic tumor
NIRF images of the pancreas showed higher accumulation of fluorescent signal in the
tumor portion of NanoICG treated pancreas compared with that of ICG, as shown in Figure
7B (7A is a bright field photograph of the pancreas for spatial reference). Figure 7C shows
the quantified fluorescence intensity from the spectroscopic pen at acquisition locations
across the pancreas to determine the NIR signal and tumor contrast. Spots in the pancreatic
tail, which correspond to the location where the KPC PDAC cells were implanted, were
brighter compared with the head and body. The point spectroscopic measurements were
consistent to whole pancreas NIR images as shown in Figure 7D, where a line was drawn
across the pancreas image to obtain as many data points as possible from non- and contrastenhanced
which depicted
healthy
tissue
and PDAC,
respectively.
Figure 83regions,
Ex vivo analysis
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accumulation
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tumor.The
(A) average
Photo
images and (B) NIRF images of a representative pancreatic tumor marked with acquisition locations of
fluorescent
intensities of the healthy and tumor portions of the pancreas were 0.35 ± 0.12
the spectroscopic semi-quantification shown in (B); (C) Fluorescence intensity excited with medium
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andpower
0.77and
± 0.12
AU, respectively,
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In comparison,
the average
fluorescence
laser
1 s integration
by the spectroscopic
component of FIGS
system; (D)
Plots of
intensity values along the red dashed line from the NIRF images quantified by ImageJ; (E)
Morphological examination (H&E) and fluorescent signal accumulation (NIR) under microscope of
tumor-bearing cancerous pancreas (left) and healthy pancreas (right) administered with NanoICG. 55
Autofluorescence (Auto) was detected with FITC filter cube which pseudo-colored green, NIR

intensity of the healthy and tumor portions were 0.41 ± 0.10 AU and 2.30 ± 0.67 AU,
respectively, for NanoICG. The average fold-increases of the tumor portion of the pancreas
compared with the healthy portion of the pancreas were 2.20 and 5.61 for ICG and
NanoICG, respectively.

Figure 7 Ex vivo analysis of ICG and NanoICG accumulation in pancreatic tumor. (A) Photo images
and (B) NIRF images of a representative pancreatic tumor marked with acquisition locations of the
spectroscopic semi-quantification shown in (B); (C) Fluorescence intensity excited with medium laser
power and 1 s integration by the spectroscopic pen component of FIGS system; (D) Plots of intensity
values along the red dashed line from the NIRF images quantified by ImageJ; (E) Morphological
examination (H&E) and fluorescent signal accumulation (NIR) under microscope of tumor-bearing
cancerous pancreas (left) and healthy pancreas (right) administered with NanoICG. Autofluorescence
(Auto) was detected with FITC filter cube which pseudo-colored green, NIR fluorescence was detected
with ICG filter cube which pseudo-colored magenta. Scale bar represents 50 m.
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During sectioning, the surfaces of the solid tumors were visually observed to be
light yellow in color, which is indicative of a high-degree fibrosis [217]. H&E stained
tumor slides displayed characteristic poorly differentiated adenocarcinoma with high
stroma content (Figure 7E, left). Normal pancreatic morphology was shown in a slide from
benign pancreatic tissue (Figure 7E, right). A higher level of NIRF signal was observed
throughout the tumor portion of pancreas treated with NanoICG compared with those
treated with ICG (Figure 7E).
The borders of splenic metastasis and healthy spleen tissue were identified by H&E

Figure 8 Histological examination of splenic metastasis of PDAC. Splenic metastasis of PDAC
administered with NanoICG (Top) and ICG (Bottom). SP = spleen, T = tumor. Scale bars in panels of
H&E, Auto, NIR and Merge represent 100 m.

stained slides as shown in Figure 8. Fluorescent signal was detected along the borderline
of tumor in the NanoICG treated group but not in the ICG treated group.

2.3.7 Relative biodistribution of ICG and NanoICG in PDAC The
fluorescence intensity of ICG and NanoICG was evaluated among organs harvested from
the mice with the orthotopic PDAC model. Overall, higher SNR signal was observed in
pancreas in the NanoICG-treated group compared with ICG-treated group with p < 0.0001
(Figure 9A). Between organs, significantly higher signals were seen in the liver, spleen,
Figure 109 Histological examination of splenic metastasis of PDAC. Splenic metastasis of PDAC

pancreas, bone, heart and lymph node in the NanoICG treated group, which were 5.3, 4.4,
administered with NanoICG (Top) and ICG (Bottom). SP = spleen, T = tumor. Scale bars in panels of
H&E, Auto, NIR and Merge represent 100 m.
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2.1, 2.1, 2.3, 2.2-fold higher compared with ICG treated group respectively. On the other
hand, ICG displayed a great propensity to be cleared by the GI tract as determined by semi-
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quantified NIRF images (Figure 9C), whereas for NanoICG, increased liver and spleen
signal, suggestive of RES clearance (Figure 9B).

Figure 9 Quantification of biodistribution of ICG and NanoICG in PDAC mice based on NIRF
images at 24 h post contrast agent administration. (A) Quantified distribution of ICG and NanoICG
in PDAC mice, N = 5, ***p < 0.001, ****p < 0.0001; (B) Representative NIRF image of indicated
necropsied organs from PDAC mice treated with NanoICG; T = tumor, HP = healthy portion; (C)
Representative NIRF image of necropsied organs from PDAC mice treated with ICG.
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2.3.8 In vivo toxicology to make a comparative study on the potential toxic effect of
NanoICG on the treated mice, we carried out blood biochemistry and hematology analysis.
Figure 10 shows the levels of standard hematological markers, such as white blood cell
(WBC), red blood cell (RBC), hemoglobin (HGB), hematocrit (HCT) and platelet (PLT);
The WBC is sensitive to the physiological response, the mean value of vehicle control was
in the normal range. There is a slight decrease in the number of WBC for NanoICG-treated
groups, but this decrease is not significantly different, and close to the anticipated value
provided by the animal supplier [50]. All the other parameters in the NanoICG-treated
groups appear to be normal compared with the control group, and be within the normal
ranges. In addition, we present the biochemistry results of the mice including albumin
(ALB), alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase (AMY),
blood urea nitrogen (BUN), total protein (TP) and globulin (GLOB). Fluctuation was
observed in ALP, ALT and GLOB for NanoICG-treated group compared with vehicle
control, but still remained within the normal ranges; no difference was observed between
NanoICG doses or with the vehicle control. The results of blood biochemistry and
hematology analysis suggest no obvious toxicity even with upper limit dose of NanoICG.
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Figure 10 Hematology and blood biochemistry assessments of the vehicle (black), low dose (0.39
mg/kg ICG equivalent, red) and high dose (2 mg/kg ICG equivalent, green) of NanoICG treated
mice 72 h after intravenous injection. The results show mean and standard deviation of white blood cells
(WBC), red blood cells (RBC), hemoglobin (HGB), hematocrit (HCT), platelet (PLT), albumin (ALB),
alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase (AMY), blood urea nitrogen
(BUN), total protein (TP), globulin (GLOB). N = 5.

To further investigate the in vivo toxicity of NanoICG, histological analysis of
major organs including liver, spleen, lung and kidney were performed 72 h after
intravenous administration of different doses of NanoICG, examined by board-certified
pathologist (SMC), and the results are shown in Figure 11. The spleens from all animals
were normal. This indicates that there was no overall effect on the immune system as there
was excellent preservation of the lymphoid white pulp of the spleen. The kidneys showed
no evidence of toxicity, either in the glomeruli, tubules, papilla, vessels, or pelvis. Thus,
there is no evidence of nephrotoxicity. In the livers, there were occasional animals with
focal mononuclear infiltrate (as indicated by the black arrows), but this was not associated
Figure 123 Hematology and blood biochemistry assessments of the vehicle (black), low dose (0.39
mg/kg
equivalent,
red) andorhigh
dose (2 mg/kg
ICGwas
equivalent,
green) zonal
of NanoICG
treated
with
anyICG
evidence
of necrosis
regeneration.
There
no consistent
area involved.
mice 72 h after intravenous injection. The results show mean and standard deviation of white blood cells

There was only 1 animal in the vehicle control group with this finding, none in the low
(WBC), red blood cells (RBC), hemoglobin (HGB), hematocrit (HCT), platelet (PLT), albumin (ALB),

alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase (AMY), blood urea nitrogen
(BUN), total protein (TP), globulin (GLOB). N = 5.
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dose group, and 2 of the 3 animals in the high dose group had this finding. Thus, this may
reflect a low level of hepatotoxicity. However, these results contradict biochemical analysis
that had normal levels of ALT and AST for the vehicle control, low dose, and high dose of
NanoICG (Figure 10). In the lung, there was 1 animal in the vehicle control group that
showed focal consolidation of the alveoli without inflammation, 1 animal in the low dose
group that showed focal peribronchiolar chronic inflammation, and 1 animal in the high
dose that also showed focal alveolar focal peribronchiolar and alveolar inflammation (as
indicated by black arrows). It is most likely that these lung changes reflect the intravenous
administration of the material and not related to the material that was injected.

Figure 11 H&E stained tissue slides (liver, spleen, kidney and lung) of C57BL/6 mice 72 after
intravenous injection of vehicle (top row), low dose NanoICG (0.39 mg/kg ICG equivalent, middle
row) and high dose NanoICG (2 mg/kg ICG equivalent, bottom row). Black arrows in livers
indicated focal mononuclear infiltrate, black arrows in lungs indicated focal consolidation or focal
peribronchiolar chronic inflammation. Black bars represent 50 m, N = 4 for vehicle control, N = 3
for low dose and high dose groups.
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2.4 Discussion
The formulation of HA-derived NPs has advantages, most notably overcoming
poor aqueous solubility of therapeutic or imaging agents [218]. Second, HA-derived NPs
exhibit prolonged circulation and low toxicity to healthy tissues [219]–[221]. Third, the
possibility of tumor targeting, including by specific binding of CD44 [222] and through
the enhanced permeability and retention (EPR) [218] effect, makes it promising for cancer
imaging and therapy. In this study, HA polymers were conjugated with PBA to obtain
amphiphilic HA, which readily entrapped amphiphilic ICG in aqueous solution. By
incorporating ICG into an HA-derived NP contrast agent, ICG accumulation in tumor was
increased (Figure 6, 7 and 9), potentially due to the so-called EPR effect [218], [223],
while mitigating potential toxicity from the innate immune system (Figure 5).
Overcoming the immune system barrier is a key step for targeted delivery of
contrast agents. Gallagher et al. reported that HL-60 cells exhibited responsiveness to
chemoattractant and phagocytic activity that were commensurate with the proportion of
mature granulocytes [224]. Others have reported that HA species of molecular weights
from 792 to 3×106 Da all stimulated phagocytic and chemotactic function of
polymorphonuclear leukocytes, and, 10 kDa HA was reported as a potent stimulator of the
innate immune system [225], [226]. However, for HA derived nanosystems, different
molecular weight of HA modified liposomes did not cause complement or macrophage
activation [227]. In the in vitro studies reported here, no significant immunotoxicity was
observed except a slight inverse dose-dependency in chemoattractant potential of test
samples. The possible explanation is that the volume ratio of SM, a potent chemoattractant
for HL-60, increased proportionally as test samples were diluted.
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Contrast enhancement within whole pancreas was observed both in ICG and
NanoICG treated groups (Figure 7, 9). ICG is a small, amphiphilic dye molecule. After
injection, ICG is bound immediately with albumin and other serum proteins and then
liberated into liver and cleared out in bile resulting in a half-life of less than 20 min in
healthy humans [223]. NIR images of S-180 tumor were reported with obvious contrast 2
h to 48 h post ICG injection, likely from the EPR effect of ICG bound albumin [223]. In
Figure 4B, a slight accumulation of ICG was observed in pancreatic tumor, which is
comparable to mice with S-180 tumors [223]. In comparison, a more apparent contrast
enhancement between healthy and diseased portions of pancreas was observed in NanoICG
recipients (Figure 5B). Qhattal and colleagues [228] reported that tumor targeting benefited
extensively from long systemic circulation of nanosystems, while Han et al. [229] assert
that HA performs like PEG by increasing plasma half-life while displaying limited
immunotoxicity. Thus, accumulation of NanoICG in tumor could be due to prolonged
circulation of HA based nanosystems.
Bouvet et al. reported that metastatic lesions of an orthotopic pancreatic cancer
model were detected in spleen, bowel, and omentum, as visualized by implanting GFP
transfected BxPC-3 cells. By inspecting intravitally, tumor and metastatic area were
quantified for growth monitoring [230]. Wang et al. [196] reported a dual optical and MR
imaging agent, denoted by Cy5.5-ATF-IO, was able to detect intraperitoneal metastatic
lesions of PDAC as small as 0.5 mm3 in optical NIR imaging. Furthermore, optical NIR
imaging could detect as little as 1×104 tumor cells, which was 1/10 of that which can be
detected by MRI [196]. Another study showed that CA19-9 conjugated AlexaFluor488
were potent at detecting micrometastases of PDAC including splenic, peritoneal and liver
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[192]. In this study, microscopic lesions of splenic metastasis were obviously visualized by
NanoICG (Figure 8) and mostly accumulated at the lesion periphery.
An important limitation for targeted delivery of HA-decorated NP is preferential
uptake by RES system [218]. On one hand, it has been empirically shown that NPs with
size less than 100 nm, neutral or anionic charge, and lower complement binding can avoid
RES uptake after i.v. administration [227]. Additionally, Qhattal et al. found that high
molecular weight (HMW) HA grafted liposomes were cleared much faster than low MW
HA [228], because HMW HA had a higher affinity with HARE or LYVE-1, which were
widely expressed in normal sinusoidal endothelial cells of the liver, spleen, and activated
tissue macrophages [231]. Consequently, NPs that derived with 10 kDa HA could
accumulate to a lower degree in liver in that scenario. However, in Figure 9A, NanoICG
displayed marked accumulation in liver and spleen (p < 0.0001) compared with ICG, which
was indicative of increased RES uptake. Further studies are ongoing to determine an
optimized HA MW for formulation of NanoICG for pancreatic tumor delivery balanced
with minimized RES uptake.
Endogenous HA may play an important role in the biology of pancreatic cancer
[232], as expression of high and low molecular weight forms of HA have been reported to
inhibit or enhance malignant properties of pancreatic cancer cells in experimental models.
Careful analysis of human samples suggests that HA is expressed by greater than 85% of
human pancreatic cancers [233]. However, its expression is not correlated with improved
or worse outcome in humans. HA is also the target of therapeutic approaches in which its
targeted degradation by PEGylated hyaluronidase is used to improve drug delivery [234],
or alternatively, HA complexes are being developed as drug delivery agents [235], [236].
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Taken together, our results presented here and the existing and emerging literature strongly
support further investigation into the biology and use of HA as delivery vehicle and/or a
targeting agent in pancreatic cancer.
In terms of in vivo safety, results from healthy C57BL/6J mice after vehicle or one
of two NanoICG doses were in concordance with others. For example, HA-derived
amphiphilic polymers were reported to demonstrate a protective effect against cisplatin or
doxorubicin-induced hepatotoxicity and nephrotoxicity [237], [238], which demonstrates
that the self-assembled drug carriers-constructed by HA conjugated hydrophobic moietyare effective at reducing systemic toxicities. On the other hand, Rao et al. reported that
HA-derived nanocarriers can control the release of drug payload, depending on the
reversible interaction of HA-containing carriers and drugs [239]. This is consistent with
the recent results of Hill et al., which showed controlled dye release rate from amphiphilic
HA nanostructures. Accordingly, we hypothesize that negligible toxicity from NanoICG
could be due to a combination of several factors: imaging agent was administered with
singular and low dose; ICG was entrapped in a stable state through - stacking with PBA
[211], which could affect ICG release, and released ICG is an FDA-approved medical
diagnostic agent with low inherent toxicity.
NanoICG, an HA-derived NP that physico-chemically entraps ICG, displayed a
nontoxic safety profile in vitro and in vivo and provided significant NIR signal for guidance
for intraoperative detection of PDAC in vivo. The fluorescence intensity of NanoICG was
higher compared to ICG both in pancreas and splenic metastasis, which was confirmed by
NIRF imaging, FIGS and microscopic analysis. In conclusion, NanoICG exhibited
improved efficacy at detecting pancreatic tumors in an orthotopic pancreatic cancer model
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with negligible NP-derived toxicity, suggesting that NanoICG is a promising potential
contrast agent for guiding pancreatic tumor removal.
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CHAPTER 3: TUNED NEAR INFRARED
FLUORESCENT HYALURONIC ACID
CONJUGATES FOR DELIVERY TO PANCREATIC
CANCER FOR INTRAOPERATIVE IMAGING
3.1 Introduction
Surgical resection remains a promising treatment for improving prognosis of cancer
patients as it is potentially curative for primary tumors and local metastases [240].
Currently, surgery is performed without contrast-enhanced image guidance to identify
tumor margins and small occult metastases due to the absence of clinically available optical
contrast agents [92], [187], [188]. Contrast-enhanced optical imaging could provide realtime guidance during tumor resection with highly sensitive, rapid, and non-radioactive
NIRF tracers to highlight the areas of extension of the malignancy [241]. NIRF is
promising for in vivo optical imaging due the relative biological transparency at
wavelengths between 700 nm and 1000 nm [92], [242], [243]. To date, however, FIGS of
tumors has not reached its full potential, in part due to contrast agents lacking high intensity,
water solubility, biocompatibility, and tissue-specific targetability [244].
Attaining high contrast-to-noise ratio (CNR: signal in region of interest relative to
neighboring region) and signal-to-noise ratio (SNR: signal in the region of interest relative
to background noise) is important for specific visual guidance of tumor detection and
removal. Sufficient CNR and SNR are achieved primarily if specific binding of the
fluorophore to the target tissue occurs, while unbound fluorophore is rapidly cleared from
the background tissue [245]. Nevertheless, most dyes are not tumor-specific and in vivo
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performance can be complicated by non-specific biological interaction, e.g. membranes,
pharmacokinetic process including absorption, distribution, metabolism and excretion, and
optical properties of the dye and tissue [246]. For instance, cyanine-based NIRF probes
with hydrophobic core structures and high surface charge bind to plasma proteins, which
results in RES organ sequestration and hepatobiliary clearance in vivo, which can
compromise tumor contrast.[247]–[250] Useful strategies for improving CNR and SNR
include, among others, utilizing tumor or tumor microenvironment specific biomarkers
[246] and altering excretion from the liver (hepatobiliary) to the kidneys (urinary) [145],
[251], [252]. Pancreatic cancer CNR was found to be significantly increased by targeting
somatostatin [253], [254] or tumor cell antigens [255] or utilizing cell-penetrating peptides
[117] for tumor-specific enhancement. Reported by Choi et al. [242], [243], [247], [250],
improved tumor SNR was achieved by using zwitterionic fluorophores, which increased
renal filtration and reduced overall background. Hence, we hypothesize that optimized
pancreatic tumor contrast could be achieved by combining tumor-specific targeting and
facilitating minimized intraperitoneal organ accumulation.
Previously, we reported the development of tumor-selective delivery of the FDAapproved NIR fluorophore, ICG, by physically entrapping the dye in HA-derived
nanoformulations, termed NanoICG, in models of breast, prostate, and pancreatic cancer
[206], [211], [256], [257]. NanoICG resulted in significant pancreatic cancer contrast
relative to a muscle reference and uninvolved pancreas, but also gave rise to strong signal
in intraperitoneal organs, especially the liver and spleen [256]. To maximize PDAC
contrast enhancement and to minimize RES capture, we now specifically examine the role
of HA molecular weight and NIRF dye properties. Compared to our previous study of using
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hydrophobically-modified HA to drive NP self-assembly and physicochemical entrapment
of dye, two dyes, Cy7.5 (relatively hydrophobic) and IRDye800 (hydrophilic dye), are
directly conjugated to HA of three different molecular weights (MWN), including MWN =
5, 20, and 100 kDa. The effects of HA MWN and physiological properties of NIR dyes on
tumor specificity and biodistribution were investigated to determine a lead agent for PDAC
enhancement in minimized RES uptake. These select agents would ideally be useful for
detection of intraperitoneal metastatic pancreatic cancer or other tumor types that required
surgical intervention in the abdominal cavity.

3.2 Methods
3.2.1 Materials Cy7.5 amine was purchased from Lumiprobe (Hallandale Beach, FL);
IRDye800CW trifluoroethylamine was purchased from LI-COR (Lincoln, NE); 5 kDa, 2030 kDa, and 100 kDa sodium hyaluronate were purchased from Lifecore Biomedical
(Chaska, MN). Lyophilized powder of bovine serum albumin (BSA) was purchased from
Sigma (St Louis, MO). Sephadex G-25 PD-10 desalting column was purchased from GE
Healthcare (Pittsburgh, PA); KPC cells were obtained from the diseased pancreas of LSLKrasG12D/+; LSL-Trp53R172H/+; Pdx-1Cre (KPC) mice which were shared by Dr.
Hollingsworth. 10-week-old female C57BL/6J mice were purchased from Jackson
Laboratories (Bar Harbor, ME). 5.0 chromic gut and 5.0 nylon surgical sutures were
purchased from Johnson & Johnson (Somerville, NJ). FITC-labeled CD44 antibody,
purified rat mouse BD Fc blocker, propidium iodide (PI) staining solution and flow
cytometry (FC) staining buffer was purchased from BD Bioscience (San Jose, CA). All
other chemicals were purchased from Fisher Scientific and used at analytical grade.
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3.2.2 Conjugation and characterization of Cy7.5 or IRDye800 HA
Conjugates. Sodium hyaluronate (3.3-6.9 mg, MWN = 5 kDa; 9.5-10.7 mg, MWN =2030 kDa; 10.2-12.7 mg, MWN =100 kDa) were completely dissolved in 2 mL of water. 1Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and N-hydroxysuccinimide (NHS)
(both 10× molar ratio to amine group), were then dissolved in the HA solution. After 15
min of activation, the pH was raised to 7.2, and Cy7.5-NH2 (dissolved in DMSO) or
IRDye800-NH2 (dissolved in ultrapure water) – both at 3× molar ratio to disaccharide units
per HA5k and HA20k chain and 9× for HA100k chain – were each added dropwise to each of
the activated HA solutions under constant stirring. The reaction was allowed to stir for 24
h at room temperature (rt). The reaction contents were then transferred to dialysis tubing
(MWCO = 3500 Da for HA20k- and HA100k-dye conjugates; MWCO = 1000 Da for HA5kdye conjugates, Spectrum Laboratories, Rancho Dominguez, CA): HA-Cy7.5 conjugates
were dialyzed against 1:1 EtOH:H2O for 24 h followed by H2O for an additional 48 h. HAIRDye800 conjugates were dialyzed against H2O for 24 h. The HA-dye conjugates were
removed from the dialysis tubing, purified by PD-10 column, followed by lyophilization,
and storage at -20 °C. Dye content and overall HA-dye conjugate optical properties were
determined relative to dye solutions using absorbance and fluorescence spectroscopy.
Specifically, an Evolution 220 spectrophotometer (Thermo Fisher Scientific, Madison, WI)
was used for scanning absorbance spectra (600-900 nm) and a FluoroMax-4
spectrofluorometer (Horiba, Edison, NJ) was used for quantifying fluorescent intensity of
dye, HA-dye, disassembled and BSA-associated HA-dye.

3.2.3 Determination of nonspecific serum protein binding. 50 M bovine
serum albumin (BSA; Sigma-Aldrich, MO) was incubated with HA20k-Cy7.5/IRDye800 (4

71

M dye equivalent) in phosphate buffer (0.01 M, pH 7.4) for 1 h at rt. 1 mL of mixture or
corresponding control was filtered through 0.22 m filter before loading onto an AKTA
Pure 25 L Chromatography system (GE Healthcare, Sweden) that was equipped with
Superdex200 Increase 10/300 GL column, UV monitor (fixed wavelength at 280 nm), and
a fraction collector. For kinetic fluorescence measurements, an outlet portal was connected
to micro cuvette (Starna, Atascadero, CA) for monitoring the fluorescence of elution using
the fluorescence specrophotometer. Sample was eluted at flow rate of 0.45 ml/min and
elution time period was 60 min. Kinetic monitoring of fluorescence was collected for 4000
s with 5 s integration time for HA20k-Cy7.5 (slit width was 20 nm, ex = 775 nm, em = 820
nm) and HA20k-IRDye800 (slit width was 10 nm, ex = 770 nm, em = 790 nm).

3.2.4 Tumor model induction All animal studies were performed under a protocol
approved by the UNMC Institutional Animal Care and Use Committee. Procedures were
followed in accordance with institutional guidelines per the Guidelines on the Care and
Use of Animals for Scientific Purposes. The guidelines were followed to ensure humane
care of the animals. Orthotopic, syngeneic PDAC induction was performed as described in
previous studies [213], [256]. Briefly, mature female C57BL/6 mice were selected for
orthotopic tumor challenge using 10,000 KPC-derived PDAC syngeneic cells per mouse.
Once anesthetized, a ~5 mm incision was made into the skin and peritoneum on the
abdomen between the hip and rib. This allowed for the spleen to be exteriorized for
injection of PBS cell suspension into the body of the pancreas. The peritoneum and skin
were then secured using an internal dissolving chromic gut and a 5.0 nylon surgical suture,
respectively. Animals were warmed, hydrated, and monitored until consciousness was
regained. Within two weeks of introduction of tumor cells, palpable tumors were detected
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in all challenged mice.
Cells will be mixed with complete media or serum-free media, both containing HAdyes, at 4C for 30 min. Next, cells will be incubated with contrast agent-free complete
growth media to allow internalization of surface-bound HA-dyes, which can then be
quantified by flow cytometry.

3.2.5 Biodistribution of HA-Dye conjugates as measured by fluorescence.
Dye (1 nmol per mouse) or HA-dye (1 nmol dye/mouse equivalent) in 80 L ultrapure
water was intravenously injected into wild type (WT) C57BL/6 mice or PDAC-bearing
mice via a tail vein (N = 5 mice/group). Mice were euthanized 24 h or 96 h post injection.
WT mice were completely necropsied to examine overall fluorescence distribution of dye
or dye conjugates. Dissected organs were imaged on a Pearl Trilogy small animal imaging
system (LI-COR Biosciences, Lincoln, NE). The fluorescence intensity of each organ was
collected with the 800 nm channel and analyzed with Image Studio Ver. 5.0 software (LICOR Biosciences, Lincoln, NE). The periphery of each organ was identified by defining
the region of interest (ROI) with free-hand. Average pixel intensity was used to calculate
signal to noise ratio (SNR), which is defined by average tissue intensity per pixel in an ROI:
standard deviation of background ROI.

3.2.6 Simulated fluorescence guided imaging of PDAC Using the
aforementioned dose, time, and contrast agents, mice were administered NIR fluorophore
or HA-NIRF dye conjugates. After euthanasia, but prior to intraoperative imaging, the liver
and spleen were removed to expose the pancreas and minimize background interference of
those contrast agents cleared by the RES. A custom-designed FIGS system was employed
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to detect contrast enhancement of dye and HA-dye in the pancreatic tumors. The imaging
system utilizes a handheld fiber-coupled spectroscopic unit that excites 785 nm and collects
wavelength-resolved NIR emission (DeltaNu; Laramie, WY). The spectroscopic unit also
serves as the excitation source for a real-time widefield imaging system (Spectropath;
Atlanta, GA, USA) that merges a NIR channel (800-950 nm) and a visible color channel
for spatial orientation of the NIR signal. The overall design and integration of these systems
has been previously reported [214], [215]. A laser power of 80 mW at 785 nm was used
for wavelength-resolved (800-950 nm) and widefield imaging.
After FIGS, all mice were necropsied. The pancreas was removed en bloc to
preserve the anatomical integrity of the primary, stromal, and healthy tissues for
fluorescence imaging (using the method described for WT mice) and histological
sectioning. To compare against the intraoperative imaging analysis of each pancreas that
was obtained during surgery, a straight line was drawn longitudinally across the pancreas
in the image obtained by the Pearl Trilogy imaging system. The NIRF intensity along the
line was quantified with the plot profile function in ImageJ 1.49v software (National
Institutes of Health, Bethesda, MD). Tumor bearing pancreas were directly compared
against WT pancreas for all contrast agents.

3.2.7 Histological analysis Tumor tissue was embedded in OCT mounting media gel
and was rapidly frozen in liquid nitrogen for staining with H&E or left unstained for NIR
fluorescence microscopy. Pancreatic tissue was positioned to obtain a maximal footprint
for both diseased and healthy pancreases. These samples were cut using a Cryostat (Leica
Biosciences, Buffalo Grove, IL) at a thickness of 8 μm. For immunohistological staining,
the pancreas was fixed with 4% paraformaldehyde solution for 24 h followed with 70%
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ethanol.

Samples

were

embedded

in

wax

and

sectioned

sequentially

for

immunohistological and H&E staining. Anti-CD44 antibody (Abcam, Cambridge, MA)
was applied at a dilution of 1:100. Representative unstained slides were scanned with
Odyssey Clx imaging system (LI-COR, Lincoln, NE) with 800 nm channel. Exposure time
was consistent among each group (HA-Cy7.5 and HA-IRDye800). H&E-stained slides
were scanned with Panoramic 250 flash series digital scanner (3DHistech, Hungary).
Representative microscopic photos for IHC and H&E were imaged and captured with an
IX73 Inverted Microscope equipped with a DP80 Digital Camera and displayed by
CellSens Dimension 1.13 software (all from Olympus, Japan).

3.2.8 Statistical Analysis Data was analyzed in Prism 7 software (Graphpad, La Jolla,
CA). Biodistribution and background interference were analyzed using a 2-way ANOVA
and Dunnett’s multiple comparisons test; ex vivo analysis of contrast within pancreas was
analyzed using one way ANOVA with Tukey’s multiple comparisons test; all data is shown
as mean ± standard deviation (SD).

3.3 Results
3.3.1 Synthesis and photochemical properties of HA-NIRF conjugates
HA-Cy7.5 and HA-IRDye800 conjugates were synthesized with 1-Ethyl-3-(3dimethylaminopropyl)-carbodiimide

(EDC)/N-hydroxysuccinimide

(NHS)

coupling

chemistry. The physicochemical and optical properties of HA-Cy7.5 and HA-IRDye800
are summarized in Figure 12-13, Table 1. HA-Cy7.5 conjugates displayed distinct,
solvent-dependent spectral properties: In H2O, the extinction spectral fluorescent peaks
were “flat” and broad compared to dissociation in DMSO, indicating self-assembly and
self-quenching, which is consistent with nanoformulation of Cy7.5 [258]. Cyanine dyes
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are capable of forming H-aggregates by hydrophobic interaction, which is characterized
with hypsochromic absorption and weak fluorescence emission. As shown in Figure S1,
the absorption wavelength blue-shifted 80 nm for HA5k, HA20k conjugated Cy7.5, while a
blue shift of only 10 nm was observed for HA100k-Cy7.5 conjugate in H2O. Furthermore,
upon disassembly in DMSO, the fluorescence emission intensity exhibited a red-shifted to
810 nm, and a 21.3-, 9.8- and 4.0- fold increase in fluorescence intensity for HA5k-, HA20kand HA100k-dye conjugates, respectively. In comparison, hydrophilic IRDye800 displayed
a limited tendency to interact with other IRDye800 molecules as opposed to interacting
with polar solvent (Figure 12C, 13). The negative charge also prevents close interaction
of the heterocyclic rings between dyes, compromising pi-pi interaction. Therefore,
conjugation of HA to IRDye800 had minimal impact on spectral properties of IRDye800
(Figure 12C). It is worth noting that HA20k-dye conjugates are not nanoparticles in aqueous
phase. In addition, BSA monomer is spherically shaped with a diameter of ~10 nm (Figure
14A). When mixed with HA20k-Cy7.5, BSA morphologically changed to irregular shape
with sizes range from 10-70 nm (Figure 14B). In comparison, BSA monomer remains ~10
nm in the presence of HA20k-IRDye800. In summary, when conjugated with hydrophobic
Cy7.5, HA-dye tends to aggregate and self-quench, but the fluorescence is recovered upon
disassembly, or partially upon BSA interaction. No fluorescence quenching was observed
in HA conjugated to the hydrophilic IRDye800, HA-IRDye800 conjugates conserved
spectral properties.
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Figure 12 Characterization of HA-dyes with different HA MWN. (A) Chemical structures of HACy7.5 and HA-IRDye800; x and y indicate the calculated number of disaccharide units and conjugated
dyes per polymer chain, respectively; x = 9, y = 1 for HA 5k-dye; x = 38, y = 1 for HA20k-dye; x = 169,
y = 3 for HA100k-dye; (B-C) absorption and fluorescence emission pattern of HA-Cy7.5 and HAIRDye800 in H2O, DMSO/H2O or BSA with corresponding schematic diagram of molecular
interaction shown as insets; the absorption was collected between 600 nm to 900 nm, the fluorescence
was excited at 775 nm for HA-Cy7.5 and 770 nm for HA-IRDye800, and collected between 790 nm
to 900 nm for HA-Cy7.5 and 780 nm to 900 nm for HA-IRDye800. The concentration of free dye for
HA-dye conjugates was consistent (4 M) among solutions with and without DMSO and in BSA.
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Figure 13 Absorption and fluorescence emission pattern of different MW of HA conjugated dyes in
ultrapure H2O and 50/50 DMSO/H2O.The excitation wavelength for absorption ranges from 600 nm to
900 nm, the fluorescence emission was collected between 790 nm to 900 nm. The concentrations of
contrast agents were consistent in altered solvents.
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The morphology of HA-dye conjugates were examined with negative staining. It is
worth mentioning that HA20k-dye conjugates are not NPs in aqueous phase, they formed
irregular shape of aggregates at the range of micrometers (Figure 14).

Table 28 Calculated characteristic parameters of HA-dye conjugates
HA5kCy7.5

HA20kCy7.5

HA100kCy7.5

HA5kIRDye800

HA20kIRDye800

HA100kIRDye800

Weight ratio
(g/g)
dye/polymer

0.57

0.15

0.10

0.26

0.05

0.02

Dyes per chain

1.23

1.15

0.56

1.18

0.69

1.40

Conjugating
efficiency (%)

77.1

88.8

78.9

57.8

27.8

18.4

37.3

33.3

21.8

45.6

68.5

75.5

Yield (%)

Table 29 Calculated characteristic parameters of HA-dye conjugates
HA5kCy7.5

HA20kCy7.5

HA100kCy7.5

HA5kIRDye800

HA20kIRDye800

HA100kIRDye800

Weight ratio
(g/g)
dye/polymer

0.57

0.15

0.10

0.26

0.05

0.02

Dyes per chain

1.23

1.15

0.56

1.18

0.69

1.40

Conjugating
efficiency (%)

77.1

88.8

78.9

57.8

27.8

18.4

37.3

33.3

21.8

45.6

68.5

75.5

Yield (%)

Table 30 Calculated characteristic parameters of HA-dye conjugates
Figure 14 TEM images
-Cy7.5
(A)
and- HA20k-IRDye800
(B)HA
with
staining,
20k20k
HA5k-of HA
HA
HA100k
HA5k20k-negativeHA
100kCy7.5
Cy7.5
Cy7.5
IRDye800
IRDye800
IRDye800
scale bar represents 500 nm.
Weight ratio
(g/g)
0.57
0.15
0.10
0.26
0.05
0.02
dye/polymer
3.3.2 In vitro assessment of protein association Plasma proteins association
Dyes per chain

1.23

1.15

0.56

1.18

0.69

can

1.40

have a significant impact on in vivo size and solubility, which can potentially alter its
Conjugating
efficiency (%)

77.1

88.8

78.9

57.8

27.8

18.4

pharmacokinetic properties and tissue specificity [259]. To prove that hydrophobicity of
Yield (%)

37.3

33.3

21.8

45.6

68.5

75.5
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Table 31 Calculated characteristic parameters of HA-dye conjugates

contrast agents implies strong non-specific protein association, the mixture of HA-dye and
BSA were chromatographically eluted for BSA recognition while being monitored for
NIRF to identify the presence of HA-dye. ICG+BSA was used to test the applicability of
chromatography-spectrofluorometer system (data not shown), elution histogram was
exhibited after the void volume (determined by FITC labeled dextran2000), delay volume
between UV detector and spectrofluorometer was 5.55 ± 0.18 mL (determined by FITC
labeled dextran2000 and ICG+BSA) and normalized in Figure 15.
BSA monomer was eluted maximally at 27 min when monitoring absorbance at
280 nm (Figure 15A), whereas minimal peaks were observed in NIRF at that time (Figure
15B-C, blue trace). The NIRF of HA20k-Cy7.5 is undetectable due to self-quenching,
whereas HA20k-IRDye800 exhibits 2 peaks which likely correspond to aggregate and
dispersed polymer conjugate (Figure 15B-C, red trace). Interestingly, an apparent NIRF
peak was detected that corresponds to BSA for HA-Cy7.5 (Figure 15B, green trace) and
is consistent with the fluorescence recovery displayed spectrofluorometrically (Figure
12B), while a corresponding peak from HA-IRDye800 attributed to BSA binding was
minimally present (Figure 15C, green trace). In order to confirm the presence of BSA,
fractionated elutions of interest from HA-dye + BSA were collected for Bradford assay,
the NIRF peak fractions were strongly positive after Bradford dye staining, indicating that
NIRF peak of HA-Cy7.5 corresponds to BSA elution (Figure 16).
We also determined the size of particle distribution for BSA with/without HA-dye
conjugates with NP tracking analysis (< 30 nm to > 1 m). The concentration of HA20kCy7.5 was 3 times lower than that of HA20k- IRDye800, indicating more of HA20k-Cy7.5
formed aggregates that are larger than 1 m (Table 2).
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Figure 15 BSA interacts with HA-dyes to different extents due to dye hydrophobicity. (A) Elution
histogram of 50 M BSA monitored at 280 nm absorption; (B) fluorescent histogram of elution of
HA20k-Cy7.5 (4 uM Cy7.5 equivalent, red), BSA (50 uM, blue) or the mixture (green) monitored at
820 ± 10 nm and integrated by 5 s; (C) fluorescent histogram of elution of HA 20k-IRDye800 (4 uM
IRDye800 equivalent, red), BSA (50 uM, blue) or the mixture (green) monitored at 790 ± 5 nm and
integrated by 5 s; samples were eluted by AKTA pure 25L Chromotography system, monitored with
absorption motif at fixed wavelength of 280 nm and NIRF spectrofluorometer. All the samples were
run at least three times.
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Figure 16 Validation of the presence of BSA in fixed fragmentation of chromatographic elution.
(A) The NIRF of BSA, HA20k-dye conjugates or the combination of BSA and HA 20k-dye conjugates
determined by the spectrofluorometer. (C-D) The elution histogram of BSA + HA20k-dye conjugates
determined by the UV absorbance at 280 nm. (E-F) Bradford protein assay of fixed fractions of interest
captured under white light. The corresponding time of elution was labeled in C-D. (G-H) The absorption
spectra from 500 nm to 700 nm for bio-rad samples of fractions of interest, absorption maxima was
labeled at 595 nm with dashed line.
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Table 97 NP tracking analysis of BSA and BSA with/without HA-dye conjugates
Mean diameter

Concentration

Theoretical

(nm)

(particle/mL)

concentration
(particle/mL)

BSA

117.9 ± 57.2

7.05×108 ± 1.16×107

3.01×1015

HA20k-Cy7.5

162.1 ± 50.9

7.34×107 ± 1.68×106

2.41×1015

HA20k-IRDye800

166.0 ± 65.8

2.35×108 ± 1.36×107

2.41×1015

BSA+HA20k-Cy7.5

130.2 ± 60.0

2.91×108 ± 1.25×107

5.42×1015

BSA+HA20k-IRDye800

136.4 ± 66.1

6.69×108 ± 1.84×107

5.42×1015

Figure 17 TEM images of BSA (A), BSA mixed with HA 20k-Cy7.5 (B), BSA mixed with HA20kFigure 622 TEM images of BSA (A), BSA mixed with HA20k-Cy7.5 (B), BSA mixed with HA20kIRDye800 (C) with negative staining, scale bar represents 100 nm.
IRDye800 (C) with negative staining, scale bar represents 100 nm.Table 98 NP tracking analysis
of BSA and BSA with/without HA-dye conjugates
Mean diameter

Concentration

Theoretical

(nm)

(particle/mL)

concentration

Protein adsorption granted the biomaterial with new “biological identity” upon i.v.
injection, which alters the pharmacokinetic properties and potentially tissue specificity. To
(particle/mL)

explore the existence
and biological
role of protein
BSA
117.9 ± 57.2
7.05×108association
± 1.16×107 on HA-dyes,
3.01×1015 cellular
± 50.9 with/without
7.34×107 ± serum.
1.68×106Protein 2.41×10
association HA
was20k-Cy7.5
determined for162.1
HA-NIRF
binding15 leads to
HA -IRDye800

166.0 ± 65.8

2.35×108 ± 1.36×107

2.41×1015

20k
increased
uptake
ofexploration
HA-Cy7.5offor
KPC uptake
cells, with
a foldof increase
of complete
medium
Figure 491
In vitro
cellular
as a result
protein association.
(A-B)
The
8
7
15
BSA+HA20k
130.2
± 60.0
± 1.25×10
protein association
of-Cy7.5
HA-dyes on the
uptake
of KPC and2.91×10
PPE cells.
Numbers represent5.42×10
the fold increase

(CM) compared to starving medium (SM) is 2-4 for HA-Cy7.5 and 1-2 for HAof MFIBSA+HA
for CM compared
with SM.;136.4
(C) Cellular
of contrast
agents7 with RAW264.7
in SM or
8
-IRDye800
± 66.1 binding
6.69×10
± 1.84×10
5.42×1015
20k

CM. N = 3,
****pindicating
< 0.0001,
***p
IRDye.(Figure
18A-B),
higher
level<

< 0.01, for*pthe <relatively
0.05.
of0.001,
protein**p
association

hydrophobic HA-Cy7.5 as compared to HA-IRDye800. The protein association extent
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could be further quantified by the macrophage binding (Figure 18C) with/without serum:
66.2 ± 4.2% of RAW264.7 would bind with HA20k-Cy7.5 without protein association,
while only 9.1 ± 0.4% bound with protein associated HA20k-Cy7.5, suggesting protein
plays less important role in mediating macrophage binding. Furthermore, negligible
percentage (0.004% in SM and 0.007% in CM) of cells would bind with HA-IRDye800,
proves that HA-IRDye800 is less immunogenic as compared with HA-Cy7.5, indicating
less RES sequestration.

Figure 18 In vitro exploration of cellular uptake as a result of protein association. (A-B) The protein
association of HA-dyes on the uptake of KPC and PPE cells. Numbers represent the fold increase of MFI
for CM compared with SM.; (C) Cellular binding of contrast agents with RAW264.7 in SM or CM. N =
3, ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05.
Figure 820 Varied biodistribution between HA-Cy7.5 and HA-IRDye800 in WT C57BL/6 mice 24
h post i.v. injection. (A, C) Quantitative organ biodistribution of HA-Cy7.5 and HA-IRDye800
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mice, which demonstrate the predominant elimination route of each contrast agent. Representative
images
of necropsied organs were acquired with NIR channel of Pearl Trilogy Small Animal Imaging
MW
N could affect the biodistribution pattern, the fluorescence intensity was examined in
System; borders of images were erased to black to eliminate the interference from the neighboring placed
a
c
each
organ
for Nboth
HA-IRDye800.
organs
of interest:
organs
and
organ
samples.
= 3,HA-Cy7.5
p < 0.05 as and
compared
to free dye, bpThe
< 0.05
as compared
to HARES
p < 0.05
5k-dye,

as

compared

to

HA20k-dye,

d

p

<

0.05

as

compared

to

HA100k-dye.

clearance organs, were compared between different MWN of HA-dye to identify the
detailed in vivo performance. Overall majority of HA-Cy7.5 was accumulated in liver,
followed by spleen and kidney, among which, HA20k-Cy7.5 displayed the highest
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Figure 821 In vitro exploration of cellular uptake as a result of protein association. (A-B) The

fluorescence intensity in liver (Figure 19A-B). Additionally, hepatic retention of HA20kCy7.5 lasts for 96 h (Figure 20). On the contrary, HA-IRDye800 did not bind with albumin
and was able to retain the small size and hydrophilicity of HA and IRDye800, thus resulting
in biodistribution of HA-Dye conjugate, not of albumin (Figure 19C-D). When comparing
different MWN of HA conjugated IRDye800, HA100k-IRDye800 tends to be retained in
RES organs, whereas HA5k and HA20k conjugated IRDye800 accumulated more so in the
kidney, as observed in Figure 19C-D.
In the PDAC-bearing mice, higher fluorescence signal was observed in pancreas in
the HA-NIRF-treated group compared with dye-treated group with p < 0.0001 (Figure 20).
The fold increase of NIR signal in pancreas was 8-28 for HA-Cy7.5 as compared with
Cy7.5; and 8-15 for HA-IRDye800 when compared with IRDye800 (Table 3-4). Between
individual organs, significantly higher signals were seen in the liver and spleen with the
HA-Cy7.5-treated groups, hepatic accumulation is 2-3 times higher for HA-Cy7.5 when
compared with Cy7.5, the fold-increase in splenic NIR signal ranges from 5-10 for HACy7.5 when compared to Cy7.5. In comparison, increased uptake was observed in the
kidney, femur and stomach due to HA5k-, HA20k-IRDye800. Furthermore, a sharp increase
of RES accumulation was observed for HA100k-IRDye800 in addition to renal accumulation.
The fold increase of HA-IRDye800 accumulation in bone ranges from 8-16 as compared
with IRDye800; the ratio of kidney specificity is 3-4 times higher than that of the free dye.
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Figure 19 Varied biodistribution between HA-Cy7.5 and HA-IRDye800 in WT C57BL/6 mice
24 h post i.v. injection. (A, C) Quantitative organ biodistribution of HA-Cy7.5 and HA-IRDye800
determined by the relative fluorescence of each organ from NIRF images; (B, D) semi-quantitative
comparison of different MWN of HA conjugated dyes accumulation in organs of interest in WT
C57BL/6 mice, which demonstrate the predominant elimination route of each contrast agent.
Representative images of necropsied organs were acquired with NIR channel of Pearl Trilogy Small
Animal Imaging System; borders of images were erased to black to eliminate the interference from
the neighboring placed organ samples. N = 3, ap < 0.05 as compared to free dye, bp < 0.05 as compared
to HA5k-dye, cp < 0.05 as compared to HA20k-dye, dp < 0.05 as compared to HA100k-dye.

After 4 days clearance, RES retention is observed due to HA-Cy7.5, indicative of
macrophage
sequestration (data not shown). In summary, HA-Cy7.5 exhibited profound
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7 for HA-Cy7.5 in comparison to 0.36 for Cy7.5 (Figure 20C, Table 3-4). However, the
PDAC signal of HA-IRDye800-treated group was less influenced by the intestines and
liver (Figure 20C). The contrast ratio is 8-25 for intestines, and higher than 1 for liver with
HA5k- and HA20k-IRDye800. HA100k-IRDye800 exhibited comparable liver contrast with
HA-Cy7.5: with an average ratio of 0.3 (Table 4). In comparison, the SNR of pancreas in
HA-dyes-treated groups, when divided by that of the GI tract, RES organs, and kidneys in
WT C57BL/6 mice, is below 1, regardless of contrast agent (Calculated from Figure 19A,
C).
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Figure 20 The biodistribution of HA-NIRF in PDAC-bearing mice and quantification of background
interference. (A) The organ biodistribution of HA-Cy7.5 in PDAC-bearing mice 24 h post injection; (B) The
organ biodistribution of HA-IRDye800 in PDAC-bearing mice 24 h post injection; SNR was calculated based
of fluorescence of organ divided by the background noise, N = 5. ap < 0.05 as compared to free dye, bp < 0.05
as compared to HA5k-dye, cp < 0.05 as compared to HA20k-dye, dp < 0.05 as compared to HA100k-dye. (C)
Ratio of tumor contrast to accumulation/clearance organs from PDAC-bearing mice treated with HA-NIRF 24
h post injection. ****p < 0.0001 as compared to Cy7.5, ####p < 0.0001 as compared to IRDye800.
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Table 3 Ratio of HA-Cy7.5-treated pancreas or PDAC fluorescence divided by signal of surrounding
organs 24 h post injection (N = 5)

W.T. C57BL/6

Cy7.5

PDAC

HA5k-

HA20k-

HA100k-

Cy7.5

Cy7.5

Cy7.5

Cy7.5

HA5k-

HA20k-

HA100k-

Cy7.5

Cy7.5

Cy7.5

Muscle

2.31±0.50

4.64±1.29

4.46±1.21

4.44±1.27

3.59±1.68

27.56±4.83

33.88±11.98

40.76±20.90

Stomach

0.78±0.31

0.58±0.08

0.60±0.36

0.79±0.12

0.36±0.11

4.98±1.78

5.45±1.28

6.94±2.10

Int

2.38±0.41

0.42±0.20

0.41±0.07

0.62±0.39

1.77±0.75

3.67±1.19

5.77±1.50

10.06±3.09

Liver

0.04±0.01

0.02±0.003

0.02±0.01

0.03±0.01

0.05±0.02

0.25±0.06

0.51±0.11

0.43±0.25

Kidney

0.08±0.01

0.11±0.02

0.29±0.12

0.12±0.04

0.12±0.04

2.02±0.42

4.68±0.28

6.93±2.74

Spleen

0.56±0.17

0.14±0.03

0.12±0.08

0.24±0.12

0.69±0.40

1.18±0.41

1.76±0.32

1.11±0.40

Table 4 Ratio of HA-IRDye800-treated pancreas or PDAC fluorescence divided by signal of surrounding
organs 24 h post injection (N = 5)

W.T. C57BL/6

IRDye

Muscle

3.38±0.85

PDAC

HA5k-

HA20k-

HA100k-

IRDye

IRDye

IRDye

0.92±0.78

2.26±0.38

1.74±0.59

IRDye

8.28±5.55

HA5k-

HA20k-

HA100k-

IRDye

IRDye

IRDye

9.96±5.63

29.81±11.2

12.42±9.00

6
Stomach

0.17±0.03

0.39±0.58

0.23±0.08

0.17±0.05

1.06±0.59

1.54±0.97

3.50±1.32

1.04±0.77

Int

1.47±0.70

0.54±0.50

1.44±0.20

1.14±0.34

6.00±3.17

11.03±5.90

25.56±10.7

8.59±7.16

4
Liver

0.08±0.03

0.11±0.09

0.09±0.01

0.04±0.01

0.36±0.14

1.65±0.66

1.81±0.69

0.30±0.20

Kidney

0.12±0.02

0.10±0.08

0.19±0.03

0.22±0.06

0.52±0.22

1.14±0.48

1.96±0.34

1.06±0.65

Spleen

0.59±0.10

0.43±0.26

0.51±0.06

0.20±0.10

2.08±1.14

5.01±1.73

3.60±0.72

0.91±0.58
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3.3.5 IGS of HA-NIRF in PDAC-bearing mouse model An orthotopic,
syngeneic PDAC mouse model was used to demonstrate the tumor contrast efficiency of
HA-dyes. The representative FIGS images from HA-dyes displayed marked contrast
within pancreas (Figure 21-22). Overall, HA-Cy7.5 exhibited higher fluorescence
intensity than HA-IRDye800, with visible or apparent background signal from GI content,
especially for HA20k-Cy7.5. In comparison, HA-IRDye800 displayed comparable or
greater contrast within the tumor-bearing pancreas along with negligible background signal
from GI tract. The fold increase of signal intensity when the excitation source is directed
at the tumor compared to when the excitation source is directed off the tumor is 0.14
(Cy7.5), 2.10 (HA5k-Cy7.5), 3.59 (HA20k-Cy7.5), 9.17 (HA100k-Cy7.5), as detected at 825
nm, and 0 (IRDye800), 2.17 (HA5k-IRDye800), 663.09 (HA20k-IRDye800), 52.32 (HA100kIRDye800), as detected at 810 nm (Figure 22). The PDAC specificity was maintained for
up to 4 days post injection with HA-Cy7.5, but contrast was compromised as time extends
for HA-IRDye800, especially for HA20k and HA100k (Figure 23). In summary, HA
conjugated dyes displayed structure-influenced robust PDAC specificity with tunable GI
background signal.
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Figure 21 Images from surgical navigation of PDAC with contrast enhancement due to HA-dye
and dye 24 h post i.v. injection. Livers and spleens were removed due to high background signal
from clearance, spleens that were completely involved with PDAC were kept. Two channels (visible
with/without NIR) and three spots [Spectropen directed at PDAC, uninvolved pancreas (UP) and (GI)]
were displayed for each experimental group: (Top) Color images depict orthotopic PDAC and the
location of the handheld spectroscopic pen, which provides NIR spectral information and serves as an
excitation source for a widefield imaging system; (Bottom) NIR signal overlaid onto the grayscale
image shows robust enhancement of syngeneic, orthotopic pancreatic cancer, green crosses indicated
the directed location of excitation laser. Improved contrast can be observed due to HA conjugated dye
but not free dye. PDAC = pancreatic ductal adenocarcinoma, UP = uninvolved pancreas, St = stomach,
SI = small intestine, Int = large intestine.

93

Figure 22 Quanlification and quantification of signal from NIR channel that corresponds to
Figure 19. (A) Pseudo colored (fire) NIRF signal from PDAC, uninvolved pancreas (UP) and GI
excited by the Spectropen pointing at green cross in Figure 5; (B) spectroscopic signal from PDAC (on
tumor, blue) and UP (off tumor, red).

94
Figure 1091 Images from surgical navigation of pancreatic tumor contrast-enhanced with HA-
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Figure 23 Images from surgical navigation of pancreatic tumor contrast-enhanced with HA-dye
96 h post i.v. injection. Livers and spleens were removed due to high background signal from
clearance, spleens that completely involved with PDAC were kept. PDAC = pancreatic ductal
adenocarcinoma, UP = uninvolved panc, St = stomach, SI = small intestine, Int = large intestine; each
group was arranged into three rows: (Top) Color images show orthotopic PDAC and the location of
the handheld spectroscopic pen, which provides NIR spectral information and serves as an excitation
source for a widefield imaging system. (Middle) Pseudo-colored signal (fire) in the NIR channel of
the widefield imaging system and the spectroscopic signal from within the contrast-enhanced region;
(Bottom) NIR signal overlaid (cyan) onto the color image shows robust enhancement of syngeneic,
orthotopic pancreatic cancer. Contrast enhancement can be observed with HA 5k-, HA20k- and HA100kCy7.5, HA5k- and HA100k-IRDye800 (see inset middle row).
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Figure 1108 Images from surgical navigation of pancreatic tumor contrast-enhanced with HA-

uninvolved pancreas and healthy pancreas, regardless of contrast agent treatment. In
comparison, a significantly higher signal was detected between PDAC and uninvolved
pancreas for HA5k-, HA20k- and HA100k-Cy7.5, HA5k- and HA20k-IRDye800 but not HA100kIRDye800 treated mice, the contrast ratio (defined by SNR of PDAC/SNR of UP) was
labeled in each figure. HA20k-IRDye800 displayed the highest fold increase of 14.04, with
p < 0.001. HA-Cy7.5 exhibited increased contrast as compared to Cy7.5, regardless of
MWN of HA. Furthermore, enhanced contrast within PDAC pancreas was detectable after
4 days, with a contrast ratio of 3.86 and 5.96 for HA20k-Cy7.5 and HA20k-IRDye800,
respectively (Figure 25).
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Figure 24 Ex vivo analysis of HA-dye accumulation within the pancreases from WT C57BL/6 (A, C) and tumorbearing mice (B, D, E). HA20k-Cy7.5 and HA20k-IRDye800 treated healthy pancreas were plotted on the left for
healthy control. Panel A-D were arranged into three rows for each group: (Top) NIRF and white-field (WF) images
of a representative healthy/PDAC-bearing pancreas marked with acquisition locations of the spectroscopic signal
shown in middle row; (middle, left) fluorescence intensity excited with medium laser power and 1 s integration time
with the excitation laser component of FIGS system; (middle, right) plots of intensity values along the red dashed
line from the NIRF images quantified by ImageJ; (bottom, left) scanned image of frozen-sectioned unstained
healthy/PDAC-bearing pancreas with NIR channel from Odyssey Clx imaging system; (bottom, right) scanned H&E
stained pancreas slides with Pannoramic 250 flash series digital scanner, for each group pancreases were sequentially
sectioned with unstained slides. All scale bars represent 2 mm; (E) SNR of PDAC, uninvolved pancreas (UP) and
healthy pancreas (HP) normalized by muscle SNR that’s been treated with (a) Cy7.5, (b) HA 5k-Cy7.5, (c) HA20kCy7.5, (d) HA100k-Cy7.5, (e) IRDye800, (f) HA5k-IRDye800, (g) HA20k-IRDye800, (h) HA100k-IRDye800. Contrast
data was obtained 24 h after i.v. injection. SNR values were calculated from NIRF images obtained with the Pearl
Trilogy Small Animal Imaging System. ***p < 0.001, **p < 0.01, *p < 0.05, N = 4-5 for each group.

red dashed line from the NIRF images quantified by ImageJ; (I) contrast within PDAC-bearing pancreas
as determined by muscle SNR weighted SNR of PDAC, uninvolved panc. and healthy panc. from WT
C57BL/6. Data were collected 4 day after i.v. injection of contrast agents by tail vein. SNR value were
calculated based of NIRF images. ***p < 0.001, **p < 0.01, *p < 0.05. N = 4-5 for each group.
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Figure 25 Ex vivo analysis of HA-dye accumulation within the pancreases from WT C57BL/6
and tumor-bearing mice 96 h post injection. (Top row) NIRF channel and white field channel
merged image of a representative pancreas marked with acquisition locations of the spectroscopic
semi-quantification shown at the in Middle row, fluorescence intensity excited with medium laser
power and 1 s integration by the spectroscopic pen component of FIGS system; (Bottom row) Plots
of intensity values along the red dashed line from the NIRF images quantified by ImageJ; (I)
contrast within PDAC-bearing pancreas as determined by muscle SNR weighted SNR of PDAC,
uninvolved panc. and healthy panc. from WT C57BL/6. Data were collected 4 day after i.v. injection
of contrast agents by tail vein. SNR value were calculated based of NIRF images. ***p < 0.001,
**p < 0.01, *p < 0.05. N = 4-5 for each group.
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Figure 26 Representative whole-body images of PDAC bearing mouse injected with HA20kNIRF conjugates (equivalent to 1 nmol of Cy7.5 per mouse and 10 nmol of IRDye800 per mouse,
respectively.) captured by the lab-FLARE imaging system 24 h post injection. Blue represents the
psudo-colored NIRF channel. Dotted yellow shape delineates the abdominal organs, while dotted red
represents the tumor. The yellow asterisk is uninvolved pancreas and red asterisk is metastatic
mesenteric lymph nodes.

HA20k-NIRF conjugates were able identify abdominal lesions smaller than 7 mm3
and lymphatic metastases (Figure 27). The presence of malignant tissue was supported by
the hematoxylin and eosin (H&E) and positive staining of Ki-67 (Figure 27B-C). To that
end, detailed histopathology investigation confirmed contrast enhancement of several
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primary and metastatic PDAC malignances. Sections of the primary lesion demonstrate
nodules of epithelioid tumor cells within a peri-pancreatic lymph node and fat, the latter
associated with a prominent inflammatory response (Figure 27B). The tumor cells
demonstrated marked cytologic atypia without definitive glandular formation and adjacent
pancreatic parenchyma was unremarkable. Immunostaining revealed that the tumor cells
showed strong, diffuse membranous staining for CD44 in the background of expected
staining within lymphocytes. While Ki-67 labeled >90% of tumor nuclei. PDAC invasion
into soft tissue immediately adjacent to the pancreas had some areas that were more poorly
differentiated with foci having a sarcomatoid appearance (Figure 27C-a). CD44 stained
all tumor cells and Ki-67 labeled approximately 75% of all tumor nuclei. PDAC metastases
to adipocytic tissue (Figure 27C-c) had consistent morphology and showed diffuse CD44
and strong cytoplasmic staining. Ki-67 labels 50-60% of tumor nuclei. In Figure 27C-d,
tumor cells are seen involving adipose tissue, surrounding individual adipocytes.
Interestingly, there is heterogeneity of morphology with some tumor cells being epithelioid
with others having a spindled, sarcomatoid appearance. CD44 strongly labels all tumor
cells, which could play a role in HA targeting of these malignancies.
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Figure 27 Probing capability of HA20k-IRDye800 on the intraperitoneal metastases of PDACbearing mice. (A) Fluorescence was accumulated at the metastatic sites of interest labeled with 1-4, as
well as the primary tumor but not involved spleen; (a) (b) represent photos captured with color channel
and NIRF channel, representatively, (c) is the color channel merged with pseudo-colored NIRF channel,
(a)-(c) were captured by Curadel Lab-FLARE imaging system; (d) is the NIRF image captured by
Fluobeam imaging system. (B) Pathology of corresponding metastatic sites identified with H&E, Ki-67,
and CD44 staining, NIRF distribution of corresponding sectioned was determined with 42 m resolution.
The intensity of 800 nm channel of Odyssey Clx imaging system was set at 9. Black bars represent 2
mm.

Acute toxicity of HA20k-NIRF was examined to further confirm their translational
potential (Figure 28, 29). Upon the administration of HA20k-NIRF conjugates at 20 times
of the dose used for imaging, a comprehensive diagnostic profile was determined for
indications of toxicities in liver, kidney, bone, GI, pancreas. Disorders including
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malnutrition, dehydration, hyperglycemia/hypoglycemia were assessed. A slight increase
of BUN for HA20k-IRDye800 could be attributed to its renal clearance (Figure 28).
Whereas reduced amount of total protein from HA20k-Cy7.5 might be correlated with the
strong protein adsorption (Figure 28). These aberrancies contradicted with the findings
that lungs, kidneys, spleen, and heart were histologically unremarkable by H&E staining
(Figure 29). Liver sections from each animal demonstrated mild, diffuse microvesicular
steatosis within hepatocytes in the absence of lobular/portal inflammation, ballooning
degeneration, or apoptosis. Brain sections overall were without abnormality with
occasional animals showing scattered red neurons in Purkinje cells within the cerebellum.
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Figure 28 Comprehensive biochemical and hematological assessments for WT C57BL/6 mice
injected with HA20k-NIRF (equivalent to 20 nmol of free dye/mouse) or vehicle control for the
acute toxicology study. N = 3.
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Figure 29 Representative images for the histological
assessments of vital organs harvested from WT
C57BL/6 mice injected with HA20k-NIRF (equivalent
to 20 nmol of free dye/mouse) or vehicle control. N = 3.
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3.4 Discussion
Tumor contrast enhancement relies not only on the accumulation of the contrast
agent in tumor tissue, but also on the ability of the contrast agent to be removed from
healthy surrounding tissues and organs. Accumulation and removal of imaging agent from
tissue that is not malignant is the sum of several factors, including native dye clearance
mechanism, physico-chemical properties of the contrast agent, and/or for potential
phagocytic interaction, which directs agents to organs of RES [260], [261]. Therefore,
several important criteria that can be tuned to control the in vivo biodistribution of contrast
agents [157]. Size and hydrophobicity are decisive factors for kidney elimination and RES
sequestration [262]: generally, particles with a hydrodynamic diameter up to 5-7 nm fall
below renal filtration threshold and are excreted [263], while particles larger than 200 nm
can be trapped in liver and spleen with prolonged retention. Hydrophilicity variation affects
the pharmacokinetics of the probes as a result of distinct protein adsorption, which is more
likely for hydrophobic than hydrophilic materials [264]. Protein adsorption could mediate
the enhanced RES sequestration by promoting opsonization [138], [264], [265]. More
importantly, serum protein adsorption increases the apparent hydrodynamic diameter of a
hydrophobic molecules by more than 15 nm, which prevents the renal excretion [266]. The
optimum pharmacological properties for in vivo application include minimum non-specific
binding and an adequate retention time in the body preferably followed by fast excretion
[267]. A better understanding with regard to how the characteristics of contrast agents
influence their in vivo behavior is an important step towards designing NIRF biomaterials
suitable for molecular imaging applications and for efficient tumor delivery [261].
On the basis of physiological parameters such as hepatic filtration, tissue
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extravasation, tissue diffusion, and kidney excretion, it is clear that physical size of imaging
agent has a profound impact on its in vivo distribution [138], [157] (Figure 19). Often
macromolecules (10 nm ≤ size ≤ 100 nm) [138] afford prolonged blood half-lives to allow
time for extravasation out of the vasculature. Nevertheless, small particles exhibited lower
background signal due to rapid clearance, but provided less time for the probe to access the
tumor

[268]. As

a

linear

homopolymer,

HA demonstrated

MW-dependent-

biodistribution.[269] Courel et al. [270] found the retention of tritiated high MW (HMW)HA was 40-fold higher than that of HA oligomers on nude mice 5 h post injection; in
addition, the highest accumulation was in kidney for HA oligomers and in liver for HMWHA. Though conjugated with NIR fluorophore, HA-IRDye800 demonstrated consistent
MW-dependent biodistribution as HA, (Figure 19C-D, 20B) because the large sized HA
moiety drives the in vivo performance instead of the hydrophilic fluorophore. Whereas the
Cy7.5 moiety is entropically favorable to bind with albumin (Figure 12B, 14B) with size
enhancement, making them excluded from renal filtration and entrapped through hepatic
filtration (Figure 19A-B, 20A).
Cyanine dyes are capable of forming H-aggregates by hydrophobic interaction,
which characterized with hypsochromic absorption and weak fluorescence emission [271]–
[273]. As shown in Figure 12B (Also in Figure 13), the absorption maximum blue-shifted
for HA5k and HA20k conjugated Cy7.5 in H2O, meanwhile the dimer absorption
(represented by shoulder peak) becomes more visible as compared to Cy7.5, all suggest
intermolecular hydrophobic interaction between Cy7.5 moiety. In comparison, the
hydrophilic IRDye800 displayed limited tendency to interact among each other as opposed
to with polar solvent molecules by strong ion-dipole interaction between sulfonate groups
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and H2O (Figure 12C, 13). The negative charge also acts as obstacle for proximity of
heterocyclic rings between dyes, compromising hydrophobic interaction. Therefore, the
spectroscopic changes of HA-IRDye800 were not apparent throughout varied solvents.
Non-specific protein adsorption affects the in vivo fate of contrast agent which is
determined by its topography, composition (hydrophobicity), heterogeneity and potential
surface physiochemical properties [274]. The strong binding of a fluorescent probe to
albumin alters the pharmacokinetics of the probe, resulting in reduced diffusion into tissues
and poor target contrast [275]. Nonuniformity of surface characteristics results in domains
that can interact differently with proteins [274]. Berezin et al. [275] proved that fluorophore
but not targeting moiety, is predominantly responsible for albumin binding of imaging
probes. Meanwhile, HA is a biocompatible and safe drug carrier capable of reducing
protein adsorption and potentially immunogenicity of the protein corona [201], [202].
Cyanine dyes such as ICG, are able to bind with plasma proteins with high affinity, results
in complete extraction by hepatic parachyma and fast elimination into the bile [276], [277].
More importantly, hydrophilic dyes exhibited up to 2 orders of magnitude lower binding
constants toward albumin than their hydrophobic countparts [275]. Beckford et al. [278]
claimed that increased hydrophobicity of the indolium side chain results in enhanced
binding interaction within limitation threshold of steric hindrance. Accordingly, our study
demonstrated that HA-Cy7.5 displayed more intensive binding with BSA as compared to
HA-IRDye800CW (Figure 14B-C), which might attribute to the fact that benzindole is
more hydrophobic than indole. Also, ionized sulfonate groups significantly weaken the
hydrophobicity of IRDye800. The charged side chain is indicative of low protein binding
and high serum stability.
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The tumoral retention of HA-dye depends on the interestitial binding of HA moiety
after blood circulation and extravasation. Unlike many tumor types, PDAC is hypovascular
with collapsed, but intact blood vessels, which is not desirable for EPR effect [279]–[281].
Cabral et al. [282] reported that sub-30 nm micelles could penetrate vasculature of
pancreatic tumor. The calculated experimental hydrodynamic diameter of 30k HA is 15 nm,
while 32 nm for 100k HA [283]. Therefore, HA5k, HA20k conjugated dye are presumed to
extravasate more easily than HA100k-dyes, meanwhile vascular bursts could potentially
enhance permeability of pancreatic tumor blood vessels for large particles [284].
Additionally, PDAC is characterized with an extensive extracellular HA deposition, which
is (34 ± 2.7) ng/mg tissue for normal pancreas in contrast to (420 ± 150) ng/mg for PDAC
in KPC mice [232], [285], [286]. A wide variety of HA binding molecules (serum-derived
HA-binding protein, versican) and receptors (CD44, LYVE-1, RHAMM) contribute to the
formation of HA meshwork and anchorage to the cell surface [285]. Followed with
extravasation, HA moiety of contrast agents bind to overexpressed CD44 (or potentially
other HA binding receptors), which could confine the conjugates in tumor interstitium as
opposed to diffusing back into blood vessels. Furthermore, the binding affinity relates with
HA MW:HA oligomers with size of 38 disaccharide units (around HA20k) showed higher
avidity with CD44 compared with that of 10 disaccharide units (around HA5k) due to
multivalent binding [287]. In summary, PDAC vasculature is available for LMW HA-dye’s
extravasation, and HA-CD44 binding plays a role in retention within tumor, which may be
the mechanism of HA-dye’s robust contrast in PDAC.
Figure 31 outlines the tuning effects of HA MW and physicochemical properties
of dyes on the accumulation of organs of interest. The CNR was defined by the tumor
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contrast which could be achieved by all the conjugation of HA (insets in the bottom). SNR
is tuned to minimize the signal from liver, spleen and GI tracts. The strategy to reroute the
native clearance of cyanine dyes from hepatobiliary to renal elimination and ease the RES
burden of macromolecules results in the finding of optimized contrast agent (HA20kIRDye800) with minimal non-specific accumulation in background organs. The dominant
factor is size, which could be affected by the HA MW as well as the protein association.
As shown with the HA-Cy7.5, protein association with Cy7.5 normalize the biodistribution
to the RES sequestered, hepatobiliary eliminated pattern, with marginal variation between
different HA MW. Whereas the LMW HA conjugated IRDye800 falls below the renal
threshold with reduced accumulation in RES organs, presumably caused by the native
small size of LMW HA and hydrophilicity of IRDye800 unfavorable for plasma protein
interaction. In summary, HA-dye conjugates provide a simple but versatile platform for
imaging pancreatic tumor. Based on that, our study screened a promising contrast agent
candidate for clinical translation as well as establishing a foundation for rational probe
design, also it concludes the guidelines for efficient delivery of therapeutics to the tumor.
To account for the tumor specificity, we determined if HA-CD44 binding is
responsible for the contrast within pancreas. When blocked with 100k HA, uptake of
HA20k-IRDye800 was significantly reduced both for KPC and PPE cells with p < 0.0001
(Figure 31A-B). In addition, uptake of HA20k-IRDye800 is energy-dependent (Figure
31D), and not involved with micropincytosis (Figure 31G), indicating involvement of
receptor-mediated pathway. Finally, uptake efficiency of HA-dyes was evaluated between
PPE and KPC cells to support PDAC specificity ex vivo and in vivo (Figure 32A-B).
Overall, the uptake efficiency was higher for KPC when compared with PPE under
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identical conditions, regardless of HA MW and dyes. The fold increase of MFI for KPC as
compared to PPE was 1.3, 3.0, 1.3, 1.2 for Cy7.5, 5k, 20k and 100k HA-Cy7.5, and, 1.6,
0.8, 1.6, 1.3 for IRDye800, 5k, 20k, 100k HA-IRDye800, respectively. The differences,
though not as high as observed in vivo, were significant. Which matches with the CD44

Figure 30 Schematic summarization of the HA MW and dye hydrophilicity affect the PDAC
contrast in tumor-bearing mice. Top: organs of interest that are considered to affect the contrast of
PDAC; middle: view of imaging field including the liver, spleen, stomach, kidney and intestines, intensity
of green indicate the accumulation of contrast agents given that PDAC contrast is consistent; LMW HAdye represents HA5k- and HA20k-dye conjugates, HMW HA-dye represents HA100k-dye conjugate; bottom:
variation trend of HA MW, extent of RES clearance PDAC contrast based on the different dye-derived
HA conjugates.
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expression between KPC and PPE cells, CD44 positivity contributes to the endocytosis of
HA conjugated dyes for both KPC and PPE, the overexpression of CD44 in KPC favors
the clustering of CD44, higher affinity and stronger binding of HA conjugated dyes, thus
results in PDAC contrast macroscopically.

Figure 31 In vitro exploration of cellular uptake supporting the PDAC specificity. (A-B) Cellular
uptake of KPC and PPE with HA-dye and free dyes, numbers represent the fold increase of MFI for
KPC compared with PPE. Error bars are obtained measuring the standard deviation among the
replicates. The uptake profile of HA20k-IRDye800 by KPC and PPE cells demonstrating (C) time
dependency, (D) energy dependency, (E-F) receptor dependency. (G) The exploration of endocytosis
pathway by amiloride blockage. N = 3, ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05.
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Figure 32 CD44 expression in PDAC cells ex vivo and in vitro. (A) Representative flow cytometry
analytical histogram of untreated, PPE and KPC cells single stained with CD44-FITC; (B) Histology
of PDAC-bearing murine pancreas; (a) scanned H&E stained murine PDAC; (b) mouse PDAC with
100 × magnification; (c) scanned CD44 stained slides of murine PDAC (d) microscopic photos of
mouse PDAC with 100 × magnification; (e) microscopic photos of mouse sarcomatoid with 100 ×
magnification. Scale bar represents 2 mm for scanned images and 10 m in captured microscopic
photos; (C) schematic representation of HA-dye interacting with CD44 receptors, which was expressed
intensively on pancreatic cancer cell but moderately on normal pancreatic cell.
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CHAPTER 4: PROBING THE CAPABILITY OF HABASED CONTRAST AGENTS FOR
IDENTIFICATION OF PANCREATIC CANCER
METASTASES
4.1 Introduction
Metastasis is the most common cause of death in cancer patients [288]. This is
particularly true for pancreatic cancer, in which majority of patients are diagnosed with
metastatic disease and few show a sustained response to adjuvant therapy [289]. As a result,
patients undergo complete resection and adjuvant therapy often died of the metastatic
development [290]. Most of the metastases occur in liver, and thus, patients likely harbor
liver occult metastases at the time of surgery [290]. Finding these metastases has prognostic
and therapeutic consequence for patients with resectable or boardline resectable PDAC.
Therefore, an accurate detection of metastases not only aid with cancer staging and
treatment planning, but also help avoid futile resection procedures that greatly decrease the
quality of life of a patient that has no hope of being cured. Staging laproscopy and MDCT
are reported for detection of intrahepatic occult metastases with controversial outcome
[291]–[294]. Houghton et al. [295] reported that NIRF imaging is able to map the sentinel
lymph node metastases of PDAC with CA19.9-targeted immunoconjugates, they also
found that NIRF signal is apparent in numerous micrometastases, indicating NIRF imaging
is applicable for imaging of PDAC metastases.
HA20k-IRDye800 were previously reported to be highly efficient for tumor
detection in PDAC mouse model with reduced background organ interference and
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excellent contrast ratio. Furthermore, HA-NIRF conjugates displayed enhanced contrast in
the primary tumor, with abdominal signal emphased in different organs. Herein, we further
explore its clinical applicability by using metastases models of PDAC, and determine the
signal attenuation under varied metastatic sites.

4.2 Methods
All animal studies were performed under a protocol approved by the UNMC
Institutional Animal Care and Use Committee. Procedures were followed in accordance
with institutional guidelines per the Guidelines on the Care and Use of Animals for
Scientific Purposes. The guidelines were followed to ensure humane care of the animals.
106 KPC cells per mouse were injected in to the spleen of WT C57BL/6 mice and allowed
to circulate for 1 minute. Vessels supplying the spleen were cauterized, and wound closed.
The cells circulated to the liver were allowed to grow for 2-3 weeks [296]. External US
imaging provide invaluable real-time data for tracking metastasis formation in liver [297].
Periodically, tumor-bearing mice will be examined with Visual Sonics Vevo 2100 US
imaging system (FUJIFILM, Toronto, Canada). Upon the observation of liver metastases,
HA20k-Cy7.5, HA20k-IRDye800, HA100k-Cy7.5, HA100k-IRDye800 and NanoICG were i.v.
injected in tail vein of mouse model and monitored with NIRF setting at 12 h, 24 h and 72
h. To demarcate the areas of specific uptake and demonstrate preferential localization of
the HA-based contrast agents, metastases located in the liver will be harvested and fixed
with Formalin. Histologic analyses for regions of interest were conducted using
hematoxylin and eosin (H&E) staining by a pathologist blinded to experimental conditions.
The mesoscopic scan of fluorescence was correlated with histological H&E scan.
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4.3 Results
The development of hepatic metastatic model was optimized with gradient
concentration (5  105, 1  106 and 5  106/mouse) of KPC cells and altered time (2 weeks,
3 weeks and 4 weeks) for tumor growth. When inoculated with 1  106 of KPC cells per
mouse and developed for 2 weeks, scattered micrometastases with the size of less than 0.5
mm were observable on the surface of the medium lobe (Figure 33), which is marginally
detectable in the white light field. It is worth mentioning that at this this level of metastases,
the aberrancies in liver function were not detected, the malignancies were also nondetectable by transdominal US (data not shown). With the NIRF channel in the
intraoperative setting, hypo-contrast of hepatic metastases was observed due to HA100k-

Figure 33 Ex vivo analysis of hepatic metastases. (A) Color and (B) NIRF images captured of liver
harboring suspected metastases labeled with yellow arrows. (C) Mesoscopic scanning of cross-sectioned
slides with H&E (left) and NIRF (right) channel for histological correlation. Black arrows were pointed
at the liver malignancies confirmed by a board-certified pathologist while white arrows were pointed at
the corresponding regions with the absence of NIRF signal.
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Cy7.5, which was demonstrated to be utmostly accumulated in the liver among all HANIRF conjugates. The contrast is able to remain for at least 72 h. As those that tend to be
trapped in the liver, HA100k-IRDye800 and NanoICG also demonstrated hypo-contrast in
identifying liver malignancies, but with limited contrast ratio due to low quantum yield.
(Figure 33) In comparison, HA20k-IRDye800 will exhibit no contrast due to minimal
hepatic entrapment shown previously. This finding is in accordance with the fact the
metabolism of contrast agents correlated with functional areas.

Figure 34 Mesoscopic correlation between the scanned H&E and NIRF of liver harboring
metastases that were treated with different contrast agents/time points.
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The hypo-contrast was also observed in metastases buried in the stomach (Figure
35) and on the surface of the spleen (Figure 36) due to HA-Cy7.5. The mesoscopic
correlation between NIRF and H&E supported that malignant areas matched with those
with the absence of NIRF. Compared with metastatic spots in the stomach wall, the splenic
metastases are more frequently observed throughout HA-Cy7.5 groups with hypo-contrast.

Figure 35 Mesoscopic correlation between the scanned NIRF (a) and H&E (b) of superficial
splenic metastases that were treated with HA5k-Cy7.5 (A) and HA100k-Cy7.5 (B). Subset c and d
in each panel represented the border between malignancy and healthy spleen with low and high
magnification, respectively. Images were acquired 24 h post injection.

Figure 36 Mesoscopic correlation between the scanned NIRF (a) and H&E (b) of superficial
splenic metastases that were treated with HA5k-Cy7.5, HA20k-Cy7.5 and HA100k-Cy7.5. Health
Figure 1324 Mesoscopic correlation between the scanned NIRF (a) and H&E (b) of superficial
spleen that was harvested from the WT mice injected with HA20k-Cy7.5 was evenly perfused as control
splenic metastases that were treated with HA5k-Cy7.5 (A) and HA100k-Cy7.5 (B). Subset c and d
on the left. Images were acquired 24 h post injection.
in each panel represented the border between malignancy and healthy spleen with low and high
magnification, respectively. Images were acquired 24 h post injection.

4.4 Discussion
Liver is the common site for PDAC micrometastases, yet not considered for
surgical resection due to uncontrollable and expansive growth pattern [298]. Therefore, a
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Figure 1323 Mesoscopic correlation between the scanned NIRF (a) and H&E (b) of superficial
splenic metastases that were treated with HA5k-Cy7.5, HA20k-Cy7.5 and HA100k-Cy7.5. Health
spleen that was harvested from the WT mice injected with HA20k-Cy7.5 was evenly perfused as control

specific imaging toolkit for detection of liver metastases will afford accurate staging and
prognosis. ICG has been shown to accumulate around hepatic metastasis of pancreatic and
colorectal cancers, probably due to retention of indocyanine green in compressed
hepatocytes, which is shown by a fluorescent rim [299]. In 16% of patients undergoing
pancreatic resection without preclinical detected hepatic metastases, fluorescence imaging
revealed micrometastases of at least 1.5 mm, which was confirmed by histopathological
examination. By revealing undetected hepatic metastases, NIR fluorescence imaging can
further decrease the rate of futile pancreatic resections. However, due to the nonspecificity
no tumor-specific targeting can be expected of ICG. Because of the permeation limit of
NIR light, this method cannot be used to identify deep hepatic lesions. The utility of this
technique is limited to superficial hepatic tumors. However, small lesions at the hepatic
surface are likely to be missed by other imaging methods, such as CT, MRI, or US, because
of partial volume effects or poor near-field resolution, whereas those conventional
modalities are better at detecting deep hepatic lesions. Therefore, fluorescent examination
seems to have complementary merits over other imaging techniques and, thus, is worth
performing to examine the entire liver in detail [299]. The hypo-contrast demonstrated by
the HA-Cy7.5 conjugates in the detection of hepatic metastases is in accordance with the
recent clinical trial using Cetaximab-IRDye800 [176], which demonstrated hypo-contrast
for the intraoperative detection of liver micrometastases.
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CHAPTER 5: FUTURE DIRECTIONS
Due to our prior success in intraoperative imaging of PDAC, further investigation
of the mechanism of targeting and the effects of extended systemic exposure is needed for
optimizing contrast obtained in vivo as well as the PK profile of HA-based macromolecular
contrast agents. We hypothesize that high contrast enhancement of HA-dyes is induced by
receptor-mediated endocytosis, the difference in expression level of CD44 between KPC
cells and healthy pancreatic epithelial cells contributes to the contrast between PDAC and
uninvolved pancreas, the total amount of protein associated with HA-dyes is significantly
reduced as compared to NanoICG, and the enriched protein species is innate to the RES
system that confers the stealth effect of HA-dyes. These assumptions are foundational to
the high sensitivity and enhanced pharmacokinetic profiles required for clinical translation
of HA-conjugated dyes. Developing a deep understanding of the targeting ability of HAdye conjugates is paramount for potential use as a biocompatible platform for effective
delivery of chemotherapeutic agents to PDAC.

5.1 Research proposed for the near future
This research proposed for the near future seeks to characterize the enhanced
contrast obtained when using HA-based NIRF probes for the detection of pancreatic cancer.
The in-depth understanding of the fundamental cellular biology leading to contrast
enhancement will not only illustrate the translational potential of HA-based contrast agents,
but also aid in the future design of other macromolecular contrast agents for PDAC imaging.
Investigating the mechanism of uptake from the perspectives of molecular pharmaceutics
and physical pharmaceutics support the robustness of tumor-specificity, based on contrast
enhancement displayed in a syngeneic, orthotopic PDAC model. Further evaluation of PK
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profiles of macromolecular contrast agents would provide another avenue of innovation in
this project, expanding impact beyond HA-based agents to other macromolecular contrast
agents and improving potential for clinical translation of such formulations.
We expect the NIRF signal from HA-dye conjugates to overlay with the CD44
positive region, especially the triple-positive region, indicating specific uptake in
malignant cells. We also expect that the lack of plasma associated proteins significantly
reduce the macrophage adhesion while promoting the cellular uptake of KPC-PC for HAdyes. HA-dyes displayed higher tumor accumulation than NanoICG, as demonstrated in
our preliminary data, which we expect is due to lower affinity for plasma proteins with
HA-dyes than with NanoICG. We also expect that the enriched proteins associated with
HA-dyes, if any, belong to the dysopsonins that shield HA-dyes from being recognized by
macrophages.

5.1.1 Preclinical investigation of in vivo performance for HA20k-Cy7.5
and HA20k-IRDye800 with PK study Detailed investigations of the PK properties
of imaging agents remain critical to their successful clinical translation [300]. Therefore,
the focus herein is to quantitatively elucidate the in vivo kinetics of HA-dye to identify
optimal dosing strategies to provide the best chance of clinical benefit.
The first step is to investigate whether the HA20k-dye conjugates will be stable in
blood. Contrast agents will be incubated with freshly collected whole blood from SpragueDawley (SD) rats, and samples will be retrieved at predetermined times. The plasma will
be analyzed for visible absorption and fluorescence emission as a function of time.
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Simultaneously, I will work on setting and validating the bioanalytical method for the
detection of HA20k-dye conjugates on the LC-MS/MS.
The PK profile of HA20k-Cy7.5, HA20k-IRDye800 and free dye will be compared
using three SD rats per contrast agent. Repeated blood sampling will be performed using
jugular vein catheterization in rats (see detail in vertebrate animals). After the surgery, HAdye will be injected into the jugular vein, samples will be taken at different time intervals
and processed if needed. The kinetic parameters will be estimated with Phonenix
WinNonlin (Certara, USA) software with non-linear PK/PD modeling.

5.1.2 Characterization of CD44-mediated cancer cell uptake and
subcellular localization of HA-based contrast agents The targeting
mechanisms and specificity of cellular uptake are integral to obtaining contrast in
intraoperative imaging. This aim seeks to develop an understanding of multifactorial
influences including HA MW, cellular CD44 receptor expression level, temperature
dependency, as well as HA blockage on the cellular uptake of HA-dye conjugates. It also
seeks to determine the endocytic pathway and intracellular localization of HA-dye
conjugates. To investigate ATP dependence on contrast enhancement, KPC cells will be
incubated at either 37ºC or 4ºC along with the HA-dye conjugates. The cellular uptake will
then be determined with flow cytometry (FC). Additionally, CD44 dependence will be
investigated using corresponding MW of HA to block the CD44 receptors. Samples with
blocked CD44 will be compared to those without CD44 blockage to elucidate the degree
to which CD44-mediated endocytosis affects uptake of HA-dye conjugates. To further
investigate whether HA-dye uptake is dependent on the expression level of CD44, we will
compare the uptake between immortalized human pancreatic nestin-expressing (HPNE,
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CD44 low expression) cells and KPC (CD44 high expression) cells to determine if high
expression of CD44 translates into higher uptake of HA-dye conjugates. To explore the
intracellular transporting mechanism of HA-dye conjugates, we will study the effects of
membrane entry inhibitors on the cellular internalization of HA-dye conjugates.
The subcellular fate of contrast agents can also influence the ultimate translational
applicability, especially for NIRF dyes which may degrade in harsh environments.
Confocal scanning laser microscopy will be used to determine the subcellular location of
HA-dye conjugates. Samples will be incubated with both HA-dye conjugates and the
primary antibody for early endosomal marker Rab5 (anti-Rab5), which will help to
determine the subcellular location and fate of HA-dye conjugates.

5.1.3 Gel separation and proteomic analysis of associated proteins of
HA20k-dye conjugates HA20k-dye conjugates at the theoretical plasma concentration
will be incubated with an equal volume of pooled mouse plasma (Sigma-Aldrich, P9275)
under constant agitation for the formation of HA-dye-protein complexes. The preliminary
separation of associated protein from unbound protein will be performed with gel-filtration
chromatography [GFC: ÄKTA Pure system (GE Healthcare) equipped with a Superdex 75
10/300 column, UV (collecting at 280 nm to detect protein) and fluorescence (ex = 760
nm; em = 810 nm to detect NIRF or HA-NIRF) detectors, and fraction collector in series
will be applied for sample elution]. Eluted fractions that are positive for NIR fluorescence
will be analyzed by bicinchoninic acid quantification to confirm the presence of protein.
The free dyes will be used for negative controls.
The eluted fractions that are positive for NIRF will be precipitated with
trichloroacetic acid. A protein pellet will be formed by centrifugation. The pellet will be
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pooled for each group, and processed for two-dimensional polyacrylamide gel
electrophoresis (2D-PAGE) [301]. The protein of interest (albumin, Complement C3,
apolipoprotien A-I, Ig heavy chain alpha, gamma, Ig chain alpha) will be identified and
compared between each group. To further analyze the proteome of HA-dye conjugates and
dye only associated proteins, the protein pellet (processed as described previously) will be
analyzed using a quantitative proteomics approach.

5.1.4 Expected results/Protential problems/Alternatives For the PK study, we
expect the HA-dye conjugates are stable in whole blood due to the amide bond, HA-dye
conjugates will have prolonged blood half-lives as compared with that of free dye, of which,
HA-Cy7.5 will exhibit the most extended blood retention. Volume of distribution is
expected to be significantly higher for HA-IRDye800 compared to HA-Cy7.5, as HAIRDye800 is a hydrophilic polymeric derivative. Potential difficulties include stability of
HA-dye in the blood, as hyaluronidase exist in the blood which degrade the HA to
oligomers, so NIRF signal may not represent the original HA-based dye. The alternative
strategy is to run GFC to separate NIRF-positive elutions and determine the time span for
HA stability. 2) As far as the endocytic analysis, a higher level of NIRF will be co-localized
with CD44 positive regions from ex vivo analysis of tissue as compared to other groups.
We expect a significantly higher amount of CD44 positivity and NIRF uptake in KPC cells
as compared with HPNE, and higher uptake with higher temperature and increased HA
MW. The CD44-mediated internalization might occur via the lipid raft-mediated
endocytosis pathway. HA-dye residues might be found in endo-lysosomal vesicles. 3) We
expect that more protein will be associated with HA20k-Cy7.5 conjugate compared to
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HA20k-IRDye800, and a higher level of complement protein and apolipoprotein will be
associated with HA-Cy7.5.

5.2 New strategies proposed for PDAC therapy
Through our preliminary data and the experiments proposed in Aim 1, we anticipate
robust tumor imaging of PDAC. However, eradication of PDAC is the ultimate goal of my
research, which remains challenging due to tumor heterogenicity and therapy resistance
[302]–[304]. In the next step, I will particularly focus on immunotherapy because it is
superior than other therapeutic modalities at multiple aspects for sustained anti-tumor
response, among which, immune checkpoint blockade (ICB) is a common denominator
approach for improving T cell response [305], [306]. However, pancreatic cancer is poorly
immunogenic and the tumor microenvironment contributes to immune tolerance [307].
Desmoplastic reaction, featured with hyaluronan and collagen deposition, contributes to
immunosuppression of pancreatic cancer both biochemically and mechanically, and thus
become a potential combinational target for immunotherapy [308]–[312]. Either
pharmacological or genetic targeting for dense matrix depletion lacks evidence for
sensitizing immunotherapy, but the combination of both create strategies for efficient
disturbance of immunosuppressive matrix [175], [313]. Therefore, my third research aim
will be to develop immunotherapy-based combinational strategies for the treatment of
advanced, resistant pancreatic tumor, including exploring delivery strategies for genetic
targeting and determination of anti-tumor immune response.
Tumors are heterogeneous and ever-evolving, so drugs that are designed to kill
cancer cells directly by targeting cell intrinsic pathways inherently select for resistant
clones that lead to relapse [306]. Clinical data confirms that stimulating a patient’s natural
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antitumor immune response can cure relapsed, refractory patients with difficult-to-treat
cancers who have exhausted other treatment options [306], [314], [315]. Immunotherapy
by immune checkpoint blockade (ICB) is a promising approach to activate therapeutic
antitumor immunity and can bring long-lasting clinical benefits [316], but only a fraction
of patients respond to treatment and significant immune-related adverse events exist [317],
[318]. ICB improved the therapeutic outcome in melanoma and lung cancer [319]–[322].
which might be related to their high mutational load-induced antigen presentation [323],
[324]. However, other solid tumors that carry less mutational burden, are resistant to ICB
due to inadequate T cell infiltration and stroma-associated immune suppression [325],
[326]. Meanwhile, ICB-based combinational therapeutic interventions are extensively
explored [327]–[329], but remains challenging due to the poor delivery and distribution of
ICB in the tumor. Specifically, tumors undergo significant remodeling that results in high
cross-linked and dense extracellular matrix, which increases interstitial fluid pressure,
constricts both tumor lymphatics and tumor blood vessels as a “binding site barrier” [330].
Of importance, dense matrix led to failure of several strategies aimed at improving effector
T cell infiltration by blocking their entry into tumor bed [331], [332]. Hence, normalizing
the tumor matrix and microvasculature using extracellular matrix-degrading enzymes,
extracellular matrix antagonists, and anti-angiogenic therapies hold promise for improving
the entry and penetration of ICB [333], [334].
Pancreatic cancer is unique from an immunological perspective with the hallmark
of dense desmoplastic reaction [308]–[310], in which hyaluronic acid and collagen
contribute to solid stress [311]. The dense matrix exerts both mechanical and biochemical
effects on immunosuppression and drug delivery [312]. Although depletion of cancer-
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associated fibroblast induce vessel perfusion, it results in tumor metastasis and immune
suppression in pancreatic cancer [335], [336]. Au et al. summarized that collagenase
promotes dispersion of larger molecules and nanoparticles, whereas hyaluronidase is more
effective for small molecules [337], [338]. Furthermore, collagenase promote T cell
penetration, indicating its relevance with immuno-therapy [337]. However, there’s a lack
of knowledge on how the blood perfusion facilitates ICB in PDAC. Based on the
background above, I hypothesize that collagenase and hyaluronidase could convert
desmoplastic tumors from ICB-resistant to ICB-sensitive for pancreatic tumors and would
improve the antitumoral immune response by enhancing the blood perfusion. To test my
hypothesis, I intend to pursue immuno-oncological research to answer the following
fundamental questions: (1) What would be the best delivery strategies for hyaluronidase
and collagenase to reduce collateral damage/risk of tumor progression? (2) How to decide
the matrix modeling window that facilities the ICB? (3) Will the anti-tumor efficiency
improve post desmoplasia depletion? (4) Will genetic targeting create a synergistic effect
with pharmacologic targeting for eradicating dense matrix?
Cancer treatment by ICB can bring long-lasting clinical benefits, but only a fraction
of patients respond to treatment [317]. In order to sensitize the pancreatic cancer
immunosuppressive microenvironment with ICB, I propose to deplete the hyaluronan and
collagen-the major component for the dense matrix-through pharmacological and genetic
targeting, and explore the anti-tumor immunity by 1) determining deliver strategies of
matrix-depleting agents; 2) determine the time-frame of matrix remodeling for ICB; 3)
investigate the immune responsive cell populations and cytokines; 4) synergistic effect of
combining the genetic and pharmacologic matrix-depletion for ICB. My hypothesis is that
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by pharmacological and genetic targeting of matrix-depletion, pancreatic tumor will be
responsive for ICB as demonstrated by reduced immunosuppressive cells, and increased
level of effector T cells and immune cytokines.

5.2.1 To determine the optimized delivery strategies for hyaluronidase,
collagenase Though bacteriophage vector was reported for the co-delivery of
hyaluronidase and collagenase [339], it raises concerns for immune responses. Poly
(Lactic-co-glycolid)-b-polyethylene glycol (PLGA-PEG) polymer-based delivery system
was reported for the delivery of collagenase and recombinant human hyaluronidase PH20
(rHuPH20) with high efficiency and biocompatibility [340], [341]. Therefore, it holds
promise for enzyme loading without interfering with IBC.
Preparation of PLGA-PEG loaded hyaluronidase and collagenase (NPhc),
hyaluronidase (NPh) and collagenase (NPc) will be similar as previously reported [341].
The thiolated enzymes will be conjugated, followed by a protective layer of fabricated PEG
for prolonging the half-life of enzymes. The conjugated unit of enzymes will be determined
by a microtiter-based assay for HA and collagen degradation. Fluorophores will be
entrapped for imaging detection (NPhc-DiD) as mentioned in 2.2.
Catalytic efficiency of NPhc: The enzymatic efficiency will be investigated with
the pancreatic tumor spheroids. Using the previous report, 3-D tumor spheroids of
MIAPaCa-2 and PANC-1 will be developed [342]. The type I collagen and HA in the
supernatants of cells before and after NPhc treatment will be quantified using enzymelinked immunosorbent assay (ELISA) for HA and Sirius Red assay for collagen,
respectively [339].
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Dorsal skinfold window chamber tumor model [343] will be applied with PANC-1
cells in BALB/c nude mice, for the in vivo determination of perfusion after matrix depletion.
NPh, NPc and a vehicle control will be used as the controls for NPhc. The time frame of
NPhc might be different than free enzymes, which will be adjusted accordingly. The
number of vessels that are opened for NPhc will be compared with NPh, NPc, vehicle
control and/or free enzymes.

5.2.2 To decide the time frame of matrix modeling for ICB perfusion The
dynamic change of tumor remodeling requires efficient therapeutic deliveries within the
optimal modeling time frame [175]. PANC-1 cells will be implanted in nude mice to
determine the biodistribution. DiD-encapsulated NPhc will be injected into the tumorbearing mice in 2.1.3 via orthotopic implantation. Upon the injection of DiD encapsulated
NP, NPh, NPc, NPhc, the tumor will be harvested at different time intervals.
Immunohistochemical (IHC) analysis of HA, collagen, CD31, and fluorescence signal of
tumor with IVIS will be used to determine the optimal time for matrix depletion. ICB will
be administered according to the predetermined optimal time. IHC of HA, collagen and
fluorescent signal will be used to visualize the desmoplastic breakage.

5.2.3 To investigate the delivery efficiency for the antitumor
immunotherapy
To define the application and mechanism of extracellular-depleted ICB, we will
examine the immune response by quantifying cellular subsets and cytokines of interest. We
will also use an advanced tumor model to study survival and molecular responses.
Mouse model of primary and metastases C57BL/6 mice will be inoculated with
Panc02 cells either in the pancreatic tail as a primary tumor or in the hemi-spleen as an
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advanced tumor model [344]. The NPhc will be injected 2 weeks post tumor implantation.
24 h post NPhc injection, anti-mouse PD-1, anti-mouse PD-L1 or IgG control will be
administered. The groups will include: NP+IgG, NPhc+IgG, NP+ICB, and NPhc+ICB.
The treatments will be given 3 times in 9 days and the mice will be monitored 3 times a
week for survival studies.
Analysis of infiltrating lymphocytes Murine livers and spleens will be mashed,
centrifuged and suspended in Percoll density gradient media for identification of the
lymphocyte layer. Cells will be labelled with CD3, CD8, CD4, CD25 and Foxp3 for the
identification of regulatory T cells (Treg) and effector T cells.
Determination of intracellular interferon gamma (IFN) isolated liver infiltrating
lymphocytes and splenocytes will be enriched for CD8 cells using CD8 negative isolation
kits. Golgistop will be added to the enriched cells, followed by the incubation of antibodies
for CD8, CD4 and a live marker. The IFN antibody will be added for FC assays. An
ELISA for mouse IFN will also be applied on the CD8 enriched cells for quantification.

5.2.4 Exploration of genetic targeting of fibrosis with ICB In addition to
pharmacologic targeting of desmoplasia; genetic targeting of fibrotic signaling has been
proved to be efficient for reducing immunosuppressive cells, but failed in the clinical trial
as single treatment [313]. Extracellular matrix deposition is a complex process and
intervention from multi-aspects to break the matrix. Therefore, the combination of
pharmacological and genetic targeting will be of interest to potentiate immunotherapy and
become a promising strategy to achieve durable regression of PDAC. We specifically
choose the focal adhesion kinase (FAK) as the genetic targeting [313], and hypothesize the
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synergistic effect will be induced with NPhc for ICB. The combination of FAK inhibitor
with NPhc and ICB will be explored with KPC and the more aggressive KPPC (p48Cre;LSL-KrasG12D;Trp53flox/flox) mice. The FAK inhibitor will be physically entrapped in
the NPhc, named NPhck. The treatment will be applied to KPC-derived orthotopic model
on C57BL/6 mice for preliminary evaluation, then using KPC and KPPC mice for the
detailed evaluation of immunotherapy. The detailed assessment includes ex vivo analysis
of cytokine profile (ELISA), the population of myeloid-derived suppressor cells, tumorassociated macrophages and Treg (FC and immunohistology). The survival time, tumor
burden and body weight will also be recorded.

5.2.5 Expected results: I expect successful completion of the experiments proposed
in Aim 2 will lead to a clear understanding of the desmoplastic depletion for sensitizing
the PDAC with ICB. I also expect that the co-delivery of pharmacological and genetic
targeting agents of fibrosis will be synergistic for perturbing tumor stasis and favoring the
T cell infiltration. Specifically, the PEG-PLGA delivery of hyaluronidase and collagenase
to tumor sites could disrupt the extracellular matrix of PDAC which would release solid
stress. The perfusion time frame will be determined with PK/PD in Aim 2.2, which we
predict will be 24 h. The immunosuppression of advanced PDAC will be reversed by the
release of solid stress from the tumor resulting in an improved immune response, as
evidenced by improved CD8 T cell infiltration, secreted cytokines, and reduced population
of immune suppressive cells. The combination of pharmacological and genetic targeted
depletion of matrix will synergistically reverse the fibrosis of PDAC for ICB intervention,
both in an orthotopic model and KPC mice.
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To obtain the skills necessary to complete these aims, I will acquire information
about gene editing ethics, gene knockout strategy, and the mechanism for breeding select
types of transgenic mice. I will also investigate methods for discovering relevant target
signaling pathways, as well as developing technical skills such as ELISA, tumor spheroid
culturing, quantification of cytokines and subcellular population of interest.

5.2.6 The challenges and alternatives would include: 1) the stability and efficacy
of NPhc might be compromised in the systemic circulation. Size-induced splenic and
hepatic uptake would raise concerns for the delivery efficiency of enzymes, antigen
presentation and T cell activation in the spleen. 2) hyaluronidase and collagenase exist in
tumors, which might enhance tumor progress, and cause collateral damage in healthy
organs. Thus, the stealth coating of PEG will need manipulation in terms of MW,
concentration and reaction time for the optimal delivery efficiency. Localized delivery
might be another alternative, for example, the peritumoral delivery of PLGA-PEG-PLGA
gel for the sustained release of enzymes [340]. 3) the basal state of the mouse immune
system might be affected by the husbandry condition of the pathogen, which could cause
significant individual differences in basal cytokine levels and lymphocyte populations. The
alternative is to keep the mice in specific pathogen free conditions, and use the same mouse
model for determining the basal immunogenic parameters. 4) FAK is not a genetic target
specific for eradicating collagen and hyaluronic acid, but HAS2 [345], ROCK2 [346] were
reported to regulate the synthesis of hyaluronic acid and collagen, which might be of value
for specific genetic targeting.
Common classification of anticancer agents includes kinase inhibitors, therapeutic
antibodies, antibody-drug conjugates, immunotherapies and chemotherapies. The kinase
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target include epidermal growth factor receptor [347], phosphatidylinositide 3-kinase [348],
[349], mitogen-activated extracellular signal regulated kinase kinase [350]. Currently,
there are four chemotherapy drugs approved by the US FDA for the treatment of pancreatic
cancer: ABRASANE (albumin-bound paclitaxel), Gemzar (gemcitabine), 5-FU
(fluorouracial) and ONIVYDE (irinotecan liposome injection). In addition, FOLFIRINOX,
a combination of three chemotherapy drugs (5-FU/leucovorin, irinotecan and oxaliplatin)
is commonly used in the treatment of metastatic pancreatic adenocarcinoma due to the
positive response in a Phase 3 trial. There are reports of new chemotherapeutics that
reported to treat advanced pancreatic cancer but end in failure: metformin [351],
nanoliposomal irinotecan in combination with fluorouracial and folinic acid [352].
Cancer immune evasion is observed in PDAC [353]. Immunotherapy is ineffective
for PDAC due to multiple reasons: first, cancer cell-specific CD8+ T cells did not respond
to two immunological checkpoint antagonists that promote the function of T cells: anticytotoxic T-lymphocyte-associated protein 4 (-CTLA-4) and -programmed cell death 1
ligand 1 (-PD-L1) [354]. Second is the poor antigenicity. As the key initial step of
launching effective anti-tumor immunity, antigenicity is inferred by the mutational
landscape [355]. PDAC has 30-40 mutations per tumor as compared to 160-170 for
colorectal cancer [356]. Third, leukocyte invasion was dominated by immunosuppressive
cell types, such as tumor-associated macrophages, myeloid-derived suppressor cells and
Treg cells.
The discovery of the perfect target and translation of molecular-targeted imaging
to the clinic remains challenging due to the need for specific exogenous imaging agents in
order to image the biochemical process of interest. The discovery and validation of such
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imaging targets is time-consuming and expensive, and rarely results in a clinically useful
agent. Many of the imaging probes reported to be efficacious in animal models have failed
to reach the clinic and are still in the investigational stage [357], [358]. Unfortunately, the
extensive approval process of the FDA makes it impossible to quickly test imaging probes
in a clinical pilot study in order to determine effectiveness in humans and thus save
resources and concentrate on more promising probes [359]. In addition, the added value of
molecularly-targeted imaging to patient benefit still needs to be proven before wide-spread
use of this technique is expected. This needs to be accomplished by increasing the number
of human trials using a standardized technique to demonstrate safety and effectiveness.
Although this is still far from current reality, the bulk of preclinical studies and the first
successful clinical studies show that more wide-spread clinical use is on the horizon.

5.3 Challenges to translate new molecularly targeted contrast
agents into the clinic
It is expected that ongoing complementary research on new biomarker and
imaging-based approaches will result in earlier detection of pancreatic cancer in the future.
However, one of the challenges in developing new molecular imaging-based approaches
with novel contrast agents is the inability to fail quickly and early during the contrast agent
development process, in particular during the costly phases of clinical testing. Ideally, once
a new contrast agent has shown to be safe and effective in preclinical studies, the agent
should be quickly tested in pilot clinical trials to assess its efficacy in patients. If the agent
continues to show promise in the clinical setting, its development could be expedited,
whereas its development could be halted immediately upon disappointing results. This
recognition of quick and early failure would give researchers the opportunity to save
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resources and concentrate their efforts on the most promising contrast agent candidates to
be moved through the different phases of clinical trials. However, since molecular imaging
agents are treated as drugs by the FDA, they must undergo the same lengthy approval
process as any other drug. This does not allow for quick go or no-go decisions for many
contrast agents.
Fortunately, for PET contrast agents that are injected with trace amounts (defined
as ≤ 100 µg for imaging agents and 30 nmol for protein products), an exploratory
investigative new drug application (IND) pathway had been introduced by the FDA,
allowing translation into early first-in-human phase 0 clinical trials, with less requirements
for preclinical animal testing than it is typically needed for a traditional IND [52]. A costeffective pipeline for obtaining traditional IND approvals from FDA to allow timely
translation of new PET agents was recently reported [360]. Through this pipeline, a
traditional IND for a PET probe can be obtained within 7 months at a cost of approximately
$50 000, if safety and toxicity assessment are obtained for several agents conjointly and by
using the internal and nonprofit facilities. The cost was estimated at $150,000 per agent
using contract research organizations [360]. Though there is less experience in clinical
translation for molecularly targeted contrast agents other than PET agents, this example
shows that the FDA approval process for molecular contrast agents can be expedited
through a team effort. It is expected that similar pipelines could be developed for other
types of contrast agents in the future, and the experience from this process could be
leveraged to expedite translating similar or next-generation US contrast agents into the
clinic [360].
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5.4 Novel imaging of molecular targets is an emerging area
crucial to the development of targeted drugs
Targeted drugs hold great promise for the treatment of malignant tumors. However,
there are several challenges for efficient evaluation of these drugs in preclinical and clinical
studies. These challenges include identifying the biologically active concentration and dose
schedule, selecting the patients likely to benefit from the treatment, monitoring inhibition
of the targeted protein or pathway, and assessing the response of the tumor to therapeutics.
Although anatomic imaging will remain important, molecular imaging provides several
new opportunities to make the process of drug development more efficient. Various
techniques for molecular imaging that enable noninvasive and quantitative imaging are
now available to aid development and evaluation of new drugs for the treatment of cancer.
In the following paragraphs, we will discuss the integration of molecular imaging into the
process of drug development and how molecular imaging can address key questions in the
preclinical and clinical evaluation of new targeted drugs. Examples include imaging of the
expression and inhibition of drug targets, noninvasive tissue pharmacokinetics, and early
assessment of the tumor response [361].
Targeted drugs have been used to treat a variety of common human solid tumors,
including breast cancer, colorectal cancer, and non-small-cell lung cancer (NSCLC).
Diverse integrated signaling pathways are involved in the development and progression of
these malignancies, each of which is genetically heterogeneous. Consequently, inhibition
of one specific pathway is likely to be efficacious only in small subsets of patients who
share a specific tumor subtype. For example, in unselected patients with metastatic breast
cancer, the response rate to the anti-HER2 antibody trastuzumab is less than 10% [362].
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Low response rates have also been reported for EGFR and mammalian target of rapamycin
(mTOR) kinase inhibitors in patients with NSCLC [363] and renal cell carcinoma [364],
respectively. Therefore, patient stratification to identify potential responders would be of
great benefit. For breast cancer, identification of probable responders to trastuzumab
therapy by use of immunohistochemical (IHC) staining of HER2 facilitated approval of
this drug and its widespread use for the treatment of HER2-positive breast cancer [362].
When new targeted drugs enter clinical trials, comparable benefit are not always
achievable throughout cancer types. Moreover, sensitivity to new drugs might not purely
rely on the overexpression of target proteins. Moreover, it might be based on factors such
as specific mutations of the target molecule, loss of negative regulators of its activity, and
other regulatory, redundant and/or compensatory tumor responses that are not currently
understood. An inability to identify the appropriate patient subsets complicates drug
development when “go-no go” decisions are made according to the response rates in
relatively small phase II studies. In such studies, poorly defined study populations might
lead to an apparent drug failure because of the large fraction of non-responders that dilute
the positive drug effect on subpopulations detected by the study. The inability to properly
identify appropriate patient subsets is confounded by the fact that the conventional size
criteria used to assess tumor responses might not be applicable for some targeted drugs,
since durable responses to targeted drugs might be cytostatic rather than cytotoxic and are
thus not associated with tumor shrinkage. As a consequence, standard response criteria,
which defines a response as a decrease in tumor size, are of limited reliability in assessing
the response to this class of drugs.
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Targeted-molecular imaging provides strategy that could address expression of the
target protein, drug–target protein interactions and drug effects in both preclinical studies.
In addition, it reduces the costs of drug development [365], stratify patient populations and
monitor therapeutic efficacy. With regard to the clinical setting, the two key imaging
techniques that will be emphasized are PET and MRI. For preclinical studies, specialized
imaging devices that include small-animal PET, SPECT instrumentation, small-animal
MRI, and optical imaging devices for fluorescence and bioluminescence, are currently
available for studies of rodents and other animal species. In addition to identify targets,
these devices enable pharmacokinetic and pharmacodynamic studies in animal models of
cancer and in humans.
Although there is little doubt that small-animal imaging will facilitate the
development of targeted drugs and imaging agents, drug targets can be species-specific.
For example, CEA is not expressed in mice. The monoclonal antibody bevacizumab, which
targets VEGF, binds specifically to human but not the mouse VEGF. In such cases, the
results of clinical imaging studies might differ from those obtained from animal models. In
the paragraphs that followed, we present selected examples to illustrate the applications of
molecular imaging, focusing on how molecular imaging can potentially contribute to “go–
no go” decisions earlier in the process of drug development.

5.4.1 Imaging of target expression
Expression of the protein or proteins targeted by a drug can generally be assessed
by standard IHC. Tissue samples for IHC analysis, however, are frequently available only
from the primary tumor, which might have a different phenotype and drug response than
metastatic lesions. By the time patients enter clinical trials, expression of the target protein,
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or its function, may have changed considerably. For example, Linden et al. [366] studied
47 patients with recurrent breast cancer. At the time of diagnosis, all primary tumors were
estrogen receptor (ER) positive. However, only 23% of the patients achieved an objective
response to salvage hormonal therapy. Whereas the degree of binding of the radiolabeled
estrogen analog [18F]fluoroestradiol (FES) to ERs in metastatic tumors, as measured by
PET, was predictive of the tumor response. Specifically, none of the patients lacking focal
FES tumor binding responded to therapy, whereas 34% of patients with FES tumor binding
responded to salvage hormonal therapy. Thus, FES-PET can be used to identify patient
subgroups that, despite expression of ERs in the primary tumor, are unlikely to benefit
from anti-estrogen therapy because the metastatic tumors are ER negative.
Besides identifying differences in expression of target proteins inter-patiently,
molecular imaging can also show intra-patient heterogeneity of the expression target
proteins. For instance, lesion-to-lesion differences in the expression of αvβ3 integrin in a
patient with metastatic soft tissue sarcoma was reported [367]. Currently, the levels of
expression of target proteins are determined by analysis of tumor biopsies. In patients with
metastatic disease, analysis of tumor biopsies allows evaluation of only a small part of the
total tumor mass. The assessment of the expression of protein targets by use of biopsies
might, therefore, be misleading, since αvβ3 integrin was highly expressed in the primary
tumor but not in the pulmonary metastases.
Currently, only a limited number of molecular targets can be imaged in clinical
studies because of the restricted number of available probes [361]. Most molecular targets
are expressed at nanomolar range in the tumor tissue, which presents a challenge for the
development of ligands. Many potential probes not only bind with their targets with high
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avidity but also demonstrate considerable nonspecific binding that resulted in unfavorable
pharmacokinetic properties for in vivo imaging. Reducing nonspecific binding and
optimizing the pharmacokinetic properties have been major challenges in the development
of new imaging probes.

5.4.2 Tissue pharmacokinetics
PET imaging has been used to study the pharmacokinetics of several anticancer
drugs, for example the radiolabeled humanized anti-VEGF antibody HuMV833 [368].
Jayson and co-authors used PET imaging with an iodinated drug analog to study the
pharmacokinetic properties of this antiangiogenic drug [369]. To quantify the drug
concentrations in the organ and tumor, labeled antibodies were administered for PET
imaging at 24 h and 48 h. The study revealed important differences in drug uptake,
clearance and biological activity between primary tumors and metastatic lesions. Some
primary tumors exhibited clearance rates that were three times faster than those of
metastatic tumors, even within the same patient. Substantial differences in the rates of drug
clearance from the tumor were also observed among different patients and tumor types.
This heterogeneous pharmacokinetic response might explain the lack of effectiveness of
treatment in some patients. The study also revealed discrepancies between the plasma
pharmacokinetics of the drug and the rate of drug clearance from tumors, as determined by
PET. In patients with multiple lesions, intra-tumoral drug concentrations varied up to 3.4fold [369]. This variance indicates that plasma pharmacokinetics cannot be used to predict
intratumoral drug concentrations.
Tansi et al. [370] reported development of NIRF immune-liposomes as quick,
effective and more reliable setup to validate the macroscopic and subcellular
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biodistribution of contrast agents in freshly excised animal organs. Confocal microscopic
imaging of freshly excised organs can detect the subcellular localization of fluorescent
probes, which could be correlated to the observations made by macroscopic imaging. Such
approach will be highly beneficial to many researchers involved in nano-drug design or in
fluorescence-based studies on disease pathogenesis. With that, single-cell and subcellular
pharmacokinetic imaging allows insight into drug action in vivo.

5.4.3 Measuring target inhibition
Noninvasive assessment of the target inhibition is important at various stages of
drug development. In phase I studies, assessment of target inhibition can define the
biologically active dose of a new drug for further phase II and III studies. Traditionally,
the dose of a cancer drug chosen for further investigation has been determined by the
maximum tolerated dose (MTD) in phase I studies. Pathway-targeted drugs, however,
frequently cause limited acute adverse effects. The biologically active dose might be
substantially lower than the MTD. Furthermore, classic cytotoxic agents are administered
over a relatively brief period of time, with the intent to eradicate tumor cells. By contrast,
many pathway-targeted drugs are developed as oral treatments for long-term use and are
designed to inhibit tumor growth. Dosing these drugs at the MTD might result in
unnecessary toxicity. Moreover, the effectiveness of some targeted drugs may actually
decrease at higher doses, owing to off-target effects on other biologically active molecules.
In phase II studies, new drugs commonly fail to produce the desired responses for
two reasons. First, the dose schedule might be inadequate indicating that the target might
not be inhibited. This fact should not lead to “no go” decisions before exploring the
outcome of optimizing the dose or schedule of administration. Second, drugs might inhibit
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the target but might not affect tumor growth if the target is not essential. This should lead
to “no go” decisions.
If the probes used in imaging bind to the same target as the drug, inhibition of the
target can be monitored by imaging the blocking of probe uptake by the study drug.
Similarly, inhibition of enzymatic activity can also be visualized by imaging probes that
are substrates of specific enzymes. Napp et al. [371] determined the activity of matriptase,
evaluate molecular efficacy of synthetic matriptase inhibitors in an orthotopic mouse model
of AsPC-1 PDAC with time-domain NIRF imaging, which can be successfully used to
separate fluorescence signals that derived from the applied probe from the autofluorescence
background. By using optical imaging in combination with a fluorescently labeled antibody
directed against matriptase and an activatable probe, expression and activity of this enzyme
in tumors was determined in vivo. By measuring increase in fluorescence intensity over
bladder we could clearly detect cleavage of the substrate and thereby activity of matriptase.
Matriptase activity can be inhibited in vivo for at least 24 h by using different synthetic
active-site directed enzyme inhibitors, apparent on reduced fluorescence intensities over
bladder.

5.4.4 Assessment of tumor response to therapy
Imaging tumors and their response to treatment is valuable toward early assessment
of therapy in patients with cancer. Imaging technology to detect molecular changes in the
asymmetry of phospholipid distribution in the cell membrane bilayer is a growing field of
preclinical and clinical research to detect tumors and measure responses to therapy.
Phosphatidylserine (PS) is the most abundant anionic aminophospholipid present in the
cell membrane of all mammalian cells and is located in the inner leaflet of the cell
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membrane of normal healthy cells. Recently, Zhao et al. [372] used NIR optical imaging,
the use of a F(ab’)2 fragment of PGN635 labeled with the NIR fluorescent dye IRDye
800CW, was used to demonstrate tumor uptake in a model of rat glioma and enhancement
of probe uptake by irradiation of tumors. Furthermore, Gong et al. sought to explore the
usage of PGN650-IRDye800 as an imaging agent to monitor the exposure of PS in tumors
and to assess responses to chemotherapy. Measurement of PS exposure in response to
chemotherapy was assessed using human breast and prostate tumor xenografts in mice. In
both tumor models, elevated levels of PS were detected in tumors following administration
of docetaxel, which was confirmed by ex vivo imaging of tumors and fluorescence
microscopy. PGN650 may be a useful probe to detect PS that exposed in tumors and to
monitor enhanced PS exposure to optimize anti-tumor efficacy [373].
Despite improved tissue penetration as compared to visible light, an essential
limitation of utilizing NIR fluorescence imaging intraoperatively is its inability to visualize
structures deeper than approximately 5-8 mm below the surface [92]. As a result of this
limitation, the field has been shifting towards developing a combination of different forms
of imaging modalities, as reported by Tummers et al. [176] in the clinical trial of imageguided PDAC resection. Furthermore, multimodal imaging modalities also have significant
potential when used as an integrated diagnostic and intraoperative technology, since this
can overcome limitations of the individual modalities. The restricted tissue penetration of
light limits the use of optical imaging probes. By use of NIRF reporters, tissue penetration
of several centimeters has been achieved in experimental studies, albeit with increasing
attenuation with depth [374]. Furthermore, image reconstruction algorithms are now being
developed to produce tomographic imaging in animal models, with the goal of quantitative
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assessment of regional concentrations of fluorescent reporters [374]. Near-infrared
fluorescence imaging might, in the future, have a role in clinical studies of superficial
tumors or tumors accessible by endoscopy.
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2. Qi B, Crawford AJ, Wojtynek NE, Ly P, Hollingsworth MA, Mohs AM. Intraoperative
pancreatic cancer imaging using hyaluronic acid conjugates tuned for minimized background
signal. World Molecular Imaging Congress; Seattle, WA, September 2018. Podium
Presentation. *Seclected for Women in Molecular Imaging Network Scholar and awarded
Student travel stipend.
3. Qi B, Crawford AJ, Holmes MB, Wojtynek NE, Souchek JJ, Almeida-Porada G, Hollingsworth
MA, Mohs AM. Indocyanine green loaded hyaluronan-derived NPs for fluorescence- enhanced
surgical imaging of an orthotopic pancreatic cancer model. World Molecular Imaging
Congress; Philadelphia, PA, September 2017. Podium Presentation.
4. Qi B, Crawford AJ, Holmes MB, Wojtynek NE, Souchek JJ, Almeida-Porada G, Hollingsworth
MA, Mohs AM. Indocyanine green loaded hyaluronan-derived NPs for fluorescence- enhanced
surgical imaging of an orthotopic pancreatic cancer model. UNMC Biopharmaceutical
Research & Development Symposium; Omaha, NE, September 2017. Poster.

AWARDS AND HONORS
2019

University nominee for NIH/NCI F99/K00 fellowship

2018-2019

Chair-elected, UNMC student chapter of American Association of
Pharmaceutical Sciences (AAPS)

2018

Student Travel Stipend awarded by the World Molecular Imaging
Congress for the excellency of abstract

2018

Women in Molecular Imaging Network Scholar by the World
Molecular Imaging Network Leadership Committee
Treasurer, UNMC student chapter of American Association of
Pharmaceutical Sciences (AAPS)

2017-2018

2016-2019

Research Assistantship, University of Nebraska Medical Center

2015-2019

Graduate Research Fellowship, China Scholarship Council

2015-2016

Teaching Assistantship, University of Nebraska Medical Center

2012-2015

National Graduate Scholarship-awarded by Chinese Ministry of
Education and Sichuan University for academic excellence and
leadership
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2009-2011

National Recognition Scholarship for Undergraduate Studentsawarded by Chinese Ministry of Education and Sichuan University,
based on academic achievements, service and leadership.

TEACHING ACTIVITIES
2015-2016
Course:

Teaching Assistant, University of Nebraska Medical Center
Introduction to Pharmaceutical Sciences, PHSC 550
Pharmaceutical Biochemistry, PHSC 520

Duties:
Prepared for lectures handouts, graded assignments, exams and
organized Q&A sessions with students
2017
Mentor for Undergraduate thesis, University of
Nebraska Medical Center
Student:
Ziling Zhao
Program:
Pharmaceutical Science (China Pharmaceutical University)

REVELENT SKILLS
• Organic synthesis (small molecule, polymer) • UV-Vis spectroscopy, fluorescence
spectroscopy • DLS, NMR, TEM • Flow cytometry • ELISA • Colony-forming assay
• Orthotopic tumor model induction • LC-MS/MS • GFC • Jugular vein catheterization
• Near-infrared fluorescence imaging • Biochemical analysis • Tissue processing and
cryostat sectioning • Fluorescence and confocal microscopy
• Adobe Illustrator • Chemdraw • DAS 3.0 • FlowJo • ImageJ • GraphPad Prism •
Photoshop

MEMBERSHIPS IN PROFESSIONAL SOCIETIES
American Association of Pharmaceutical Scientists (AAPS)
World Molecular Imaging Society (WMIS)
American Association for the Advancement of Science (AAAS)
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